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ABSTRACT
As in the rest of the world, renal transplantation in Scotland is under tremendous
pressure due to increasing demand but a limited supply of donor organs. In this
setting issues of organ allocation, equity of access, standards of the assessment
process and appropriateness of transplantation in certain groups of patients become
very important indeed. This thesis set out to answer the following questions:
1. Are there any benefits of regional kidney sharing alliance?
2. Is there equity of access to the transplantation service? If not, which are the
sociodemographic and comorbidity factors which may be responsible for
these differences?
3. Does transplantation provide a survival advantage over dialysis in various
renal failure populations? Is there any benefit in transplanting high-risk
groups of patients?
4. Can the risk factors identified at the assessment process be quantified into a
patient survival risk score?
An initial analysis examined the current organ allocation system and the activity of
the new Scotland-Northern Ireland kidney sharing alliance. This study showed a
substantial benefit of a wider regional sharing alliance, with an improvement in the
proportion of favourable matched kidneys and a higher organ exchange rate without
any detrimental effect on the length of the cold ischaemic time or graft survival.
A study of equity of access to transplantation showed that women, elderly patients,
diabetics, patients starting replacement therapy on haemodialysis and patients
starting dialysis in a renal unit which is not adjacent to a transplant centre are less
likely to be listed. Age, the primary renal disease and centre of listing are predictors
of access to transplantation, once listed. In addition, left ventricular hypertrophy,
respiratory or cerebro-vascular diseases exert a negative effect on the speed of access
to the renal transplant waiting list, while access to transplantation is diminished for
those with cardiac arrhythmias and hyperparathyroidism.
Survival on dialysis and transplantation were compared. Transplant recipients have a
68% lower long-term risk of death and a 3.6 times better life expectancy compared
with patients on dialysis on the transplant waiting list. The magnitude of this survival
benefit is not equal for all, but it is present even in high-risk groups of patients such
as elderly recipients or patients with diabetes.
There are significant variations in the assessment of the renal transplant candidate
between the four transplant centres in Scotland. Results highlighted a lack of
consensus, particularly with regards to the high-risk patients.
The sociodemographic and comorbid conditions were quantified into a survival risk
score. This allowed the prediction of survival on dialysis or after transplantation,
based on an individual patient's general health at the moment of listing. Using such a
score, patients could make an informed decision regarding the benefits and the risks
associated with either form of treatment.
xi
ABBREVIATIONS:
ALD Alcoholic liver disease
BMI Body mass index
BSD Brain stem death
COAD Chronic obstructive airways disease
CAPD Chronic ambulatory peritoneal dialysis
CCPD Chronic cycling peritoneal dialysis





ESRD End stage renal disease
GI Gastrointestinal
GN Glomerulonephritis
GORD Gastro-oesophageal reflux disease
HD Haemodialysis
HLA Human leukocyte antigens
HSP Highly sensitised patient
IHD Ischaemic heart disease
IN Interstitial nephritis
IQR Inter-quartile range
LVH Left ventricular hypertrophy
MHC Major histocompatibility system
MS Multisystem disease
PCR Polymerase chain reaction
PE Pulmonary embolism
Pmp Per million population
PRA Panel reactive antibodies
PVD Peripheral vascular disease
PTH Parathormone
RR Relative rate
RRT Renal replacement therapy
SEM Standard error of the mean
SRR Scottish Renal Registry
TIA Transient ischaemic attack
TURP Trans-urethral resection of prostate
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UNOS United Network for Organ Sharing







Transplantation is one of the youngest and fastest developing fields of medicine. It
was only in 1954, when after decades of unsuccessful experiments around the world
(1-3), that Murray and Merrill performed in Boston the first successful kidney
transplant between identical twins. They wrote the first page in what was going to be
a fascinating success story in medicine. In less than half a century, more than half a
million people received a second chance for life by means of a solid organ transplant.
Liver, heart, lung, heart-lung and pancreas transplants were introduced (4-8) and are
now established therapeutic options.
Other procedures such as live partial liver transplants (9; 10), intestinal
transplantation (11), islet-cell transplantation (7), although still in their infancy are
rapidly gaining their place as accepted treatment modalities. 'During the last decade,
xenografts from genetically engineered animals (12), stem cell technology and the
mapping of the human genome have opened a new dimension for transplantation.
Better technologies for organ storage and transportation (13), antigen screening and
typing have been developed (14). Although we have not yet found the Holy Grail of
immune tolerance, we are a few steps closer to complete control of rejection due to
an incredible array of immunosuppressive medication.
The field has seen numerous advances in public policy and legislation. Brain stem
death was accepted in the UK in 1976 (15) and laws and codes of practice aimed at
regulating transplantation activity have been enacted (16). National networks and
international alliances for obtaining and allocating organs have come into being,
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together with improved allocation schemes and recipient selection guidelines
(17; 18).
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1.2 BENEFITS OF RENAL TRANSPLANTATION
Renal transplantation has evolved tremendously since the days ofMurray and Merrill
from being an occasional procedure into the "gold standard" treatment for patients
with end stage renal failure.
It is widely accepted nowadays that transplantation provides the best chance of
survival with a reduced risk of death and a projected life span twice longer when
transplant recipients are compared with those who remain on dialysis (19). However,
comparative survival rates for various treatment modalities are difficult to construct,
as often data in the literature do not reflect the fact that patients change treatment
modalities frequently and that the characteristics of those selected for each modality
may differ significantly. Several risk factors and associated medical conditions can
adversely affect survival and therefore should be taken into account in any
comparison between therapeutic modalities. It has been suggested that patient's state
of health rather than the treatment modality itself is the most important factor
determining survival (20). Even with these caveats in mind, one cannot dismiss the
increasing amount of evidence from carefully constructed analyses showing a
reduction in the relative risk of death if a patient receives a transplant rather than
continues on dialysis. (19;21-23).
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Most studies have shown that the quality of life of patients receiving a transplant
exceeds that of patients receiving dialysis (24;25). The obvious benefit of
transplantation is freedom from the constraints of dialysis. On average, patients
spend 40 to 50 hours a month receiving haemodialysis (HD), 60 to 70 hours
receiving chronic ambulatory peritoneal dialysis (CAPD) or 280 hours receiving
chronic cycling peritoneal dialysis (CCPD). A successful transplant will save a
patient nearly 100 days a year which results in a greater flexibility and independence,
an increased earning potential and increased family and personal time (26). Life
satisfaction, physical and emotional well-being and the ability to return to work or
school are all significantly better in transplant recipients than in dialysis patients.
A successful kidney transplant is more cost-effective to the health care system than
haemodialysis. Although most of the data on the economic aspects of transplantation
comes from the United States, where a transplant provides a relative net saving after
a period of 3-4 years (27), this cost effectiveness was seen in all countries that have
developed a renal transplant programme (28). In the United Kingdom,
transplantation costs on average £15000 to £25000 in the first year, with an estimated
cumulative cost of around £1500 to £3000 for each subsequent year, due to reduction
in immunosuppressive medication (29). Compared to an estimated annual expense of
£12000-18000 for peritoneal dialysis and £20000-25000 for haemodialysis, renal
transplantation provides significant economic advantages, which are achieved today
when the one-year graft survival is exceeding 85%.
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1.3 RENAL TRANSPLANTATION RESULTS
The "Transplant activity report 2000" published by UK Transplant (30) showed a
one year and a 5-year transplant survival estimate after first cadaveric kidney
transplant of 86% and 69% respectively (table 1.1)
Transplant Year of No. Survival 95% CI % follow-
survival time transplant analysed estimate (%) up
One year 1997-1998 2222 86 85-88 80
Three years 1995-1996 2681 77 76-79 87
Five years 1993-1994 2722 69 67-71 79
Table 1.1 Transplant survival after first kidney only transplant in UK and Republic
of Ireland, 1993-1998. (Source: UK Transplant Activity Report 2000)
Looking at changes in survival over time (table 1.2), one can see that there has been
a constant increase in one-year transplant survival rates as well as an improvement in
the estimated kidney half-life. (Log rank test, p=0.006).
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Kidney half-life One year transplant
survival
Year of graft Estimate 95% CI Estimate 95% CI
1984 - 1986 9.8 9.0-10.5 74 72-76
1987- 1989 9.3 8.7-9.9 80 78-82
1990- 1992 11.6 10.7-12.5 82 80-84
1983 - 1995 14.0 12.5-15.6 83 82-85
1996 - 1997 13.5 12.5-15.6 85 83-86
Table 1.2 Kidney half-life and one year transplant survival estimates for first adult
cadaveric kidney by year of transplant, January 1984 - December 1997
{Source: UK TransplantActivity report 2000)
Similar improvements were seen in the one-year survival rates for living donor
kidney transplants {appendix, table A. I, page 330). In addition, an analysis of patient
and graft survival at one, three and five years following cadaveric kidney transplants
revealed that 96% and 87% of the patients survive at one and five year respectively,
while 88% and respectively 76% of the grafts are functional at the same time points
(appendix, table A. 2, page 330).
Recent data from the United States Renal Data System (USRDS) (31) showed an
improvement from 74.7% to 88.8% in one-year graft survival following first
cadaveric kidney transplants and from 86.1% to 94.5% in one-year graft survival for
first living donor transplants over a ten-year period (figure 1.1). These short terms
results were associated with a 17% improvement in the five-year survival following
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first cadaveric kidney transplants (appendix, table A.3 page 331). Even so, the most
recent data from USA show that the 5-year graft survival is 18% lower than in UK
for the same period (58% in USA vs. 76% in UK, 1990-1992) (appendix, tables A.2,











—Cadaveric donors Living donors
Figure 1.1 One-year graft survival rates following first cadaveric and living donor
transplants in USA 1988-1998 (Adapted from "The 2001 USRDS Annual Data
Report Atlas ")
Data from 15 European centres collected by the Collaborative Transplant Registry
Study showed that the 5 years survival for a first kidney transplant exceeds 68% for
graft (figure 1.2) and 85% for patient survival.
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Number of Transplant
Cadaver Kidney Transplants 1985-2000
1.TX 11=141302
2.TX n= 20299
3. TX n= 2934
> 3. TX n= 443
OTS Collaborative Transplant Study CTS-K-11101 -Dec2001
Figure 1.2 Graft survival for cadaveric kidney transplants in Europe 1985-2000 (1st
graft vs. regrafts). (Source: Collaborative Transplant Study)
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1.4 DEMAND AND SUPPLY OF
TRANSPLANTATION
On 31st of January 1968, Sir Peter Medawar opened the Nuffield Transplantation
Unit at the Western General Hospital in Edinburgh. In his address he said: "... We
cannot hope that medicine and public health and humane social legislation will
preserve all of us into advanced old age, and at the same time reasonably expect that
the supply of human tissues and organs for transplantation will measure up to what is
likely to be the demand." Those were prophetic words as today the demand for
transplantation exceeds by far the supply available. The benefits of renal
transplantation have lead to increasing numbers of end stage renal disease (ESRD)
patients being referred for transplantation.
A recent report from the Scottish Renal Registry (SRR) (32) has shown that the
incidence of ESRD in Scotland is rising (figure 1.3) and is now exceeding 108 new
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Figure 1.3 Annual incidence (pmp) of new patients with ESRD in Scotland 1989 -
1999. {Source: Scottish Renal Registry)
According to a UK Renal Survey (33), the UK national incident rate in 1998 was
slightly lower, at 94.6 pmp. There is a significant variation between the acceptance
rate in England, Wales, Scotland and Northern Ireland (p<0.0001, Poisson
regression), with the lowest rate in England (table 1.3). Given the larger ethnic
minority in England, the low rate suggests that there may be an underestimated need
for RRT in this part of the country.
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Scotland England Wales N. Ireland Total UK
Acceptance rate pmp 105 92 128 107 96
(95% CI) (96-114) (90-95) (115-141) (92-124) (93-98)
Table 1.3 Variations in acceptance rate for RRT in UK in 1998 (Source: The Renal
Registry 2000 Report)
The more recent UK rates are unknown as no further surveys were carried out and
the Renal Registry data accounts for only 40% of the units in England and Wales
compared with 100% in Scotland. Nevertheless, based on available data, it is
expected that the rate is rising across the whole of the UK.
A report by the European Renal Association (ERA-EDTA) has shown that the need
for replacement therapy is increasing in most European countries, the highest
incidence of new ESRD patients being noted in Belgium (165 pmp) while the lowest
is in Norway (89 pmp) (appendix, figure A.l, page 331).
Worldwide, the problem of ESRD is growing at an alarming rate. In 2000, in USA
alone, over 300.000 people were on maintenance dialysis. The number increased at
an annual rate of 6% between 1992 and 1996 and by 4% between 1997 and 2000
(appendix, table A.4, page 331). The ESRD annual incidence rate in USA was 317
per million population in 1999, by far the highest in the world (figure 1.4). With
accurate identification and reporting of ESRD cases in more countries, it is certain
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Figure 1.4 Annual incidence of new ESRD patients (pmp) in 1999 {Source: The
2001 USRDS Annual Data Report (21))
As many of these patients have been or will be referred for transplantation, clearly,
the supply of donor organs could not keep pace with such an increasing demand. The
effects were quick to follow: a constant increase in the length of time spent waiting
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Figure 1.5 Changes in the median waiting time on the active list for a kidney
transplant in UK and USA, 1990-1998. {Source: UK Transplant and USRDS)
Year ,! olid
1988 1989 1990 1991 1992 1998 1994 1995 1996 1997 1998 1999 2000 2001 *
800 784 951 995 1080 1320 1390 1538 1854 2053 2419 3205 2841 1307 22537
Table 1.4 Reported deaths on the waiting list for a kidney transplant in USA, 1988-
2001 {Source: UNOS, * - until October 2001)
Moreover, in many countries, including the UK, the cadaveric donor pool has been
shrinking. The number of patients waiting for a kidney transplant in United Kingdom
has increased by about 45% in the last decade on a background of a 10% reduction in
the number of cadaveric donor organs (figure 1.6). Other European countries, despite
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Figure 1.6 Number of cadaveric donors and transplants in the UK and Republic of
Ireland and patients on the waiting list at 31 December, 1990-2000 (Source: UK
TransplantActivity report 2000 (30))
In the USA, the slow but steady increase in the number of donated kidneys in the last
decade (table 1.4) was not enough to resolve the demand of over 50.000 patients
waiting for a kidney transplant in September 2001.
1990 1991 /992 1993
Year Donor Recovered
1994 1995 1996 1997 1998 1999 2000 2001*
4304 4268 4276 4609 4795 5000 5038 5082 5343 5373 5488 1283
Table 1.4 Number of cadaveric kidneys recovered in USA, 1990-2001 (UNOS,
Annual Report 2001)(*- until October 2001)
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Many reasons are responsible for the reduction in donation rates, including a
decrease in the rate of fatal road accidents, an ageing process of the donor population
(figure 1.7), procurement arrangements and lack of a coordinator network,
insufficient funding and lack of intensive care unit beds, cultural and religious
attitudes, family refusals as well as health professionals training and legislation. Each
of these factors will have to be addressed ifwe are to improve the current situation.
Age groups
-♦-UK-1989 -A-US-1989 -»-UK-1998 -*-US-1998
Figure 1.7 Changes in the age distribution amongst the cadaveric organ donors in
UK and USA {Source: UK Transplant and UNOS)
And there is evidence that improvements are in our grasp, various studies estimating
the true potential for donation in the region of 45-50 donors per million population
(34). Moreover, the Spanish system has shown the way, successfully increasing
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Figure 1.8 Donation rates per million population in Spain 1989-2000 (Source: ONT
- Organisation Nacional de Transplantes)
The Spanish miracle, as it often has been called, is in essence a huge organisational
success, with an extensive coordinator network in every hospital, (35) excellent
cooperation between autonomous regional organisations and a national coordination
agency whose role is merely promoting the transplant and donation activity (36).
Several countries have been adapting this model to local conditions and hope to see
significant improvements in donation activity (37;38).
Most of the changes in the organisation of donation cannot be separated from the
legislation governing this activity (39). The donor's legal situation varies across the
globe (table 1.5)(40). In some countries, an "opt-in" law, which requires "informed
consent" from the relatives prior to proceeding to donation, is in place. Most
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European countries have adopted the so-called "opt-out" or "presumed consent" law,
whereby organs are removed from every identified donor unless they have expressed
their wishes against donation ("Hard form" opt out) or after inquiring from the
relatives whether they were aware of such wishes ("soft form" opt out). The only
notable exceptions are UK where coordinators have to register the "lack of
objection" from the relatives and USA where physicians have to prove that donation
was requested from the relatives (technically, both are forms of informed consent).
Country Donation rates (pmp) Donor's legal situation
UK 13.4 Lack of objection
USA 22.3 Required request
Italy 15.3 Informed consent
New Zealand 10.7 Informed consent
Australia 10.2 Informed consent
Eurotransplant 14.4
Austria 24.3 Presumed consent
Belgium 25.6 Presumed consent
Netherlands 12.6 Informed consent
Germany 12.2 Informed consent
Scandiatransplant 14.3 Presumed consent (except
Denmark)
Spain 33.9 Presumed consent (soft)
Portugal 19.5 Presumed consent
France 17.0 Presumed consent (soft)
Table 1.5 Donor's legal situation and donation rates in various countries in 2000.
There is an endless debate whether an "opt-out" law is better than "opt-in" and
whether it would be ethically and morally acceptable as a basis for the donation
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activity. Beyond the philosophical disputes, there is substantial evidence that the
introduction of a decentralized organ procurement system has lead to a significant
increase in the number of organ donors (41;42). It is yet unclear whether replacing an
"informed consent" with "presumed consent" legislation has a similar effect on organ
donation rates, but some studies (43;44) suggest that a significant increase was noted
in countries where the change in legislation was adopted.
In an attempt to increase the number of transplants, live donation has been revisited.
There is an increasing drive in the transplant community to promote this type of
transplantation, as it leads to a better long term outcome compared with cadaveric
renal transplants irrespective of whether the donor is related or unrelated to the
recipient (45). Furthermore, the availability of a live kidney donor allows a more
accurate timing of transplantation, making pre-emptive transplantation (before the
onset of dialysis) possible or reducing the length of time on dialysis, both with a
beneficial effect on long-term graft function (46-48). Although the living donor rate
in UK has increased by a factor of four in the last decade, at 5.3 per million
population in 2000 it is still much lower than some other countries (Norway: 17 per
million population, Sweden: 10.1 pmp) (49), but regional experiences have shown
that there is a great potential for this form of transplantation (30).
The widening of the acceptance criteria for donors (50-52) together with asystolic
donation (53-57) are just a few of many other ways in which we seek to correct the
deficit of donor organs. But for a complex problem there is no simple answer. Until
we find an endless supply of donor organs (such as genetically engineered xenografts
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(12;58;59)) or eradicate renal failure, we have to accept that not all patients will have
access to a renal transplant and there is a need for an objective and fair way to




As the supply diminishes, the transplant community has come to accept that the
question is not why but how to ration the resource. How then should donated organs
be allocated? The typical answer is "fairly" or "equitably", but the problem is to
determine the meaning of those terms in the special context of organ transplantation.
The allocation of cadaveric kidneys for transplantation confronts the decision makers
with a web of competing responsibilities: to maximize graft survival, to improve
patient quality of life and life expectancy, to minimize waiting times and to promote
equity across a range of socio-demographic dimensions (60). No single set of criteria
is likely to meet all these demands in the complex medical, ethical and social reality
of organ allocation.
Furthermore, transplantation is a complex process, with several layers of decision
making and multiple deciders (60-63). Organ allocation only tackles the last two
steps of the process (figure 1.9), as patients with end stage renal disease must be first
of all identified, referred for evaluation and accepted as potential recipients. Any
attempt to address the ethical and practical issues surrounding organ allocation must
therefore not lose sight of the wider context of the selection process and the values
and principles that prevail at each stage.
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Moving up the waiting list
Kidney available
Local allocationpolicy
Figure 1.9 The cadaveric renal transplantation process
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In facing rationing decisions, there are many philosophies that can be adopted (64-
68), but whichever we choose, it has to incorporate the basic principles of medical
ethics:
i.) Beneficence (doing good for the patient)
ii.) Primum non nocere (avoid harming the patient)
iii.) Respect for patient's autonomy
iv.) Justice (promote fairness).
Two of the most important concepts in medicine are justice (equity in distribution)
and utility (providing the 'best' outcome for the 'majority' of the patients) (69;70).
Applying purely a justice concept, the transplant process should provide equal access
to those in need. Several interpretations of this principle have been proposed, from
radical solutions (e.g. if the resource is too scarce so not everyone has access to it,
then nobody should (71)), through random lottery (72) and a more neutral queuing
(e.g. first-in-first-out (67)), to prioritisation of specific groups of patients (e.g. most
critically ill, rare blood groups, or those waiting longest (73)).
On the other hand, if the principle of medical utility would be given primacy,
transplantation would provide only for patients who are likely to have the best
outcome (e.g. young versus elderly patients, first transplant versus re-transplants),
who are the most deserving (e.g. the mother-of-two versus the drug addicted
alcoholic), who make the greatest contribution to society (e.g. the scientist versus the
lorry-driver)(67). Such a strict principle would discriminate on the grounds of age,
race, gender, social status, religious or political beliefs and is generally unacceptable.
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It is important to acknowledge that fairness may not always be compatible with
achieving the greatest overall good, as exemplified above. Both principles must be
applied in a broad sense (74;75). The problem is further compounded by the
deontological tradition (69;70) of our medicine whereby the physician has a duty to
his/her patient even in the face of a poorer prognosis (e.g. offer transplantation to a
patient that has already lost three grafts to recurrent disease). Clearly, the whole
process of selecting transplant candidates and allocating organs is a value-laden
issue. Many of the difficult ethical questions surrounding transplantation are rooted
in conflicts of values (figure 1.10), which are not between good values and bad
values, but rather between one important value and another.
Greatest good for the
for the patient
Figure 1.10 Ethical dilemmas in transplantation
A number of philosophers have cast doubt on whether all things that we rightly value
can be combined into a single framework (76;77), and the same may be true in
seeking agreement on patient selection and allocation criteria.
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Whatever the ethical principle, deciding eligibility for the transplant waiting list and
transplantation has to take into account some degree of efficacy, in other words, an
implicit expectation that transplant success must be higher than some minimum
standard. Yet, how low or high this minimum should be set has not been formally
agreed (62), but it should certainly consider all medical and non-medical factors
(social, economical, life-style, family support, emotional, cultural) which impact on
outcome (63). There are two further important points on this issue: a defined
minimum acceptable level must be reviewed and evaluated periodically, as overall
results of transplantation change rapidly and hence the significance of the chosen
level may be obsolete. Secondly, but equally important, a minimum standard should
not be used as a cloaking device for biases against certain groups of patients (e.g.
high-risk ones) (78).
The best way to address these conflicts of value is through sustained discussion
among informed and thoughtful individuals representing all those involved in the
transplantation process (care-takers, patients, funding organisations). Making these
kind of decisions is difficult, but we owe it to the public (on whom we rely for
altruistic donation) to do it in an open manner and to ensure that criteria guiding
these judgements could be acknowledged as the best available by all to whom they
apply. As philosopher Thomas Scanlon has suggested, an act can be justified if it
follows from a system of rules that, on reflection, cannot reasonably be rejected by
anyone seeking informed, unforced, general agreement about the matter in question
(79).
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l.S.ii Principles of allocation schemes
Beyond the ethical dilemmas surrounding transplantation and organ allocation, there
is the question of practicality. On what basis should we allocate available donor
kidneys? It can be argued that there are six major factors to be considered in
cadaveric kidney allocation (80):
a. Immunological factors (e.g. ABO group compatibility)
b. Regulatory factors (e.g. legislation)
c. Outcome (patient rehabilitation, graft survival)
d. Access to organs
e. Costs (to the society and patient)
f. Effects on the total pool of organs
Any practical allocation system must be devised within the constraints of the first
two factors and have a sizeable effect on the remaining four. Unfortunately, there is
such a strong interaction among these variables that devising a method or an
algorithm, which will reach a well-grounded agreement on these matters would be
practically impossible. But this should not stop one from trying to develop a scheme,
which is acceptable for a particular society's medical, ethical and practical settings.
Since the early days of transplantation, there have been attempts to devise a way to
allocate kidneys, based on factors that have a significant impact on outcome and
provide an additional efficacy for transplantation over alternative ways of treatment.
The founding fathers scientifically demonstrated a genetic basis for allograft
rejection (81-83) and noted a substantial benefit of HLA (human leukocyte antigen)
26
matching on graft survival (84). Most allocation schemes, which were developed
until the present day are based on this finding and have the HLA matching as the
foremost principle.
l.S.iii HLA system as the basis of kidney allocation
After several unique discoveries in organ transplantation, it has become clear that
rejection and acceptance of a particular transplant organ are inherited characteristics.
An array of inherited cell-surface antigens (proteins) defines the "foreign" nature, or
allogeneity of transplanted organs and tissues. The genes that encode for these
proteins are termed histocompatibility genes and are located on different
chromosomes in each species. Because of its central role in antigen recognition and
transplant immunobiology, this group of genes has been defined as the major
histocompatibility complex (MHC). The human MHC complex, known as the human
leukocyte antigen (HLA) system, is a genetic region located on the short arm of the
chromosome 6 (6p21.3) which contains over 200 genes (85;86). Six HLA loci have
been identified, with an extensive polymorphism, some with more than 300 alleles
(87), which make the HLA system the most polymorphic system found in humans.
The HLA antigens can be grouped into two different classes based on their structure
and cellular distribution. There are some 20 Class I molecules ofwhich HLA-A, -B, -
C are the most important from an immunological point of view. They are expressed
on most nucleated cells and bind and present peptides derived primarily from
27
endogenously synthesized proteins (e.g. viral proteins) to CD8+ T cells. Class II
molecules are named HLA-DR, -DP, -DQ and have a more restricted distribution
than Class I because they are generally expressed by antigen-presenting cells (APCs)
such as monocytes, macrophages, dendritic cells, renal mesangial cells, Kupfer cells,
alveolar type 2 lining cells and other elements of the immune system such as
lymphocytes and thymic epithelial cells (88).
The HLA molecules have a fundamental role in T-cell activation (figure 1.11), which
become reactive to "foreign" tissue and mount a formidable attack that culminates in
the destruction of the graft. This process is part of a complex chain of events, which
is as yet not fully understood (89).
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Figure 1.11 Immune recognition by T cells and the role of MHC molecules in
antigen presentation (TCR = T cell receptor, APC = antigen presenting cell)
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The remarkable degree of polymorphism of the HLA antigens accounts for the great
difficulty in tissue matching, as opposed to the relative ease of matching for the less
polymorphic ABO blood group antigens. More than 81 HLA-A, -B and -DR antigens
can be detected using serologic methods (table A.J, appendix, page 332), and at
present, most laboratories use a microlymphocytotoxicity test (14) in which
antibodies are allowed to react with the lymphocytes to be typed in the presence of
rabbit complement. More recently, several DNA based HLA typing methods have
been developed. DNA-based typing offers several advantages over serology:
• Typing can be performed on any tissue containing nucleated cells (e.g. buccal
swabs)
• Samples can be stored dried without refrigeration for long periods of time
• The accuracy of DNA typing is better than that achieved using serology and
the more difficult HLA specificities, those for which highly specific
alloantisera are rare or not widely available can be easily determined using
this method.
Once the HLA typing of a potential recipient has been determined, a second test is
carried out. This estimates the probability that a patient will have a positive donor
crossmatch, in other words has antibodies against the HLA molecules of the donor
(sensitised). This test is very important, as the detection of a high level of anti-HLA
antibodies (panel-reactive antibody ~PRA) leads to a lower probability of finding a
crossmatch-negative kidney. In a simplistic way, the finding of 75% PRA in a test
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suggests that 75% of donors will be unacceptable for the patient because they have
circulating antibodies that react with one or more of the donor's HLA antigens and
therefore they are exposed to a higher risk of graft rejection.
The importance of HLA matching in determining the graft outcome is now well
established (90-93). Large analyses from the UNOS and CTS databases showed that
graft survival decreases in a step-wise manner with poorer HLA matching (figure
1.12).
HLA-A+B+DR Mismatches
First Cadaver Kidney Transplants 1985-2000
0 MM n= 5656




5 MM n= 9538
CTS CoHab&ai/vo Transplant Study CTS-K-21101-Dec200t
Figure 1.12 Relationship between graft survival and HLA matching
The effect of HLA matching on graft outcome is persistent even under the condition
of short ischaemia (0-6 hours) and is enhanced in pre-sensitised patients (PRA >
50%).
But HLA matching has not been always accepted as a determinant of outcome,
except for transplants involving the complete match (full-house match: 0 HLA-A, 0
30
HLA-B, 0 HLA-DR mismatches) (94;95) and one must acknowledge that the
differences between each individual step of mismatch are very small (figure 1.12).
Nevertheless, results from a complex multivariate analysis of the factors affecting the
graft outcome in UK (96) have shown a substantial benefit of a complete match over
all other matches, while any HLA-DR mismatch will lead to the worse graft
outcome. The analysis also revealed that 110 (J HLA-A, 1 HLA-B, 0 HLA-DR)
mismatches did not differ significantly from 100 (/ HLA-A, 0 HLA-B, 0 HLA-DR)
and 010 (0 HLA-A, 1 HLA-B, 0 HLA-DR) mismatches in terms of transplant survival
(table 1.6). This suggests that the effects of HLA matching are more obvious for
groups of matches rather than individual levels and this seems to be supported by
other studies (97).
Overall Relative risk p value Relative risk (95%CI) of


















Table 1.6 Relative risk of renal transplant survival after transplantation according to
the level of HLA matching (Adjusted for year of graft, donor's age, recipient's age,
kidney exchange, waiting time, cause of donor's death and diabetes. Baseline
reference groups have a relative risk of 1.0) (Adaptedfrom (96)).
Another argument used by the critics ofHLA matching is that even using the current
convention of matching for 75 serologically defined HLA-A and -B antigens and
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considering only 10 broad HLA-DR specificities, fewer than 20% of cadaver kidneys
are transplanted to an HLA-matched recipient. Furthermore, if all known alleles of
HLA (appendix, table A. 5, page 332) were used for identifying a matching kidney
donor, it would be necessary to match 119 A locus alleles, 238 B locus alleles and
204 DR locus alleles in order to provide a perfect match. However impossible this
may seem, there is emerging data, which suggests that matching at the allele level
may result in an improvement in transplant survival (98).
This emphasis on high resolution of the HLA alleles enhances HLA differences that
have evolved anthropologically. This phenomenon called linkage disequilibrium
explains the presence of certain haplotypes within racial groups. Because grafts are
preferentially assigned to patients with relatively frequent HLA specificities, HLA
matching has also been criticized for diverting organs from hard-to-match recipients
(e.g. rare haplotypes, certain racial groups) (99). It has, therefore been suggested that
grouping broad HLA specificities into even broader cross-reactive groups (CREG)
(99; 100) tends to group individuals regardless of their racial background. The CREG
are based on the fact that when an individual makes antibody, it usually reacts with a
group of HLA antigens rather than individual ones (table A.6, appendix, page 333).
Another definition of CREGs takes into account the epitopes (antibody binding sites
on HLA antigens) shared by cross-reactive antigens, and the whole rationale of using
this approach would be that kidneys with epitopes more similar to those in the
recipient are less likely to elicit a vigorous immune response.
Recent retrospective analyses revealed mixed results. Some studies suggested a graft
survival comparable or better than allocation based on HLA specificities (101; 102),
while others suggested a worse outcome (103). Whatever the outcome of ongoing
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studies, CREG does not deny the impact of HLA matching on graft survival, as a
broader level of matching will be achieved anyway, but merely ensures a more
equitable distribution of kidneys among various recipient groups.
Perhaps the strongest opposition to the HLA matching arises from the fact that in
order to achieve a better match, a larger pool of recipients is required, which implies
sharing kidneys on a wider geographical area. This could lead to longer cold
ischaemic times and hence may diminish the potential benefit of better matching, but
whether this is true or not remains to be determined. In addition, sharing means that
centres situated in areas of high donation have to export organs to low donation
centres. This could be viewed as a drain of a precious local resource, which could
ultimately be a disincentive for donation.
The final argument against the use of HLA for kidney allocation was delivered by
the proponents of matching when a better survival from living un-related transplants
was noted when compared with better HLA-matched cadaveric kidneys (45).
Despite the pros- and cons- of how significant HLA matching is, and beyond the
back stage political debates (45; 104) a few statements are undoubtedly true:
1. HLA matching does influence the outcome of a kidney transplant
2. Levels of HLA matching (e.g. 000 vs. 100/010/110 vs. all other matches)
rather than individual matches should be used in allocating kidneys
3. HLA is not the only factor that dictates the outcome and any allocation
algorithm should not be based on HLA matching alone.
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1.5.iv Allocation schemes and organ sharing
Most allocation systems can be defined as a two step-process. In the first step, the
pool of patients with end stage renal disease is separated into two groups of eligible
and ineligible candidates for transplantation with an available donor kidney. In the
second step, allocation policies in place in individual systems will select a successful
recipient (figure 1.9). In deciding whether a candidate is suitable for transplantation
with a particular donor kidney the knowledge of the factors which influence the
outcome plays an important role. Although HLA matching remains the main
criterion, other donor (age, comorbidity, cold ischaemic time) and recipient factors
(age, comorbidity, length of time on the waiting list, level of sensitisation, previous
transplants, distance from the transplant centre) should be taken into account.
Allocation algorithms have been proposed since the early days of transplantation but
following the development of powerful IT systems, computer-based point-scoring
allocation schemes were implemented. It is now widely accepted that a points system
leads to a structured and systematic decision (62), focusing the attention on the full
range of data as well as helping to achieve an equitable selection of recipients and
ensuring the public and the patients that a sound, routine plan is in place (105).
Furthermore, computerised systems allow a prospective simulation and evaluation of
any given allocation algorithm, eliminating the inherent bias and difficulty created by
a retrospective assessment after several years of operation (106). However, the
debate is still wide open with regards to which criteria should be used and especially
the weight which should be given to particular factors.
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The rapid development of renal transplantation and the proposal of allocation
schemes brought about the concept of organ sharing. It was soon realised that in
order to have a better match between the donor and recipient, wider pools of
recipients/donors were required. Thus, in 1967 Eurotransplant was founded, unifying
the activity ofGermany, The Netherlands, Belgium and Austria. Shortly after this the
United Network for Organ Sharing (UNOS) was developed in the United States
through collaboration between the 15 regional organ procurement organisations
(107). Other national organisations were soon developed in all countries with
transplant programmes in order to optimise the use of available donor kidneys.
a. Allocation of organs for transplantation in the US
In 1987 UNOS devised an allocation scheme largely based on a local system
developed by Starzl in Pittsburgh (108;109), which took into account the time of
waiting, the quality of antigen matching, the pre sensitisation state and the medical
urgency. There was mandatory national sharing of kidneys for recipients matched at
all six histocompatibility antigens. Since then, the system has been changed twice to
include kidneys with the same HLA antigens as the recipient even though fewer than
six antigens were identified (1990) and in March 1995 to include zero-A, B, DR-
mismatched kidneys from donors presumed to be homozygous - at least one Ag
identified at each donor locus - to zero-mismatched heterozygous recipients.
The current US allocation system stipulates that there is mandatory sharing of zero
antigen mismatch kidneys. ABO O kidneys should be transplanted only in O blood
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group recipients except in the case of zero antigen mismatch patients who have a
different blood group. The final decision to accept a particular organ rests with the
transplant surgeon/physician. Due to geographic conditions in the US, there is a time
limit of eight hours (defined as cross clamping of the donor aorta) for the offer to be
made to the appropriate recipient centre via the UNOS Organ Centre. Once a donor
has been registered, the potential recipients who have an ABO blood group
compatible with that of the donor, are assigned points (table 1.7) and prioritised
according to the following criteria:
1. Waiting time - The point calculation is conducted separately at three
geographic levels of allocation: local, regional and national.
2. Quality of antigen mismatch - Donors with only one antigen identified at an
HLA locus are presumed homozygous.
3. Panel reactive antibodies - points are allocated for PRA>80%, based upon
historical or current serum sample.
4. Medical urgency is used to allocate points only at a local level.
5. Paediatric recipients - these points are retained until the candidate reaches 18
years of age. A time goal has been set to transplant paediatric recipients {e.g.
maximum 18 months for those aged 11-17). If this time goal is not achieved,
those patients receive extra points and have the second priority, after the
highly sensitised patients (PRA>80%), for the non-shared kidneys.








0- A, B, DR mm
0- B or DR mm
1- B or DR mm
2- B or DR mm
Sensitisation 4 points >80% PRA and negative
crossmatch
Waiting time 1 point
fraction of a point
1 point/year
longest waiting in a blood
group category
all others (depending on
position on the waiting list)
each additional full year of
waiting
Medical urgency Points allocated only locally




Donation status 4 points Previous donation within US
Table 1.7 Current UNOS point system for cadaveric kidney allocation
For multiple zero mismatches for the same donor, tie points are allocated in a
descending sequence for identical blood groups first, and next to compatible blood
type. Within both groups, priority is given to local patients, followed by paybacks
(when more than 2 kidneys paybacks are accumulated) and then regional and
national lists, according to the degree of sensitisation.
Alternative local allocation systems, which weigh differently the national allocation
criteria, must be approved by the UNOS prior to implementation. These local
variances must demonstrate that they have a sizeable impact on patient waiting time,
graft survival and organ availability after three years in order to be validated.
Combined transplants (kidneys and other organs) obey the same zero antigen
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mismatch policy with only one kidney being shared together with the accompanying
transplantable organ.
The local and national impact of this new scheme has been extensively investigated
(110-116). In 1998, Hata et al. (113) published a comparative analysis of the three
major changes in the UNOS allocation system and their national impact. Despite a
limited follow-up period, the 1-year survival for zero-mismatched kidneys (latest
change) was similar to the other HLA-matched groups: 90% for six Ag mm, 87.3%
for phenotype match and 87.8% for zero mismatches. Significant changes were noted
in the percentage of matched kidneys that were transplanted. 17% of the HLA-
matched organs were transplanted to 6 Ag mm patients and 24% to phenotypically
matched ones. There was a significant increase in the access to HLA-matched
kidneys for minority recipients and this was mirrored by a similar change in the
racial distribution of donors of the HLA-matched organs. These results were
confirmed by other investigators (who also noted an increase in the number of long-
waiting recipients that have been transplanted) both at regional (111) and national
level (110).
b. Allocation of organs for transplantation in Eurotransplant
Since 1988, Eurotransplant (ET) used an allocation scheme which included a
mandatory exchange for 000 mismatched kidneys. The initial system was centre
oriented and was criticized for the high percentage of long waiting time patients,
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inequity of access for rare HLA phenotype patients and for a growing percentage of
transplantation programs with large exchange imbalances.
In 1993, Wujciak and Opelz (117;118) published the results of a computer simulated





> local transplant rate
> import/export exchanges
could achieve better results than the existing scheme. Therefore Eurotransplant
adapted their proposal and in March 1996 implemented a new kidney allocation
scheme (ETKAS). In this new scheme, patients are initially selected based on donor-
recipient ABO blood group compatibility (0 to 0+B groups, A to A+AB groups, B to
B+AB groups and AB to AB). Following that, patients are prioritised, the highest
priority being given to 000 mismatches, followed by high urgency recipients and
then the remaining elective patients. All candidates are assigned points on the same
five allocation criteria as XCOMB, which were adjusted for the ABO blood group
matching and PRA level according to the ET rules. A correction was applied to the
distance factor to incorporate the regional and national levels. Paediatric recipients
are defined as age <16 years and they receive waiting time bonus according to their
age: 3 years bonus for 0-5 years old, 1 year bonus for 6-10 years old and 2 years
bonus for 11-15 years old. After an initial 6 months, a further correction was applied.
Double HLA mismatch points were assigned for paediatric recipients and higher
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points were given to local patients compared with no points assigned for the distance
and balance factors for ET non-residents patients (table 1.8).
The new system does not include combined kidney-pancreas and kidney-liver
transplants as well as the acceptable mismatches and highly immunised patients, for
whom special programs are in place.
Initial results were published in 1998 (119), one year after the implementation of the
scheme and were compared with those obtained in 1995. There was no significant
change in the number of transplants performed in the two periods and no change in
the level of HLA immunization. Important changes were noted in the percentage of
long waiting patients who have been transplanted. There was a statistically
significant increase in the 2-4 year waiting group and more than a 100% increase in
the >5 year group. However this increase did not incorporate highly sensitised
patients who are currently not covered by this allocation scheme.
Significant changes were also noted in the matchability profile with more poorly
matchable patients being transplanted. Even in subgroup analysis, this positive effect
persisted, preventing the accumulation of rare HLA phenotypes or homozygous HLA
loci in the long run.
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Non-residents* No points for distance and balance
Table 1.8 Points system in the new ET kidney allocation scheme. * reflects changes
in October 1997
A sensitive issue was the international import-export balance with a fear that
Germany, which accounts for 75% of the Eurotransplant waiting list, would continue
to maintain a significant import surplus. However, after an initial period of four
months, equilibrium of the balance was attained and was maintained throughout the
study period, with variations between -20 and +20. Nevertheless, there was a sudden
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but transient fall in the activity of some transplant programs in certain countries since
maintaining an import-export balance among transplant centres was not one of the
main priorities of this patient-oriented allocation scheme.
The new system was found to be easily adaptable for various needs as was
demonstrated by the changes made for the paediatric patients and non-residents,
which were implemented without affecting the overall balance of the system.
c. Allocation of organs for transplantation in New Zealand and
Australia
In New Zealand, cadaveric kidneys were traditionally allocated by renal transplant
physicians on the basis of local needs and factors known to influence graft survival,
in particular HLA matching and the crossmatch results. This approach was not only
subjective, but also led to some patients waiting long periods mainly because of an
unusual tissue type. Therefore in 1999, a computer-based allocation scheme was
developed. In order to enlarge the likelihood of an excellent match, it was even
considered that New Zealand would join the Australian Allocation system, but
logistic, legal, financial and ischaemic time delays made this impractical.
In the first instance, the New Zealand allocation system (120) now takes into account
recipient factors affecting graft outcome (increased age, co-morbid conditions,
primary renal disease, previous transplants) to ensure an equitable access to the
waiting list for every patient. The level of sensitisation is not a factor per se, as it is
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believed that the length of time spent on the waiting list will be a good substitute
marker for it. The only donor factor taken into account is the age match, as it is
considered that in the setting of this country, the cold ischaemic time is unlikely to be
a significant issue.
As with all the systems described previously, the New Zealand allocation system has
the closeness of HLA matching between the donor and recipient as the prime
criterion. The scheme has three ranks (levels) of allocation and points are allocated
for rank 1 and 3 independently (table 1.9).
If the total score in rank 1 is less than 58 000, then kidneys will be allocated on rank
2 - if there are any suitable children (humanitarian grounds) or diabetics receiving a
simultaneous kidney-pancreas transplant - or rank 3, where consideration is given to
the HLA-DR matching, which is deemed more important than Class I matching. The
waiting time is taken into account only when two or more recipients have identical
scores by HLA matching.
The results of this new allocation scheme have not yet been published.
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Rank 1 allocation protocol 0,1,2 HLA mismatches
1. Initial score 60 000




3. Add time for each month* 0.1
Rank 2 allocation protocol Children with no potential live donor
Diabetic patients for SKP transplant
Rank 3 allocation protocol Remainder of the HLA matches
1. Age






3. Time points for each month* 0.3
Table 1.9 Points system in the New Zealand kidney allocation scheme. * recipient
waiting time
In October 1999, the Transplantation Society of Australia and New Zealand
published a revised allocation scheme for cadaveric donor organs in Australia (121).
After an initial elimination procedure based on ABO compatibility, HLA antibody
specificity, previous transplants with specific mismatched donor HLA Ag and
positive lymphocytotoxic crossmatch, the potential recipients are ranked by
weighting a number of factors relevant to graft survival. The allocation criteria are
weighted in the order shown in table 1.10.
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Matching criteria National score
Base score 60 000 000
1. HLA match group Deduct for each HLA-DR mm
Deduct for each HLA-A mm
5 000 000
1 000 000
Deduct for each HLA-B mm 1 000 000
2. Sensitisation Add for each Pkab>50% 10 000
3. Waiting time on
dialysis
Add x no. Months dial 100
4. State exchange
balance
Add x state exchange balance 10
5. Paediatric bonus Add for paediatric patient 30 000
Table 1.10 Points system in the Australian kidney allocation scheme.
There is mandatory exchange of kidneys with 000 HLA mismatches (level 1).
Kidneys with 1 HLA-A or B but not DR mismatches (level 2) are exchanged if the
balance of exchange is greater than 5 and the recipient has greater than 50% peak
PRA and a negative crossmatch, while kidneys with 2 HLA-A or B but not DR
mismatches (level 3) are shared if the exchange balance is greater than 10. Each
Australian state has its own allocation policy for kidneys that do not fall in the best-
matched groups (level 3 patients, who score less than 58000000 on the national HLA
matching scheme). These schemes are also based on the HLA mismatches but take
into account a variety of other factors (waiting time on dialysis, medical urgency,
recipient fitness, donor-recipient CMV status).
The new Australian allocation protocol was introduced in October 1999 and results
are yet to be published.
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d. Allocation of organs for transplantation in the United Kingdom
On the first of July 1999, after extensive computer modelling, the United Kingdom
Transplant (UKT) special authority introduced a new allocation scheme (17). This
scheme acknowledged the degree of HLA matching as the main factor of the
distribution system and assigned the potential recipients in three groups. Full match
(000 mismatch) represent Tier 1 group, those with other favourable matches (100,
010, 110, 200, 020) form the Tier 2 group, while the unfavourable matches are
grouped under the Tier 3 heading. Priority is given to local patients versus national
ones and to highly sensitised patients (PRA>60%). Both adult and paediatric organs
are initially offered to paediatric recipients (table 1.11).
Adult organs Paediatric organs
Tier 1 Child HSP Local Children Tier 1 HSP Local
National National
Child Non-HSP Local Non-HSP Local
National National
Adult HSP Local Tier 2 Local
National National
Adult Non-HSP Local Tier 3 Local
National National






Table 1.11 New UK kidney allocation scheme priority order. (HSP= highly
sensitised patient)
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A points system is used if more than one patient satisfies the initial criteria. Points
are allocated for the length of waiting time, for the degree of sensitisation, for the
recipient age and donor-recipient age difference and for the centre balance of
exchange (table 1.12).
Criteria Criteria range Points Aim
Recipient age Old to young 1-10 points Favours younger recipients
Donor/Recipient
Age Difference
Large to small 1-10 points Avoids large age difference
Waiting time Short to long 0.5-5 points Favours longest waiting
Matchability Easy to hard 1-10 points Favours rarer HLA types
Sensitisation High to low 0.5-3.5
points
Favours low sensitisation
Avoids +ve cross matches
Balance of
exchange
Low to high 1-10 points Favours higher centre
balance
Table 1.12 Points scoring mechanism used by the UK donor organ sharing scheme.
The initial results were presented at the British Transplantation Society meeting in
March 2000. There was a 9% increase in the number of fully or favourably matched
adult transplants compared with the previous year. This was associated with an 18%
increase in organ exchange among the transplant centres. A 14% increase in Tier 1
and 2 transplants was observed in the paediatric group, where 26% more organs were
exchanged. This change was not associated with a significant increase in the length
of the cold ischaemic time, but there was a small statistically significant difference
47
(p=0.03) between local transplants and imported organs. The report also highlighted
that there was no significant effect of points scoring factors and no change in the age
distribution of the transplanted patients. As a result of this analysis, two
improvements to the scheme were introduced. The first one was a prioritisation of
HLA-DR homozygous patients for HLA-DR homozygous donor kidneys and the
second one was the initial offering of the second adult kidneys to national paediatric
recipients before locally matched adults.
A two-year analysis (122) confirmed that HLA matching improved significantly for
adults and children and for both first and re-graft recipients. There has been a three
fold increase in the number of HSP 000 mismatch grafts, donor-recipient age
differences have decreased and the matchability point scoring seems to have the
desired effect of transplanting more patients who are difficult to HLA match.
However, it was noted that the adults transplanted through this new scheme are
younger than previously, and therefore further monitoring is required to investigate
whether there is a bias towards younger patients.
e. Regional alliances and allocation of organs for transplantation in
Scotland
A significant development in the allocation of organs in UK was the creation of
regional sharing alliances. The purpose of these alliances was to optimise the local
use of kidneys, increasing the sharing of well matched organs with a minimal impact
on the length of cold ischaemic time. The alliances have a unified waiting list and act
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as a single organisation in the exchange of kidneys with the national pool managed
by UKT. They represent an additional kidney sharing level, participating centres
exchanging well matched kidneys at this regional level, before offering them to the
national organisation. At the moment there are 6 regional alliances in UK (table 1.13)









Lacks a point scheme
Lacks a point scheme
Based on the national scoring system
Own scoring system
Based on the national scoring system
Based on the national scoring system
Table 1.13 Regional alliances in UK and local points scoring systems
In April 1997, Aberdeen, Dundee and Edinburgh formed an alliance in the South-
East of Scotland. This was prompted by several reasons. Firstly, there was evidence
suggesting that in the current era of modern immunosuppression, matching for
anything less than a full house match (000 mismatch) had little impact on outcome
and therefore placing the kidney with a slightly poorer matched recipient, but with a
shorter cold ischaemic time, may produce a good outcome. Secondly, South East of
Scotland had a highly positive balance of exchange with the national pool. Thirdly, a
major determinant as to the fate of the kidney is in the size of the waiting list in a
particular area, and therefore the alliance would ensure a better distribution of locally
retrieved as well as UK shared kidneys.
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The alliance had its own internal scoring system based on HLA matching, length of
time on the waiting list and recipient age. At least one of the kidneys retrieved
locally was retained within the alliance (both if there was a significant positive
balance of exchange with UKT) and offered sequentially to patients from the unified
waiting list, ranked in order of their points scoring. The alliance functioned in this
format until 1st of September 1999, when Glasgow and Northern Ireland joined in to
form the Scotland-Northern Ireland Alliance. The start date allowed for the new
National Allocation Scheme to be implemented and used as a base for the new
alliance's activity. The regional scheme applies to kidneys identified within the
alliance, which are initially offered to the participating centres before being offered
nationally. All kidneys retained locally are allocated according to the national Tier 1
and Tier 2 criteria set in table 1.11, while for Tier 3, kidneys are first offered to HSP
(>85% PRA) patients. In the event of ties, waiting time is used as a factor, but the
ultimate discriminator is the distance between the retrieval and transplant centre.
Since the introduction of the Alliance, there have been two changes in the sharing
protocol, first to incorporate the offering of kidneys with cold ischaemic time in
excess of 20 hours back to the retrieval centre into their local scheme and second to
permit blood group compatible matches for well HLA matched children.
In summary, most organ sharing networks throughout the world allocate cadaveric
kidneys in a similar manner, although the exact scoring systems vary. Despite the
continuous debate, HLA matching remains the main allocation criteria in most
systems, but other significant factors (waiting time, sensitisation, age, geography) are
given the appropriate weight in order to make a system equitable and useful.
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Allocation algorithms must be dynamic and allow for changes in population
demographics as well as the social and ethical needs of a particular society.
Nevertheless, one has to bear in mind that any allocation policy deals only with the
last step in the pathway to transplantation and to reach this stage, a patient must have
access to a renal replacement centre, be referred and have a thorough assessment and
finally listed, if considered suitable for transplantation.
1.6 ACCESS TO TRANSPLANTATION
Access to transplantation is a very important topic for the renal patient and the
transplant community. Despite general agreement on surgical technique, organ
preservation, transplant immunology and immunosuppression, the way we select
patients onto the renal transplant waiting list is still subject to wide debate.
With the current shortage of donor organs, it is inevitable that some groups of
patients will be discriminated against in gaining access to transplantation (123-126)
and despite the philosophical arguments, this is widely regarded as unacceptable.
Several studies have confirmed that gender-based disparities documented in the use
of other medical services, such as cancer-screening tests (127), cardiovascular
procedures (128) and treatment for HIV (129), also exist in access to the renal
transplant waiting list and renal transplantation (124-126; 130-132).
It has been argued that the higher proportion of men that are transplanted is simply
due to their increased requirement of renal replacement therapy and there is no
evidence of unintentional discrimination (133). Most authors would now agree that
although this is a genuine observation, it is a rather simplistic explanation. It has
been hypothesized that differences in health and socio-economic status may be partly
responsible (123;124;134), but these factors, although reducing the magnitude of the
disparity when taken into account, do not fully explain the lower listing and
transplant rates noted among female patients (130; 135). Several investigations have
shown that men and women are referred at similar stages of renal failure (136) and
the incidence of non-compliance or psychiatric illness is similar in both genders
(137) and hence do not stand as pertinent explanation for these differences. In
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addition, concerns about outcome after transplantation are not likely to be
explanatory as patient and graft survival are comparable for both genders
(21; 138; 139). Some have speculated that a few of the gender-based differences, in
particular the longer waiting time for a transplant after listing may be a result of
differences in antibody status between men and women (124). Little is known about
gender differences in patient or family preferences for transplantation and although
studies have not shown a lesser preference for transplantation among women (140),
there is scope for further research on this subject. Finally, the possibility of a gender
bias by health care providers has been demonstrated for other medical therapies
(141) and raised in transplantation by a study indicating that women are less likely to
be identified as potential transplant candidates by renal unit staff (131). Although a
specific cause for gender differences has not yet been identified, undoubtedly, the
explanation is complex and most of the above factors have an intrinsic role. It is
likely that variables which are difficult to quantify or insufficiently explored (such as
patient preferences, attitudes and beliefs, the role of education and employment
status and the provider bias), rather than biologic and clinical differences are
responsible for the reduced access to transplantation for female patients.
Even greater differences in access to health services were reported according to the
patient's race (128; 141). Ethnic minorities, and in particular those of African origin
have a significantly higher risk of renal disease (142), which is doubled by a lower
chance of being listed for transplantation and receiving a kidney transplant compared
with white patients (123; 126; 132; 143). These differences have been documented for
over a decade and several explanations have been advanced. Some of the reasons lie
with the socio-economic and educational disadvantages often encountered by these
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patients (144), but even after a fully informed choice of the treatment options and a
clear preference for transplantation (145), further access to a kidney graft is much
slower than for white patients (146). It has been argued that racial disparities reflect
underlying clinical differences, as black patients are more difficult to match and are
more likely to have a positive crossmatch than similar white recipients, precluding
transplantation from a given donor (147). In addition, due to various non-
immunologic (more uncontrolled hypertension, higher rate of non-compliance) and
immunologic (higher incidence of delayed graft function and acute rejection
episodes) factors, transplant results are poorer in black recipients (148).
Other factors such as subconscious bias or financial disincentives for the health care
providers as well as regional variations in the matching algorithm may also play a
role (123; 148), but require further study. The lower transplant rates observed in
certain ethnic minorities have been linked with the lack of suitably matched donor
organs. This is partly due to lower donation rates among these groups which may be
explained by cultural problems with brain stem death (BSD) diagnosis rather than
religious constraints (as most religions have accepted BSD). Several initiatives to
increase donation rates in these ethnic groups and allow more patients to be
transplanted have been proved to be successful (149).
Many transplant centres are reluctant to accept elderly patients on their waiting lists
(125), as they are frail, have a higher comorbidity index (150) and a lower life
expectancy. An increased age has a significant impact on long-term graft survival
and more than 40% of the grafts in elderly recipients are lost due to patient's death
(150; 151). In the current shortage of organs this has been viewed by many as a waste
of organs which could otherwise be suitable to younger patients. Nevertheless, as the
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number of elderly requiring RRT is progressively increasing and the evidence of
transplantation being a safe and successful procedure is mounting (152; 153), the
attitude towards the age criteria has been revisited. Nowadays it is largely agreed that
age per se does not represent a contraindication to transplantation and a careful
evaluation of the older candidate and tailored post-transplant management may allow
for further expansion of indications for grafting in this particular age group.
Similarly, there are differences in access to transplantation according to the primary
renal disease. In particular diabetic patients are markedly disadvantaged both for
listing and transplantation (143). It has been argued that these patients have a higher
comorbidity index pre-listing, associated with an increased risk of developing further
complications once listed, which precludes them from being a transplant recipient.
A low income has been shown to reduce the likelihood of completing the
transplantation process (123). Although the transplant outcome is not influenced by
poverty (154), it has been suggested that these patients have an overall poorer access
to health care, are more non-compliant and are less likely to appreciate the
advantages of transplantation. Therefore, they may not be good advocates for
themselves when it comes to choosing the best treatment option (146).
It is not surprising that patients with certain comorbid conditions have a lower access
to transplantation, but unfortunately, this is not the sole explanation of the substantial
differences in access noted for various age, gender, race and socio-economic groups.
In addition to the factors already mentioned, other issues such as religion, fear, lack
of knowledge my be responsible for some of the differences noted at different stages
of the transplantation process.
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The identification of these potential barriers on the way to transplantation will allow
a more focused research into ways to overcome their causes as well as producing
standardized listing criteria which could be an important step towards correcting
some of the disproportions noted in the current system of access to renal
transplantation.
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1.7 ASSESSMENT FOR TRANSPLANTATION
The assessment process is an important stage which will ensure that a patient is fit to
undergo transplantation. This process must not be used as a cloaking device to
exclude patients on the grounds of age, race, gender or other demographic or socio¬
economic factor. It should rather be an evidence-based process, which assesses the
risk of each comorbid condition exhibited by individual patients and provides useful
information regarding the operative risk and the chances of a successful long-term
outcome. At the end of this process, the patient should be advised about the risks and
benefits of transplantation and a decision regarding the best therapeutic approach to
follow should be reached.
Each transplant candidate is unique and faces distinct clinical and psycho-social
challenges and therefore it is not possible to design a comprehensive assessment
process to meet the needs of every single patient. On the other hand, the large
amount of often conflicting information relating to the evaluation of a transplant
candidate has lead to significant practice variations (155; 156) and highlighted the
need for a standardized approach and universally accepted listing criteria. Some
clinical practice guidelines have been issued, in an intent to address some of these
differences (18; 157).
As we are getting better in managing difficult cases and as the demographics of the
RRT population are rapidly changing, the assessment process is likely to evolve to
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allow an increased number of patients with complex medical history to be accepted
for transplantation. Therefore any set of guidelines must be reviewed and updated on
a regular basis to keep pace with these changes.
The fundamental role of the assessment process is to identify the comorbid diseases
which are likely to adversely affect the outcome and to determine whether the risk
factors will render transplantation less effective than dialysis. Once the need for
transplantation has been established and the patients have indicated their willingness
for transplantation, they should undergo a detailed clinical evaluation (figure 1.13).
The presence of a cancer must be ruled out as it is generally accepted that
immunosuppressive therapy increases the aggressive nature of any tumour. A waiting
period between the cancer treatment and transplantation longer than 5 years would
exclude 87% of the patients who would develop a recurrence, but this may not be
practical in elderly candidates where shorter waiting times (e.g. 2 year waiting time
eliminates 53% of recurrences) may be more appropriate (158).
Patients should be screened for the presence of overt or occult infections (urinary
tract infections, dental caries, dialysis access sites, tuberculosis) and any focus
should be eradicated prior to acceptance onto the waiting list. At present, HIV is an
absolute contraindication to transplantation because most of the HIV positive
patients undergoing transplantation have fared badly (159). The viral status of the
patient, in particular CMV and EBV viruses, should be determined as effective
























Figure 1.13 Overview of the assessment algorithm (adapted from (18))
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Patients suffering from certain renal diseases such as Wegener's granulomatosis,
focal segmental glomerulonephritis, IgA nephropathy, type I membrano-proliferative
glomerulonephritis, to mention just a few, have a well defined risk of disease
recurrence in the transplanted kidney which can be as high as 50%. These patients
must be advised of the risks and if transplantation is unlikely to produce a significant
benefit over dialysis. The decision whether listing is appropriate should involve the
patient and the whole transplant team.
Symptoms and/or liver enzymes abnormalities should prompt further investigation.
There is controversy surrounding the need for pre-transplant cholecystectomy, but
with an increased risk of life-threatening cholecystitis after transplantation (161) it
may be prudent to recommend that diabetics with gallstones or patients with
persistent symptoms should be considered for surgery prior to transplantation.
Similar controversies surround patients with positive hepatitis viruses. There is some
evidence to suggest that both hepatitis B (162) and hepatitis C (163) patients are at
increased risk of dying in the post-transplant period, but the exact risk has not yet
been determined, and therefore transplantation is generally recommended in these
patients. However, patients with evidence of active viral replication or patients who
are hepatitis delta positive may best decide against transplantation as they are at very
high risk of disease progression (164).
There is little information about assessment for patient with respiratory diseases
(other than pulmonary infections) but the same principles for the preoperative
evaluation as for any other type of surgery would apply (165). There is general
agreement that patients with controlled asthma or chronic obstructive pulmonary
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disease can be transplanted, while smoking increases the risk of surgery as well as
the risk of cardiovascular diseases (166) and graft failure (167).
Cardiovascular diseases including acute myocardial infarction, cardiac arrhythmias,
heart failure, cardiomyopathy and stroke are the leading cause of death following
transplantation, accounting for over 50% of death in these patients (168). Mortality
rates from coronary disease for transplant recipients are 25-fold greater than that of
an age and gender matched population (169). Furthermore, the risk of cardiovascular
events is not just a result of the early post-transplant events, but tends to accumulate
over time. Previous studies have identified several risk factors including age,
diabetes, hypertension, hypercholesterolaemia and cigarette smoking (170) as well as
pre-existing diseases including coronary heart disease, peripheral vascular disease
and cerebrovascular disease (168; 171). The identification of the risk factors as well
as pre-existing diseases allows for a risk stratification of the prospective transplant
recipients and for more complex investigations such as isotope myocardial perfusion
scanning or dobutamine echography, coronary angiography and intracoronary
ultrasound to be performed only in those considered at high risk (172). In addition,
the identification of pre-transplant cardiac diseases and risk factors allows for timely
risk modification intervention strategies, which could lead to a successful
management of the cardiovascular risk and prolongation of patient and allograft life
(173). The use of ACE inhibitors to lower the blood pressure, of statins to lower the
lipid levels, glucose control, aspirin prophylaxis and smoking cessation may
favourably influence the incidence of cardiovascular diseases (174; 175). Despite an
increased risk of cardiac surgical procedures in renal failure patients (176), it has
been suggested that patients with critical coronary lesions should undergo
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revascularization (angioplasty, stenting, by-pass surgery) prior to transplantation
(177), as it leads to a lower post-transplant risk of cardiovascular events.
There is an increased risk of cerebral vascular disease after renal transplantation
(170) and patients who already have a history of cerebrovascular disease should be
advised and the risk factors should be addressed. Patients with transient ischaemic
attacks or other evidence of cerebral vascular disease should be referred for
neurological assessment and treatment and transplantation should be undertaken only
after a minimum symptom free period of six months (18). There is no evidence to
suggest that screening renal transplant candidates with asymptomatic carotid bruits
for cerebral vascular disease is beneficial and no firm recommendations have been
made so far for their management.
The incidence of peripheral vascular disease (PVD) in renal transplant candidates is
high (18; 178), but the evidence analysing the impact on clinical outcome is scarce
(179). Peripheral vascular disease, and in particular aortoiliac disease can pose
significant technical problems and therefore symptomatic PVD should be
investigated by a pretransplant angiogram and surgical reconstruction carried out
before or even at the time of transplantation (180).
Psychological and social issues are very important in transplantation. A patient
should be able to give an informed consent for the procedure and must have the
capacity to adhere to the strict post-transplant medication regimen. The assessment
procedure will identify issues such as personality disorders, psychosis, substance
dependence or abuse, which are likely to affect compliance (181;182) and patients
should be referred for evaluation and treatment prior to listing. It is generally
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accepted that appropriate psychiatric treatment can and should eliminate the barriers
to transplantation in this group of patients (181).
Particular attention in the assessment process must be paid to those patients who
have developed renal failure due to urinary tract problems. A comprehensive genito¬
urinary work-up (ultrasonography, voiding cystourethrogram, cystoscopy, retrograde
pyelograms) and urological expertise are necessary in these patients to ensure the
problem will no longer be present to damage the transplanted kidney (183).
Gastrointestinal diseases present in a transplant candidate should be documented at
the assessment clinic, as they can complicate the post-transplant course. Colonic
complications occur in about 2% of the transplanted patients, but screening should be
reserved only for those with previous episodes of active diverticular disease or
inflammatory bowel disease (18). It is important to mention that there is no
demonstrable increase in the risk of colon cancer after transplantation, but there is
insufficient data for those already at risk, such as ulcerative colitis patients. Many
studies have demonstrated an increased incidence of peptic ulcer disease in the renal
failure population (18-40%) with a significant impact on the comorbidity in the post-
transplant period. This has prompted some centres to advocate the routine use of H2
receptor blocker treatment and surveillance endoscopy (184). Little data is available
for the impact of pre-transplant pancreatitis, but any reasonable cause should be ruled
out during the assessment process, as a relapse post-transplantation is often
associated with high morbidity and mortality (185).
Obesity is a well-defined risk factor for post-transplantation morbidity and a body
mass index (BMI) of less than 30 has been suggested by some as a prerequisite for
placement on the waiting list (186). Secondary hyperparathyroidism, particularly if
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symptomatic, should be treated surgically prior to admission onto the waiting list
(18).
Advanced age and diabetes pose a higher risk for transplant failure and in these
groups of patients, the threshold for investigations for all of the conditions
highlighted above should be low. Eligibility for transplantation should be judged on
the overall clinical condition of the patient and not based solely on the belonging to a
particular high-risk group.
Once the assessment process is completed, several blood and tissue typing tests
should be carried out to determine the compatibility of the recipient with a potential
donor and to ensure that the candidate is immunologically acceptable for the waiting
list.
The assessment process may be long and time-consuming, but addressing all the
issues highlighted in this synopsis will ensure a successful listing and a better
outcome for the patient and the renal allograft.
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SUMMARY AND AIMS OF THE STUDY
Transplantation has seen a huge progress during the last three decades. Despite that,
the service is under tremendous pressure due to increasing demand but a limited
supply of donor organs. This has highlighted, yet again, a series of controversial
issues concerning organ allocation, equity of access, standards of the assessment
process and appropriateness of transplantation in certain groups of patients.
There is virtually no data on these issues in the Scottish renal transplant setting and
therefore the aims of this thesis are to provide a comprehensive picture of the current
status of the service and to identify areas where improvements are required to make
it more accessible and successful. Consequently, this thesis aims to answer the
following questions:
1. What are the benefits of the current allocation schemes and the influence
of the new regional Scotland - Northern Ireland Alliance on the
transplant activity?
2. Is there equity of access to the transplantation service? If not, which are
the sociodemographic and comorbidity factors which may be
responsible for these differences?
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3. Does transplantation provide a survival advantage over dialysis in
various renal failure subpopulations? Is there any benefit in transplanting
high-risk groups ofpatients?
4. Are there any differences in the assessment process? Can the risk factors










The success of transplantation as a form of treatment for end-stage renal disease has
contributed to increasing numbers of patients on the waiting list. As has been
demonstrated, this increase over the years has been exacerbated by a fall in the
number of available cadaveric kidneys. The shortage of organs has prompted the
need for improved allocation schemes and the new systems, which have been
implemented worldwide, showed encouraging results (110; 187).
On the 1st of July 1998, after a multifactorial analysis and computer modelling, the
national transplant authority (UK Transplant) introduced a new allocation scheme in
the United Kingdom (17). The new scheme allocates adult cadaveric donor kidneys
to ABO identical recipients based on three tiers ofHLA matching (table 2.1).
Full house match Favourable matches Non favourable matches






One or two HLA-DR
Definition
No HLA mismatches and/or two
mismatches mismatches for HLA-A
and/or HLA-B
Mismatches 000 100,010,110 All other matches
Table 2.1 Levels ofmismatches for the UK donor organ sharing scheme.
68
At each level priority is given to paediatric over adult, highly sensitised (PRA >
85%) over non-sensitised, local over national recipients respectively. In Tier 1 both
kidneys are offered to patients with 000 HLA mismatches (if two such patients
exist), while in Tier 2 only one kidney will be made available for national allocation
when there are no patients (or one patient only) in either Tier 1 or Tier 2 on the local
list. Tier 3 kidneys may be retained for local use, but if no suitable recipient is found,
they are offered nationally through UKT to the unit with the highest balance of
exchange. When two or more equally matched patients are identified for any kidney,
a points scoring mechanism is used as a discriminator to determine the recipient
(table 2.2).
Criteria Criteria range Points
Aim
Recipient age Old to young 1- 10 points Favours younger recipients
Donor/Recipient
Age Difference Large to small
1 - 10 points Avoids large age difference
Waiting time Short to long 0.5 - 5 points Favours longest waiting
Matchability Easy to hard 1--10 points Favours rarer HLA types
Sensitisation High to low 0.5--3.5 points Favours low sensitisation
Balance of exchange Low to high 1 - 10 points Favours higher centre balance
Table 2.2 Points scoring mechanism used by the UK donor organ sharing scheme.
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In case of a tie between patients following the points score, the shorter transport time
between the retrieval and recipient centre will be used to make the final decision. The
introduction of this new donor organ sharing scheme has encouraged more centres to
join or create new sharing alliances in an attempt to optimise regional waiting lists,
organ procurement activity and distribution, decrease ischaemia time and improve
the access to transplantation.
A recent analysis of the first two years of this new scheme (188) suggested that the
aims of improving exchange rates of favourable matched kidneys between centres,
reducing the waiting time on the waiting list for difficult to match recipients and
ensuring fair access to the service have been achieved. However this analysis does
not take into account the fact that in UK there are several regional alliances, which
may produce significant variations in the transplant activity at a regional level.
Furthermore, some of them do not use the national sharing criteria in allocating
cadaveric organs and hence a pooled national analysis may not reflect the true
magnitude of the changes for a particular area.
The new Scotland-Northern Ireland alliance is one of 7 regional kidney sharing
alliances existing in UK in 2001. The alliance was formed in August 1998, unifying
the activity of the former East Scotland Alliance, which included Edinburgh, Dundee
and Aberdeen with that of Glasgow and Belfast. In November 1999, the Dundee unit
merged with Edinburgh, so that the alliance has four centres with a catchment
population of 6.6 million. The alliance territory is divided into four retrieval zones
covered by the participating transplant centres - Aberdeen and Edinburgh for the
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East of Scotland, Glasgow for the West of Scotland and Belfast for Northern Ireland.
Kidneys may be procured in non-transplanting hospitals by a transplant team from
the regional centre and are counted towards the balance of exchange of that centre.
All donor organs are allocated through the standard national allocation system,
described earlier, and run by United Kingdom Transplant (UKT). For all imports and
exports of cadaveric kidneys the alliance acts as a single organisation with a single
transplant waiting list.
One of the main concerns within the new established alliances was the potential
imbalance of activity, which could arise due to the different sizes of the participating
centres. This is one of the main reasons why many UK centres have opted to stay out
of regional alliances. The Scotland-Northern Ireland alliance unifies the activity of
two small centres - Aberdeen and Dundee (performing less than 25 transplants per
year), two medium size centres - Edinburgh and Belfast (25 to 50 transplants per
year) and one large centre - Glasgow (more than 50 transplants per year) and
therefore represents an ideal model to investigate this issue.
We were interested to analyse the results of the new alliance and to investigate:
1. Whether there is an increase in the number of very well matched kidney
transplants
2. The effect of a regional sharing alliance on the length of cold ischaemic time
3. Whether there are any positive or negative effects on the activity of a large
transplant centre




Data regarding the activity of the alliance is collected prospectively, at the moment
of retrieval and allocation and stored in a computerised database at UKT. An analysis
was carried out for the first two years of activity (1st of September 1998 to 31st of
August 1999 and 1st of September 1999 to 31st of August 2000) and compared with
the results of the last pre-alliance year data (1st of September 1997 to 31st of August
1998). Prior to September 1998, all kidneys were exchanged through the national
system, and not directly between centres. In order to perform a meaningful
comparison and to illustrate the impact of forming a regional alliance on the balance
of exchange, all kidneys shared between centres in the pre-alliance period were
counted towards an "alliance internal balance of exchange". In other words, the four
centres were considered as part of an alliance, although technically the organ sharing
activity took place through the United Kingdom Transplant.
Information regarding retrieval and transplant activity, the internal balance of
exchange, the balance of exchange with UKT, the degree of HLA matching, the
number of kidney offers and their outcome as well as the cold ischaemic time (CIT)
and graft survival were analysed.
Chi square, unpaired sample Student-t test, Fisher exact test and Log rank test were
used to estimate the statistical significance of any differences. All statistical analyses
were done with the SAS software package (version 9).
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2.3 RESULTS

























; | Kidneys identified
H Kidneys not used
□ Kidneys retained locally
□ Exported to UKT
□ Imported from UKT
I Exported to Alliance
□ Imported from Alliance
□ Kidneys transplanted
Figure 2.1 Overview of the Scotland-Northern Ireland alliances' activity for the
three year period (1.09.1997 - 31.08.1998, 1.09.1998 - 31.08.1999 and 1.09.1999 -
31.08.2000)
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2.3.a Retrieval and transplant activity
The population of the alliance has been stable throughout the study period, around
6.61 million people (table 2.3). 183 donor kidneys were identified as being
potentially suitable for transplantation in the first year of the alliance (1st of
September 1998 and 31st of August 1999), giving an average of 13.9 donors per
million population (pmp), slightly above the UK average for the same period (13
donors pmp). This level of activity was similar to the pre-alliance year, when 180
kidneys were identified (13.6 donors pmp). Only 167 kidneys were identified in the











Pre-alliance year 6.61 180 90(13.6) 158
Year 1 6.61 183 92(13.9) 164
Year 2 6.61 167 85 (12.8) 186
Table 2.3 Alliance's population (millions), number of kidneys retrieved, number of
donors per million population and number of transplants performed in the first two
years of activity and the previous year.
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There are significant centre variations in retrieval activity over the three-year period
as shown in figure 2.2.
Aberdeen Belfast Edinburgh Glasgow Dundee Total
□ Pre-alliance year DYearl a Year 2
Figure 2.2 Retrieval activity for the alliance and each centre over the three year
period
The donations rates ranged between 7.5 pmp in Dundee in alliance's second year of
activity and 26.7 pmp (twice the national rate) in Aberdeen in the first year of the
alliance. Detailed data for each period and centre are shown in the appendix, table
A.7.a-c, page 334.
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While the retrieval activity decreased, over the two-year period there was an 11 %
















Aberdeen Belfast Edinburgh Glasgow Dundee Total
□ Pre-alliance year DYearl a Year 2
Figure 2.3 Transplant activity for the alliance and each centre over the three year
period
The highest increase was noted in Aberdeen (the smallest centre) where the number
of transplants doubled (21 compared with 11). A 40% increase in the number of
transplants performed was noted for the largest centre (Glasgow) in the second year
of the alliance, mainly due to kidneys imported from UKT. Detailed information on
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the transplant activity for each centre are shown in the appendix, table A.7.a-c, page
334.
The destination of the retrieved kidneys is illustrated in figure 2.4. With the
introduction of the new alliance, there was a significant increase in organ exchange
(p=0.0001, x2)- 135 kidneys (79%) have been shipped out of the retrieving centre in
the first year, 69 being used within the alliance and 66 exported to UKT, while in the
second year, 123 kidneys (77%) were shipped out, 74 within the alliance and 49 to
UKT.
□ Retained locally ■ Exported UKT □ Exported Alliance
Figure 2.4 Destination of kidneys retrieved in each of the three year period
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As expected, there are significant centre variations (table A.8.a-c, appendix, page
335). In the pre-alliance year, Dundee, the smallest centre, exported all retrieved
kidneys, while Glasgow, the largest centre, retained 67% of the organs retrieved. The
remaining centres retained between 18% and 44% of the kidneys harvested.
Although the introduction of the alliance has altered these proportions significantly,
(table A.8.b-c, appendix, page 335) the largest centre still retained nearly 45% of the
organs retrieved, in contrast with all the other centres which shared more than 50%
of organs with the rest of the alliance.
2.3.b Balance of exchange with the national pool of organs
In the pre-alliance year, all centres were exporting kidneys to the national pool of
organs, the overall balance of exchange of the alliance being +13. This trend
continued in the first alliance year with a positive balance of +9. However, in the
second year the alliance has imported more kidneys than it has exported (negative
balance of -28) to compensate for the positive balance from the previous two years
(figure 2.5). More than half of the kidneys imported in the second year went to the
largest centre.
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Pre-alliance Year 1 Year 2
□ Export to UKT B Import from UKT
Figure 2.5 Alliance balance of exchange with UKT for each of the three year period
The individual centre balance of exchange with the national pool of organs varied
between -2 to +6 in the pre-alliance year and -34 to + 6 in the following two years
(figure A.2.a-c, appendix, page 336-337). Before February 2000 the balance was
calculated on all exchanges of the previous three years, including kidneys exported
for paediatric recipients. However, in February 2000 a new calculation method was
introduced counting only kidneys exchanged for adult recipients in the previous two
years. Therefore, at the end of the study, on the 1st of September 2000, the individual
centre balance of exchange with UKT varied from -45 to +9. There is a significant
centre disproportion, the largest centre being a net importer with an increasing
negative balance, while all other centres are net exporters (figure 2.6).
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Aberdeen Edinburgh Glasgow Belfast Dundee
□ Export to UKT B Import from UKT
Figure 2.6 Individual centre balance of exchange with UKT at 1st of September
2000.
2.3.c Internal balance of exchange
The internal balance of exchange accounts for the organs exchanged among the
participating centres but not for those organs that are transplanted in the retrieving
centre. Details for the annual balance of exchange are given in the appendix, table
A.9.a-c, page 338. On the 1st of September 2000, due to the change in balance























Export to Alliance □ Import from Alliance
Figure 2.7 Inter-centre balance of exchange on the 1st of September 2000 (end of
study).
There is a similar centre disproportion as seen in the external balance of exchange,
the largest centre being a constant importer of kidneys from all other centres.
2.3.d Kidney offers
With the introduction of the alliance, there
kidneys offered for transplantation to the
translates in 2.4 offers per available kidney
was a 3-fold increase in the number of
participating centres (table 2.4). This
in the pre-alliance year, 2.85 in the first
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year and 3 in the second year. Details on the offers made to individual centres in the
three year period are given in the appendix, table A. lO.a-c, page 339).
XT , » xr u x- Number of kidneys CentreNumber of Number of
x \Year , ., ~ , accepted and not variationkidneys offered kidneys accepted r d(0/) (°/)
Pre-alliance year 73 49 19(38) 17-80
Year 1 197 103 34(33) 6-46
Year 2 222 97 23 (23) 9.5-33
Table 2.4 Number of kidneys offered within the alliance, accepted and accepted
and not used (excluding those retained locally)
Over the three year period there was a significant reduction in the proportion of
kidneys which were accepted and not used, from 38% in the pre-alliance year to 23%
in the second alliance year (p = 0.031, x2)- There is however, a persistent centre
variation (17-80% in the pre-alliance year, respectively 9.5-33% in the second year)
(table A. lO.a-c, appendix, page 339) and various causes may be accountable for it.
A positive crossmatch at the receiving centre remains a significant cause for organ
re-allocation throughout the three year period (table 2.5). 63% of the kidneys that
were accepted and not used in the pre-alliance year had a positive crossmatch at the
recipient centre, these levels being maintained in the subsequent 2 years (67% and
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61% respectively). As shown in table A.ll.a-c (appendix, page 340), there are
significant centre variations throughout the study period.
Kidneys
Centre accepted and not
used
Kidneys not accepted












Year 2 23 14 61 (33-75)
Table 2.5 Kidneys accepted and not transplanted due to positive crossmatching at
the receiving centre
2.3.e HLA matching
One of the declared aims of the new allocation scheme was to improve the quality of
HLA matching. An analysis of the degree of HLA matching found a significant
improvement (p=0.01, % ) during the first two years of the alliance compared with










Figure 2.8 % HLA matching for transplants performed within the alliance in each
year of activity
By the end of the second alliance year there was an 11.5% increase in the number of
fully matched transplants (Tier 1) and an 8.5% increase in the number of favourable
ones (Tier 2).
A comparison with the national figures (188) demonstrates that only 64% of the
transplants performed in the whole of the UK were very well matched (Tier 1 and
Tier 2) in contrast with 79% of the transplants performed in the alliance (table 2.6).
The difference is highly statistically significant (p=0.0001, y2).
Pre-alliance year Year 1 Year 2




Period , ° i° * % Tier 1 % Tier 2 % Tier 3 by thetransplants . . .^
retrieving
centre
Alliance activity ~s9 9n ,Q 91 ?9
(Sep 1998-Aug 2000)
UK activity* 10 C1
(July 1998-June 2000) 2377 13 51 36 56
Table 2.6 Comparison of Alliance and UK results for the first two years of activity
following the introduction of the new allocation scheme (% transplants in each Tier
group) (* UK Transplant Bulletin 2000; 38: 10-11)
These improvements have been achieved through significant greater organ exchange
(33% reduction in locally used organs) (p=0.0001, Fisher's 2-tailed t test). On
average 78% of kidneys were shipped out of the retrieving centre since the alliance
was created, compared with only 44% for the whole of the United Kingdom.
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2.3.f Cold ischaemic time
A major concern with the introduction of the new allocation scheme and regional
alliances was the effect on the length of the cold ischaemic time (CIT). The three
year analysis shows that there is no statistical significant increase (t=0.7018,
DF=226, p=0.483, Student t-test) in the length of CIT between the three periods
(table 2.7).
Period Mean (hours) Std. Dev. (hours)
Pre-alliance year 22.15 9
Year 1 22.28 8
Year 2 22.95 7.2
Table 2.7 Mean CIT for the three periods (unpaired samples Student t-test)
An analysis of the cold ischaemic times according to kidney origin and irrespective
of the year of activity (table 2.8) shows no difference (t=1.237, DF=239, p=0.217,
Student t-test) between kidneys transplanted by the retrieving centre (L) versus
alliance imported organs (A). There is however a significantly longer CIT for UKT
imported kidneys (I) compared with both locally used or alliance imported kidneys
(t=3.032, DF=251, p=0.002 for I vs. L, respectively t=2.095, DF=248, p=0.037 for I
vs. A, Student t-test).
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Source Mean (hours) Std. Dev. (hours)
Locally used kidneys (L) 20.82 8.97
Alliance imported kidneys (A) 22.09 6.79
UK imported kidneys (I) 24.11 8.29
Table 2.8 Mean CIT for the three sources irrespective of the year of activity
(unpaired samples Student t-test)
A further analysis shows that the introduction of the alliance had no effect on the
length of CIT, which remained at similar values for both locally used, and alliance
shared kidneys (table 2.9).




Year 1 + Year 2 (L1+L2)
Pre-alliance year (AO)













Table 2.9 Comparisons ofmean CIT for locally used and alliance imported kidneys
by year of activity. (L= locally transplanted kidneys, A= kidneys imported from
other alliance centres, 0= pre-alliance year, 1= first year of the alliance, 2= second
year of the alliance) (unpaired samples Student t-test)
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2.3.g Graft survival
Despite significant changes in organ allocation and sharing, there has been no decline
in the graft survival. From the data reported to UKT, the one year survival rates are
comparable for each of the three periods, irrespective of the degree of matching
(p=0.1533, Log rank) (table 2.10).
_ . , Number transplants n/ , 95% confidencePeriod , f % survival . . ,
in analysis interval
Pre-alliance year 157 81.5 75.5 - 87.6
Year 1 161 86.8 81.5 -92.1
Year 2 170 88.4 82.9-93.9
Table 2.10 One year graft survival for the transplants performed in each year
(p=0.1533, Log rank test)
When the survival analysis incorporated the number of mismatches as well as the
transplant era, the one year graft survival for fully matched transplants improved
from 86.7% in the pre-alliance year to 88.9% in the post-alliance era. For the other
levels of matching the improvement was from 79.5% to 85.4% for tier 2 and from
83% to 93.8% for tier 3 respectively (table A.12.a-c, appendix, page 344). These
changes did not reach statistical significance.
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2.3.h Waiting list composition
Between 1st of September 1998 (beginning of the alliance) and 1st of September 2000
(end of the two year period) there has been a reduction in the proportion of long-
waiting patients (> 5 years) from 11.2% to 10.4% and in the proportion of highly
sensitised (PRA> 85%) patients from 9% to 7.3%. Similarly the proportion of re-
transplanted patients decreased from 27.1% to 25.6%.
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2.4 DISCUSSION
The widening gap between the supply and the demand of cadaveric kidneys, has
highlighted the controversial issue of allocation of donor organs to recipients
(189; 190). Introduced nearly two decades ago (109), allocation schemes are
constantly reviewed in an attempt to achieve an optimal balance between the best use
of a scarce resource and equity of access (110-112;187; 188). Extensive work by
Terasaki et. al. in Los Angeles, proving the benefit of better HLA matching (91),
forms the theoretical basis of the modern allocation systems. Recent data from the
USA (110; 111) and Europe (187) have shown that the new allocation schemes based
on HLA matching have improved the allocation of donor organs.
In July 1998, the UK transplant community adopted a new allocation scheme for
adult kidneys (17) which was described in chapter 1. This acknowledges the degree
ofHLA matching as the main factor determining the fate of the kidney. The length of
waiting time, the degree of sensitisation and geographical factors are taken into
account and points are allocated for each criterion. The new scheme gives priority to
local patients, and therefore the concept of regional alliances experienced a new
revival. However, there are concerns about the practicality of larger alliances, in
particular about the future of the small participant transplant programmes and of
those centres that opted to remain outside alliances.
The retrieval activity in Scotland and Northern Ireland was not influenced by the
introduction of the new alliance and the decrease noted in the second alliance year
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was consistent with the national reduction in donation rates. These levels of retrieval
are still low compared with other countries, but above the UK average for the same
periods (30). It is worth mentioning that during the study period, the rate of
irremediable organ damage during retrieval was only 2%, which is an improvement
from that which was previously reported in UK (191). The reduction in retrieving
activity is set against an increase by 11% in the number of transplants performed
since the alliance was introduced, this being largely due to an average 30% increase
in the number of kidneys imported from outwith the alliance.
There has been a significant improvement in the degree ofHLA matching, by the end
of the second year nearly 80% of the transplants being either fully or favourable
matched. It could be argued that some of the improvement in matching has resulted
from the introduction of the new allocation scheme for the UK two months before
the Scotland-Northern Ireland alliance was created. However, as shown by these
data, there is a 15% better matching in the alliance compared with the national
figures (188). In addition, in the second year of the alliance, when no more changes
were made to the national allocation system, there was a further 8% improvement in
matching in the alliance compared with only 2% for the UK activity. Furthermore,
the higher degree of matching was achieved through an increased organ exchange. In
the pre-alliance year all the exchanges amongst centres were done solely through the
national pool, with 45% of the kidneys being retained by the retrieving centre. Since
the alliance was founded, the exchange with the national organ pool has remained at
similar levels, but this additional level of sharing has led to 28% more kidneys being
exchanged regionally, between the four participating centres. This contributed to
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significantly higher levels of kidney sharing in the alliance when compared with the
national activity. By the end of alliance's second year, for each accepted kidney, two
more offers were made indicating the scale of the organ exchange process. And
finally, comparing the structure of the waiting list at the beginning of the alliance and
at the end of the two year period, there was a reduction in the proportion of the long
waiting patients, highly sensitised patients and re-transplants on the waiting list.
These points suggest that there is indeed an added benefit of a regional waiting list
alliance and one can safely say that the goal of increased exchange of favourable
matched kidneys between participating centres has been accomplished.
The main worry expressed by the critics of these types of schemes (188; 192), was the
deleterious effect of a longer CIT due to an increased organ exchange and shipping
which would diminish the benefit of a better HLA match. Although obtaining an
accurate recorded CIT may prove sometimes difficult, these data from the National
Transplant Database demonstrate that there is no difference between kidneys
imported from the alliance and those transplanted by the retrieving centre or between
the pre- and post-alliance era. The cold ischaemic times may vary significantly from
centre to centre, but these results suggest that perhaps other local elements such as
access to theatre rather than an increased organ sharing should be investigated as
causal factor. Similarly, there is no detrimental effect on the graft survival. From the
data reported to the national transplant organisation, the one year graft survivals are
similar if not better for all levels ofmatching since the alliance was created.
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A serious concern was the effect of regional alliances on the small and medium size
participating transplant programmes. Previous studies reported that smaller centres
tend to become relative exporters due to the size of their recipient pool (193), this
effect being counterbalanced by a higher rate of unfavourable HLA matched
transplants (117). A similar imbalance, was noticed in the international exchanges
between different sized programmes at the beginning of the new Eurotransplant
allocation scheme (187). As recently reported at the European society for Organ
Transplantation meeting in Lisbon (194), this imbalance still persists even five years
after the implementation of the scheme. It has been argued that a centre with a larger
waiting list has a mathematically higher probability of attracting more donor kidneys.
To counterbalance the effect of waiting list size, most allocation systems include a
balance of exchange criterion. As Scotland-Northern Ireland alliance includes a large
centre and four other medium or small sized centres, a similar analysis was possible.
At the end of the three year study period, all small and medium size centres were net
exporters of kidneys to the national pool in order to compensate for the increasing
negative exchange balance of the large centre. The internal balance of exchange had
a similar profile, with the largest centre importing organs from the rest of the
alliance. Despite the fact that the centre balance of exchange is one of the scoring
system criteria, two years since the introduction of the new allocation scheme, there
is a persistent centre disproportion which will need to be addressed properly and not
just by a balance rollover.
A recent report from UKT (195) highlighted the fact that one in four offers are
accepted but subsequently have to be reallocated, in 61% due to a positive
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crossmatch at the receiving centre. Similar levels were observed within the Scotland-
Northern Ireland Alliance, and there has been no improvement since the introduction
of the new sharing scheme. It is therefore important that uniformity between the
authorized laboratories should be achieved in order to minimise the unnecessary
shipping or loss of kidneys. Some have even suggested regional centralization (196)
as the way forward.
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2.5 CONCLUSION
In summary, a series of questions were raised at the beginning of the study:
1. Is there an improvement in the level ofHLA matching in a wider alliance?
2. Is there a longer cold ischaemic time with increased organ sharing?
3. What impact has the alliance on the activity of a large centre?
4. What impact has the alliance on the activity of a small centre?
All these questions were answered by this analysis. Despite a status quo of the
retrieval activity, following the introduction of the Scotland-Northern Ireland
alliance, the number of kidney transplants has increased, with a substantial
improvement in the proportion of favourable matched kidneys and a higher exchange
rate.
Experience within the Scotland-Northern Ireland alliance, applying the UK
allocation criteria, shows a clear benefit of improved HLA matching without any
detrimental effect on the length ofCIT or graft survival.
There is however, a persistent disproportion in kidney distribution amongst the
participating programmes, the largest centre receiving a significant proportion of all
organs shared within the alliance. Although this will require correction, the ways to
do it may not be as easy as it seems.
This study has shown that changes at this stage of the clinical pathway to
transplantation have resulted in an improved matching which could create the basis
of better long-term results. Nevertheless, one question remains and that is whether or
not there is equity of access to the transplant waiting list and renal transplantation.
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CHAPTER 3
EQUITY OF ACCESS TO THE






The number of patients starting renal replacement therapy in Scotland has risen
















Figure 3.1 Annual incidence per million population of new patients starting RRT
1989-1999 (Source: Scottish Renal Registry)
Kidney transplantation has been shown to be the most successful, economical and
cost-effective (18;21) form of treatment that improves the quality of life (24;25;197)
1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
Year
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and survival for these patients (19;21;152) and therefore should represent the gold
standard when considering treatment options for these patients.
However, not all patients receiving dialysis are suitable for transplantation (198).
Furthermore, there is evidence from United Kingdom (199;200) and elsewhere
(131;155) that selection criteria vary widely. Because of an increasing demand, yet a
diminishing supply of donor organs (figure 3.2), there is a rising pressure on the
transplant community to devise appropriate selection criteria to optimise the use of
this scarce resource.
1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
Year
-♦-Waiting list -•-Transplants -♦-Donors
Figure 3.2 Number of patients on the waiting list, number of donors and number of
kidney transplants in Scotland 1989-1999 (Source: United Kingdom Transplant)
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Nevertheless, as highlighted in the "Renal Association treatment of adult patients
with renal failure standards and audit measures" (201) it is equally important to
ensure that there is equity of access to transplantation irrespective of age, gender,
race, district of residence and social welfare. Since the inception of the National
Health Service in Britain there have been concerns about equity of access to health
care (202;203) and priorities in access to renal transplantation have also come under
scrutiny (204). A sequence of potential barriers along the clinical pathway to
transplantation has been previously documented (123) and there is a growing body of
evidence, coming mainly from the USA demonstrating that transplantation rates vary
significantly across different age (143), gender (125;205) and race (132;206;207)
groups. The likelihood of a patient being listed for transplantation and transplanted is
significantly associated with the health status as well as socio-economic and
geographic factors (130;208;209).
In order to investigate whether inequities in access to the renal transplant waiting list
and renal transplantation are present in Scotland, we performed a longitudinal
analysis on all adult patients starting dialysis between 1st of January 1989 and 31st of
December 1999. This study, one of the first of its type in UK, investigates the
relationship between socio-economic and geographic factors and access to the renal
transplant waiting list and renal transplantation, following a patient from the first




The study population consisted of all adult patients (age >18 years old) who started
ESRD therapy in Scotland between 1st of January 1989 and 31st of December 1999.
Patients were followed to listing and then on to first transplant, death or study end
(31st of December 2000). Patients were identified using the Scottish Renal Registry
(SRR) and United Kingdom Transplant (UKT) databases.
The Scottish Renal Registry is a comprehensive database for all patients receiving
replacement therapy in all renal units in Scotland. It provides information regarding
the date of birth, gender, primary disease causing ESRD, date and type of first
dialysis, treatment changes, dialysis and transplant centre and patient survival.
Furthermore, a postcode of residence for each patient is held in the database. This
allows the determination of a map reference - used to calculate the distance between
the patient's home and the transplant centre - and also, the measurement of social
deprivation by means of the Carstairs score. This score is a complex calculation,
which is derived from the census and is based on a combination of four variables
(male unemployment, car ownership, social class and overcrowding) (210) (table
A. 13, appendix, page 345).
The deprivation scores for each postcode sector (211) range from -8.48 (affluent) to
+12.82 (deprived) and are classified into seven categories from 1 - which is the least
deprived to 7 - which is the most deprived (table 3.1).
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Table 3.1 Deprivation scores grouped into categories and proportion of Scottish
general population in each category
The United Kingdom Transplant database records the transplant waiting list and
transplant activity in UK and provides demographic data, date of listing for an active
transplant waiting list, the length of time on active waiting list and periods of
suspensions, the date of a transplant if one is performed as well as follow-up data
including patient and graft survival.
Because the two databases did not contain unique identifying variables, a
combination of birthdate and gender were used to match the patients, after obtaining
ethical approval from the local ethical committee and preserving patients' anonymity
in accordance with the relevant legislation.
3.2. b Exclusions from the study
In total 408 cases (9%) were excluded from the analysis. They included patients who
received a renal transplant as their first mode of end stage renal failure therapy (44),
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patients who were registered for transplantation prior to commencing renal
replacement therapy (123), patients registered in more than one centre during the
analysis period and patients with missing data. Because some patients were
temporarily removed from the waiting list due to medical illness or other reasons, all
periods of suspension were excluded and only the time on the active waiting list was
used in the analysis of access to transplantation.
3.2.c Outcome
The clinical outcomes were listing for transplantation and transplantation. Patients
dying before either of these events were censored at the time of death. Similarly,
patients permanently removed from the waiting list were censored at date of removal
while those patients still waiting to be listed (for access to the waiting list) or on the
active waiting list (for access to transplantation) at 31st ofDecember 2000 were
censored at that time.
3.2.d Statistical analyses
The factors associated with the likelihood of listing in the dialysis population and
those associated with the likelihood of transplantation in the waiting list population
were investigated using both univariate and multivariate Cox proportional hazards
regression analysis. On the basis of log cumulative hazards plots there was no
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evidence of non-proportionality across the various factors used in this analysis. The
results are presented in terms of relative risks between groups of patients, compared
with that of a reference group. A relative risk of greater or less than 1.0 indicates
respectively, a higher or a lower risk than in the reference group. For each relative
risk, 95% confidence intervals (CI) were calculated. Kaplan Meier curves were used
to determine the median time to listing and transplantation and the p values were
derived from a univariate log rank test. A 5% level of significance was used
throughout the analyses, which were carried out using SPSS software, version 9.0.
a. Access to the transplant waiting list
For each variable two indicators of access were analysed: i.) the proportion of
patients being listed within three years of starting renal replacement therapy and ii.)
the length of time spent on dialysis before listing. In the absence of a variable in the
Renal Registry which can identify patients who will never be suitable for listing and
transplantation, the median time of access to the waiting list was calculated using an
"intention to treat" approach whereby all patients starting RRT were considered
suitable for listing. This method, although statistically correct, does not give a true
indicator of how long it actually takes for someone considered suitable for
transplantation to be listed. Therefore, a separate analysis, taking into account only
those patients listed within the study period, was performed as an indicator of current
clinical practice.
The variables considered were:
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• patient's age when starting replacement therapy
• gender
• social deprivation
• distance from patient's home to the transplant centre
• primary renal disease
• type of first dialysis and year of 1st RRT
• centre where 1st RRT was performed
• centre of listing for transplantation
The primary renal disease was coded using the EDTA-ERA code list and grouped
into five categories (32) to simplify the analysis: glomerulonephritis, interstitial
nephritis, diabetic nephropathy, multi-system disorders and other/unknown
diagnosis. Age was divided into 5 groups according to the ones used by the UK
Transplant: 18 to 34 years, 35 to 49 years, 50 to 59 years, 60 to 65 years and 65 years
and older. The linear distance from patient's home to the transplant centre was
analysed as a continuous variable as well as a categorical one (less than 50 km, 50 to
100 km and more than 100 km). Each renal unit and listing/transplant centre was
randomly numbered. To investigate the centre effect two separate models were built.
The first one included socio-demographic data and whether or not patients started
dialysis in a unit situated in the same hospital as a transplant centre. The second
model contained the same socio-demographic data and grouped the patients
according to the four transplant centres where they were referred for listing.
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b. Access to transplantation
The indicators of access analysed were:
i. the proportion of patients transplanted within three years of listing and
ii. the length of time spent on the active waiting list.
The median time of access to transplantation from listing was calculated excluding
the periods of suspensions, as patients were not exposed to the risk of transplantation
during these intervals. The same variables as before were included, plus the time




4532 adult patients started replacement therapy in Scotland between 1st of January
1989 and 31st of December 1999. 1736 (38.38%) of these patients were listed for
transplantation and 1095 (24.20%) received a kidney transplant by the end of the
follow-up period. The mean age at the onset of RRT was 57.73±16.03 years
(mean±SD), while the mean ages at listing and transplantation were 46.60±14.14
years (mean±SD) and 44.30+13.52 years (mean±SD) respectively. The median time
of access to the waiting list was 2.84 years while the median time from listing to
transplantation was 1.74 years (95%CI: 1.55-1.92).
3.3.1 Access to the waiting list
Univariate analysis
Table 3.1 shows the distribution of gender, age, deprivation category, primary renal
disease and the type of first RRT modality at the onset of RRT and the proportion of















Male (ref. group) 58.3 38.3
Female 41.7 33.7 0.87 (0.78-0.96)
Age groups <0.0001
18-34 (ref. group) 10.8 82.9 1
35-49 16.1 69.4 0.76 (0.66-0.87)
50-59 17.5 55.7 0.46 (0.30-0.53)
60-64 13.7 26.3 0.21 (0.17-0.25)
>65 41.8 8.5 0.07 (0.59-0.87)
Deprivation category 0.0019
1 (ref. group) 4.9 36.9 1
2 12.6 35.5 0.99 (0.76-1.30)
3 21.9 41.2 1.07 (0.84-1.38)
4 25.2 37.4 0.95 (0.74-1.22)
5 15.0 33.9 0.84 (0.65-1.09)
6 12.9 35.7 0.87 (0.67-1.14)
7 7.5 26.3 0.67 (0.49-0.92)
Primary renal disease <0.0001
Primary GN (ref. group) 16.4 57.9 1
Interstitial nephritis 20.8 50.9 0.80 (0.70-0.92)
Multisystem disease 24.0 22.7 0.37(0.31-0.43)
Diabetes 16.3 33.5 0.53 (0.45-0.62)
Other/unknown 22.5 24.0 0.39 (0.33-0.46)
Type of first dialysis <0.0001
Haemodialysis 70.2 30.9 1
Peritoneal dialysis 29.8 49.7 1.49(1.34-1.65)
Table 3.1 Socio-demographic and end-stage renal disease distribution of the RRT
population, proportion on the waiting list (WL) at three years after starting RRT and
relative rates of listing for subgroups (Univariate Cox regression analysis)
107
Gender
There is an imbalance in access to the waiting list based on gender, females being
less likely to be listed for transplantation compared with males, as shown in table 3.1.
Moreover, the median time of access for males (2.11 years) is significantly shorter




Figure 3.3 Median time of access to the waiting list by gender
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Age at 1st RRT
As expected, there is a trend towards the older patients requiring replacement
therapy. 41.8% of all adults starting RRT were over 65 years old and only 11% were
younger than 35 years old (table 3.1). However, the proportions listed from each age
group at three years show a completely opposite trend, 83% in the youngest age
group being listed compared with only 8.55% in the eldest one. In addition, the older
the patient, the more time spent on dialysis prior to listing (p<0.0001, Log rank test).
Less than 50% of the patients in age groups 60-64 and >65 were listed within 9 and
11 years respectively (figure 3.4).
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Age groups
>65"
Figure 3.4 Median time of access to the waiting list by age groups (Analysis
limited at this time point as less than 50% of the patients were listed)
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Deprivation category
The deprivation category profile of the RRT population is statistically identical with
that of the Scottish general population (figure 3.5). Three years after starting renal
replacement therapy, the proportion of patients from each deprivation category
admitted onto the waiting list is significantly different (table 3.1) (p=0.0019, Cox
regression analysis).
■ % Scottish population
□ % RRT population
Figure 3.5 Social deprivation distribution for the RRT population compared with
Scottish general population (Carstairs groups, l=least deprived, 7 = most deprived)
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There is a significant disparity in the length of time spent on replacement therapy
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Figure 3.6 Median time of access to the waiting list by deprivation category
Primary renal disease
The proportions of patients listed within 3 years of 1st RRT are illustrated in table
3.1. Multi-system disease was the recorded cause of renal disease in nearly a quarter
of the RRT population, but these patients had the lowest chance of listing (p<0.0001,
Cox regression analysis). Diabetes caused renal failure in 16.3% of the patients but
only one in three diabetics was listed within three years. There are huge differences
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in the length of time spent on dialysis prior to admission onto the waiting list (figure
3.7). Patients with diabetes as primary renal disease wait the longest time amongst
patients with known causes of renal failure, more than 50% of those starting RRT not
being listed within 10 years (p<0.0001, Log rank test).




Figure 3.7 Median time of access to the waiting list by primary renal disease
Type of first RRT
The type of first renal replacement therapy is chosen according to the patient's
general status, primary disease, tolerance and ease of use. There are a significant
number of patients who will switch between treatment modalities and therefore the
influence of this variable is difficult to quantify. 70% of the patients in this cohort
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started on haemodialysis while the remaining patients started on peritoneal dialysis.
Only 30% of haemodialysis patients were listed and did so after a significantly
longer time (median time 4.5 years) on replacement therapy compared with
peritoneal dialysis treated patients (median time 1.23 years) (pO.OOOl, Log rank
test).
Renal unit
In Scotland, there are 11 adult renal units, which are allocated to one of four
transplant centres (at that time) based on geographical criteria. Four of the renal
units are situated in the same hospital as a transplant centre. There are significant
differences in the proportion of patients being listed within three years of starting
RRT (table 3.2) as well as in the length of time spent on dialysis pre-listing
according to the renal unit where the patients starts replacement therapy.
Furthermore, patients treated in the four renal units situated in the same hospital as a
transplant centre (57% of the cohort) are more likely to be listed (p<0.0001, Cox
regression) and wait significantly shorter compared with the remaining patients (1.94
years versus 4.4 years) (table 3.3).
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% ofRRT % of group Relative rate p value
population on WL at of listing
in this group 3 years Cox regression
(C.I.)
Renal unit (1st RRT) <0.0001
1 9.3 52.2 1
2 10.8 41.7 0.73 (0.60-0.89)
3 16.3 37.0 0.47 (0.39-0.57)
4 20.8 31.9 0.42 (0.35-0.50)
5 14.2 36.2 0.46 (0.38-0.56)
6 5.5 27.6 0.34 (0.26-0.45)
7 3.5 30.1 0.44 (0.32-0.61)
8 3.0 21.3 0.27 (0.18-0.41)
9 5.4 34.2 0.42 (0.32-0.55)
10 3.7 41.7 0.62 (0.47-0.82)
11 7.7 34.9 0.46 (0.36-0.57)
Renal unit in same
hospital with Tx centre <0.0001
Yes 57.1 38.5 1








9.7 41.2 0.83 (0.68-1.01)
19.7 34.7 0.51 (0.43-0.61)
58.0 33.3 0.50 (0.43-0.57)
Distance to listing centre





Distance to listing centre
<50 km 83.7 35.7
50- 100 km 7.2 41.9





Table 3.2 Geographic distribution of the RRT population, proportion on the waiting
list (WL) at three years after starting RRT and relative rates of listing for subgroups
(Univariate Cox regression analysis)
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When the units were grouped by the listing centre to which they are geographically
allocated, there was a bimodal distribution, with two of the centres listing patients
within a year, while the median waiting time for the remaining two was longer than
3.7 years (table 3.3).
Distance to listing centre
When the linear distance between the patient's home and the listing centre was
calculated (table 3.2), it was found to be a significant predictive factor of access to
the waiting list (p=0.0014, Cox regression) (distance as a linear variable analysis).
When distance was analysed as a categorical variable (<50 km, 50-100 km, >100
km), the difference between the proportions of patients listed from each group was
significant and furthermore, there was a significant trend towards shorter waiting
time, the further away from the unit the patient lived (p=0.0283, Log rank test) (table
3.3).
When an analysis was carried out limited to those patients listed during the study
period, the results shown in table 3.3 indicate that all factors, except gender, maintain
a significant influence on the median time of access to the waiting list.
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Factors in analysis Access to the waiting list
All patients+ Listed patients *
Median time P value Median time P value


















Primary renal disease <0.0001 <0.0001**
Primary GN 0.79 5.52
Interstitial nephritis 1.09 5.88
Multisystem disease 9.39 8.04
Diabetes >10.59* 5.40
Other/unknown >10.32* 6.84
Type of first RRT <0.0001 0.001*
HD 4.5 6.36
PD 1.23 5.28
Renal unit in the same <0.0001 <0.0001*
hospital with a Tx centre
Yes 1.94 5.16
No 4.64 6.72
Transplant centre <0.0001 <0.0001**
Centre 1 0.88 3.84
Centre 2 0.98 4.68
Centre 3 3.73 6.84
Centre 4 5.03 6.60
Distance to listing centre 0.0283 0.04**
<50 km 3.29 6.00
50- 100 km 1.99 5.04
>100 km 1.47 6.00
Table 3.3 Median time of access to the waiting list
[+ "intention to treat analysis"; ** patients listed during the study period] (*- Mann-
Whitney U test; **- Kruskal-Wallis test;analysis limited at this time point as less
than 50% of the patients listed)
116
Multivariate analysis
A proportional hazards model, which included the year of first RRT in addition to all
of the above covariates, was built. Table 3.4 shows the relative rates (RR) of access
to the renal transplant waiting list for the various covariates and their corresponding
p values. The listing rates in the reference groups are arbitrarily assigned a value of
1.0 and the comparison group's RR are expressed relative to the reference group.
Women have a 19% lower listing rate than men (RR=0.81; p<0.0001), other
covariates equal. Relative to patients 18 to 34 years of age, listing rates decline the
older the patient. Patients aged 60 to 64 years old have a 79% lower listing rate
compared with the reference group (RR=0.21, p<0.0001), while those over 65 years
old have very little chances of listing, their rate being 93% lower than the youngest
group (RR=0.07, p<0.0001).
Social deprivation remains a significant predictor of access to the waiting list. All
other covariates equal, the relative rate of listing decreases with increased
deprivation, when compared with the reference group (group 1 = least deprived).
Patients with diabetes causing ESRD have the lowest rate of listing (RR=0.50,
p<0.0001) when compared with those with glomerulonephritis and they are followed
by patients with multisystem disease (RR=0.54, p<0.0001).
Peritoneal dialysis as the first RRT modality has a positive effect on the access to the
waiting list, these patients having a 46% better chance of listing compared with those
haemodialysed (RR=1.46, 95%CI: 1.32 - 1.64).
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The relative risk (95% CI) p value

























































Type first RRT PD vs. HD 1.468 (1.32- 1.64) <0.0001


























Year of 1st RRT, per year 0.95 (0.93-0.97) <0.0001
Table 3.4 Relative risks of access to the transplant waiting list (Cox proportional
hazards model) (*-model including renal unit in same hospital with Tx centre, **-
model including transplant centre)
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The rate of listing for transplantation is 28% lower (RR=0.72, p<0.0001) for patients
who start RRT in a renal centre which is not in the same hospital as a transplant unit.
The distance from patient's home to listing centre remains a predictive variable of
access to the waiting list (p=0.001) even in the multivariate analysis, while the centre
effect is persistent, with patients referred for transplantation to centres 1 and 2 being
more likely to be listed compared with patients in centres 3 and 4, who have almost
60% lower listing rates. The year of onset ofRRT is a significant factor and there is a
5% reduction in listing rates with each year closer to the end of the follow-up period
(RR=0.95, p<0.0001).
3.3.11 Access to transplantation
Univariate analysis
Once a patient is listed, an analysis of the proportion of patients transplanted within
three years of continuous listing (only time spent on the active waiting list
considered) (table 3.5) and the median time to transplantation was performed (figure
3.8).
Age remains a significant independent factor governing access to transplantation, the
elderly the patient, the lower the proportion on the waiting list and the longer the
waiting time (p<0.0001, Cox regression).
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Also, there are significant differences in access to transplantation based on the
primary renal disease, patients with multisystem disease waiting longest prior to
transplantation (p=0.001, Cox regression).
The time spent on dialysis pre-listing has a significant impact (p=0.0062, Cox
regression) on access to transplantation, the chance of transplantation decreasing by
15% for each additional year spent on dialysis.
There are significant centre variations (p<0.0001, Cox regression), but they are
mainly due to one centre (centre 2), where patients wait significantly longer (3.95
years) and have a reduced chance of transplantation once listed, compared with the
remaining three centres (table 3.5).
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% ofWL % of group RR
population Tx at three Cox regression p value
in this group years (C.I.)
Gender 0.37
Male (ref. group) 61.4 52.5 1
Female 38.6 54 0.94 (0.82-1.07)
Age groups <0.0001*
18-34 (ref. group) 23.7 69.33 1
35-49 29.8 56.48 0.76 (0.64-0.89)
50-59 25.1 48.30 0.65 (0.55-0.78)
60-64 10.2 43.59 0.60 (0.46-0.77)
>65 11.1 29.00 0.39 (0.29-0.52)
Deprivation category 0.6635
1 (ref. group) 5.0 50.00 1
2 12.2 54.30 1.07 (0.76-1.52)
3 24.7 50.13 0.97 (0.70-1.34)
4 25.6 57.03 1.15 (0.84-1.59)
5 14.1 52.56 1.05 (0.75-1.48)
6 12.7 50.52 0.99 (0.70-1.40)
7 5.7 55.17 1.09 (0.73-1.63)
Transplant centre <0.0001*
Centre 1 (ref. group) 16.9 52.32 1
Centre 2 10.9 33.53 0.55 (0.41-0.74)
Centre 3 18.7 59.09 1.19(0.96-1.49)
Centre 4 53.4 55.21 0.97 (0.81-1.18)
Primary renal disease 0.0010*
Primary GN (ref. group) 25.9 62.27 1
Interstitial nephritis 29.0 58.69 0.90 (0.76-1.06)
Multisystem disease 15.3 42.30 0.71 (0.57-0.89)
Diabetes 14.8 45.57 0.80 (0.64-1.00)
Other/unknown 14.9 44.73 0.67 (0.54-0.83)
Type of first dialysis 0.4014
Haemodialysis (ref. group) 60.0 52.24 1
Peritoneal dialysis 40.0 54.42 1.06 (0.93-1.20)
Distance to Tx centre 0.9768
<50 km 82.2 53.46 1
50- 100 km 8.2 51.2 1.02 (0.80-1.31)
>100 km 7.7 53.39 0.99 (0.77-1.28)
Time on dialysis pre-listing 0.85 (0.75-0.95) 0.0062*
(per year)
Table 3.5 Socio-demographic, end-stage renal disease and geographic distribution
of the waiting list population, proportion transplanted at three years after listing and
the relative rates of transplantation for subgroups. (Univariate Cox regression
















Median time of access to transplantation




A Cox regression model adjusted for all of the above variables and including the year
of listing was developed. Patients over 65 years old have a 55% lower chance of
transplantation compared with patients aged 18 to 34 years old, all covariates equal
(table 3.6). The chance of transplantation decreases by 4% for each year closer to the
end of the study. In a multivariate analysis, the time on dialysis pre-listing loses the
statistical significance but there is a persistent centre effect.
The relative risk (95% CI) of p value
access to the transplantation Cox regression
Age groups
18-34 (reference group) 1
35-49 0.77 (0.65-0.91) 0.0025
50-59 0.69 (0.57-0.83) 0.0001
60-64 0.64 (0.49-0.84) 0.0012
>65 0.45 (0.33-0.61) <0.0001
Primary renal disease 0.0498
Primary GN 1
Interstitial nephritis 0.90 (0.76- 1.07) 0.2255
Multisystem disease 0.77 (0.62-0.97) 0.0278
Diabetes 0.81 (0.64-1.01) 0.0684
Other/unknown 0.75 (0.60 - 0.94) 0.0126
Listing transplant centre
Centre 1 (reference group) 1
Centre 2 0.57 (0.42-0.78) 0.0005
Centre 3 1.18(0.92-1.51) 0.1838
Centre 4 0.92 (0.74- 1.15) 0.4857
Year of listing,per year 0.96 (0.93-0.98) 0.0004




This longitudinal study demonstrates for the first time that there are significant
differences in access to the renal transplant waiting list and renal transplantation in
United Kingdom. Similar disproportions have been identified in USA, Canada and
Europe (143;205;212-214) indicating that equity of access is a problem beyond the
boundaries of a single transplant system.
Age has been identified in this analysis as a significant factor influencing the access
to the renal transplant waiting list. Older patients are less likely to be listed, even
after adjusting for all the other variables, listing rates declining by about 20% for
each age group. Once a patient is listed, the same trend persists, elderly candidates
being less likely to be transplanted, but the differences between the age groups are
less prominent (figure 3.9).
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18-34 35-49 50-59 60-64 >65 18-34 35-49 50-59 60-64 >65
Figure 3.9 Relative waitlisting rates among incident dialysis patients and relative
transplantation rates among listed dialysis patients, according to the age groups.
Rates adjusted for age, gender, social deprivation, cause ofESRD, year of incidence
and transplant centre
The sharper decline in access to the waiting list indicates that the main selection
process takes place at the listing stage and may be attributable to the increased
presence of comorbidity in the elderly, which may preclude them from being
accepted as transplant candidates. Once listed, the difference is diminished as
healthier candidates have already been selected and probably other additional factors
such as the structure of the organ allocation system and decision making process
influence the differences. The new donor organ allocation scheme introduced in UK
in July 1998 (17) caters for equity of access by age, incorporating a donor-recipient
age difference factor in the points scoring mechanism. There were insufficient data
and length of follow-up in this study to allow for a comparison of the age differences
in access to transplantation prior to and after the introduction of this new scheme.
Other options, including separate allocation schemes for elderly and old-for-old
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programmes have been implemented in other countries (Eurotransplant), with good
results (215).
Gender is a significant determinant of access to the waiting list. We found that there
is a 19% lower rate of listing for females than for males and this disparity is not due
to age or socio-economic status, both variables being adjusted for in the multivariate
analysis. A similar gender difference was reported previously (124; 135) and
strikingly similar rates of listing (RR=1 for males and RR=0.84 for females) were
recently observed by Wolfe et al. in the USA in a national study (143). Several
potential explanations for these differences have been advanced including patient
preference (216), gender selection by health professionals (131 ;217), socio-economic
and health status (134;218), non-compliance and gender-based differences in family
preferences for transplant.
Once admitted onto the waiting list females have an equal probability of receiving a
kidney transplant compared with males, after adjusting for all the other covariates.
This finding suggests that the allocation system in place in UK may have eliminated
gender differences, unlike other transplant programmes where a persistent gender
disparity after listing is still noted (124;125;212).
The socio-economic status, assessed by deprivation scores (210), was found to be a
significant predictor of access to the renal transplant waiting list. After adjustment
for other factors, the listing rates decline the more deprived the patient. The reasons
for these discrepancies rest with both patients and health professionals. Patients who
are socio-economically disadvantaged may have a higher index of comorbidity,
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while medical non-compliance may be more frequent in this group (18). It is
conceivable that patients in this group may not appreciate the advantages of
transplantation and as a result may not be good advocates for themselves when it
comes to choosing the best treatment option. In addition, it is possible that health
care workers may be biased to manage patients in ways that allow some to be listed
sooner than others (146). Unlike other analyses (130), this study has shown that once
listed, patients have an equal chance of transplantation, irrespective of their socio¬
economic status. This may indicate that most of the above potential reasons are
eliminated with the assessment process prior to listing for transplantation.
Patients with diabetes and those with multisystem disease leading to ESRD have the
lowest rate of listing for transplantation. When compared with primary
glomerulonephritis patients and after adjusting for other factors, a patient with
diabetes as primary renal disease has nearly half the rate of listing of a patient with
GN. This may result from additional and more severe comorbidity that may preclude
transplant candidacy. Once listed for transplantation, primary GN patients are the
most likely to be transplanted. Although the rate of transplantation for diabetic
patients is better than their rate of listing, the likelihood of further complications may
be the underlying reason for the persisting differences in access to transplantation.
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Figure 3.10 Relative waitlisting rates among incident dialysis patients and relative
transplantation rates among listed dialysis patients, according to the primary renal
disease (G.N. = primary glomerulonephritis, I.N. = interstitial nephritis, M.D. =
multisystem disease, DM = diabetes mellitus, O = other/unknown). Rates adjusted
for age, gender, social deprivation, cause of ESRD, year of incidence and transplant
centre
The type of 1st RRT (peritoneal dialysis versus haemodialysis) was found to be a
significant predictor of access to the waiting list, patients starting RRT on PD being
more likely to be listed. Although this variable was included in the final model, one
must interpret its significance with caution, for various reasons. The type of first
renal replacement therapy is chosen according to the patient's general status, primary
disease, tolerance or preference. Furthermore, there are a significant number of
patients who will switch between therapeutic modalities (up to six times in the
present cohort) throughout the course of their treatment and therefore a proper
analysis of the impact of dialysis modality on access to the waiting list should
include not only the type but also the length of time spent on each modality.
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A longer waiting time on dialysis pre-transplantation has recently been correlated
with a poorer outcome. In a multivariate analysis, Meier-Kriesche (47) noted a
substantial reduction in the success rate of a kidney transplant, the longer the time on
dialysis, suggesting that once patients reach the end stage of the renal disease, they
should be transplanted as early as possible. In the multivariate analysis, we found no
correlation between the chances of transplantation and the length of time spent on
dialysis pre-listing suggesting no discriminatory effect against those referred later in
the course of their renal disease.
Differences in access according to geographical criteria have been previously
reported (208). A univariate analysis of the linear distance between the patient's
home and the transplant centre revealed a surprising finding. The further away from
the transplant centre the patients lived the quicker the access to the waiting list. The
distance factor remained a predictive variable of access to the waiting list, even after
adjustment for the transplant centre to which the patient was referred.
To investigate the centre effect, two different models were built. The first one,
including all the socio-demographic variables and grouping the patients by the
proximity of the dialysis unit with a transplant centre found that patients starting
RRT in a renal unit, which is in the same hospital with a transplant unit, have a 28%
better listing rate than patients dialysed elsewhere. The second model included the
same socio-demographic indicators and grouped the patients according to the
transplant centre to which they are referred depending on the geographical allocation
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of the renal units to a transplant centre. There seems to be a persistent centre effect
both for access to the waiting list and access to transplantation as shown in figure
3.11. On close analysis, the effect on access to transplantation was mainly due to one
centre with significant longer waiting time and lower chances of transplantation for
listed patients. Hence, it would be fair to say that the centre effect on access to





Figure 3.11 % patients transplanted and length ofwaiting time from listing to
transplantation (years) in each transplant centre in Scotland 1989-1999.
We can only speculate about the reasons behind these transplant or renal unit
differences, but it has been suggested that centre characteristics (126), renal unit size
and organizational aspects (131), health care staff attitudes towards transplantation
(199;200) and training may affect transplant status. Clinical practice guidelines in the
evaluation of renal transplant candidates have been introduced in USA (18) and
suggested in Europe (157) and may help to eliminate the centre effect.
130
Comorbidity may account for some of the differences highlighted here. This analysis
is based on all incident adult patients that started RRT between 1989 and 1999 and
comorbid conditions were not available throughout this period, so their effect could
not be examined. However, there is evidence from the USA (130), where similar
inequities of access were noted, that the addition of the comorbid factors in the
analysis does not alleviate the effects of the sociodemographic variables and only
modestly improves the predictive power of the model.
Racial differences in access to transplantation have been documented for over a
decade (126;132;207;219). The lack of ethnic origin details in the Scottish Renal
Registry and UK Transplant database for the study period did not allow us to
undertake such an analysis.
In the absence of a way to identify patients who will never be suitable for listing and
transplantation at the time when RRT is begun, the median time of access to the
waiting list was calculated on an "intention to treat" basis. Although statistically
correct, this method, produces long waiting times which give little information of
clinical value when one is interested in the time taken to listing for a patient who is
obviously fit for transplantation. This is compounded in certain categories because a
large proportion of patients in these categories are never listed. Therefore, a separate
analysis, taking into account only those patients listed within the study period,
irrespective of their length of follow-up, was carried out. This analysis, although in
statistical terms in danger of bias, gives an indication of the actual time taken for
assessment and listing in the different categories (data shown on page 116, table 3.3).
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Of the 408 cases excluded from the analysis, 167 patients were removed as they were
listed prior to starting dialysis and they could not be fitted in these models, which
include age at the beginning of RRT (for access to the waiting list) and time on
dialysis pre-listing (for access to transplantation). 44 of these cases were transplanted
pre-emptively while the remaining patients spent some time on dialysis before
receiving a kidney transplant. However, separate analyses, which include these cases,
were carried out and produced identical results with the models presented in this
study (data shown in table A. 14, appendix, page 346 and table A. 15, appendix, page
347).
A sequence of potential barriers along the clinical pathway to transplantation has
been documented (123). Our study has shown that for some of the factors, like
gender and socio-economic status, the barrier seems to be at the listing stage rather
than transplantation, while for other, like age and primary renal disease the
differences persist at both steps. The current data did not allow exploration of the
various issues, which may explain these differences, and therefore studies designed
to address these factors are needed.
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3.5 CONCLUSION
In summary, for whatever reasons, there appear to be inequities in access to the renal
transplant waiting list and renal transplantation in Scotland. Since the management of
end stage renal failure, referral pattern for transplantation and the transplantation
process itself are similar throughout the UK, it would be surprising if these inequities
do not exist in other parts of Britain. The explanation of these differences is complex
and warrants further investigation.
It is important that patients with advanced renal disease and those who care for them
are aware of the factors associated with successful listing and transplantation. The
transplant community often concentrates on graft and patient survival rates following
a transplant procedure and there is no doubt from this study that transplantation
provides the best outcome (figure 3.12).
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Survival from 1st RRT (years)
Figure 3.12 Patient survival in Scotland according to the treatment status (1989-
1999).
These findings are equally important from the public's point of view. A system that
does not grant access to transplantation to all patients that need it will be viewed as
an unfair system. The perception of inequity threatens the very foundation upon
which altruistic donation and transplantation are built and therefore fairness in access
should be pursued with the same dedication with which we seek new
immunosuppressive medication or better dialysis regimens.
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CHAPTER 4
IMPACT OF COMORBIDITY ON ACCESS
TO THE RENAL TRANSPLANT WAITING
LIST




The differences in access to the transplant waiting list and renal transplantation
highlighted in the previous chapter are very important for both health care
professionals and end-stage renal disease patients. Some of the results (e.g.
differences in access to the waiting list by gender) are intriguing and difficult to
interpret, while others (e.g. differences in access by age groups) were more
predictable.
The main factor, which has not been included in the analysis and is believed to have
a major impact on the prognostic value of the proposed model is comorbidity. The
difficulties in building a complex model including comorbidity are multiple. First of
all, collecting accurate data may prove to be a difficult and daunting task, as there is
no computerised database containing this information, and retrieving case notes to
obtain retrospective data is time consuming and exposed to bias. Secondly, there is
no agreement on what comorbidity - if any - should be recorded in a database.
Thirdly, there are limited data on the impact of comorbidity on a patient's chances of
being listed or transplanted. Finally, a prospective data collection is the desired
approach, but this requires significant financial and human resources.
Not surprising, even the largest analysis to date, which investigates differences in
access to renal transplantation in over a quarter of a million patients in the US (143)
has used only a sociodemographic model. It is widely accepted that these sort of
analyses are useful, but they are not perfect. Recognizing these weak points, a series
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of papers (130; 131), have included comorbidity in a predictive model for access to
transplantation, but none of them gives a national perspective or collects data
prospectively at the moment of 1st RRT, listing and transplantation. Interestingly,
Gaylin et al. showed that the addition of comorbidity does improve the predictive
power of the model, but only by a small margin, without diminishing the predictive
value of the sociodemographic variables.
To address these issues and to investigate the impact of comorbid conditions on the
access to renal transplant waiting list and renal transplantation in Scotland, an
analysis was performed on patients listed for transplantation for which comorbidity
was collected from case notes review and combined with sociodemographic data
from the SRR and UKT. The questions were whether comorbidity accrued until the
time of listing influences:
i) the speed of access to the waiting list and




As shown in the previous chapter, 1736 adult patients started dialysis and were listed
for transplantation between 1st of January 1989 and 31st of December 1999. A single
investigator visited all four transplant centres and collected the comorbidity data
from patients' notes. 1022 case notes were available for investigation. The remaining
714 were destroyed (deceased patients, or not in the care of the unit for more than 5
years), missing, or unavailable. In total, data was collected for 58.9% of all listed
patients.
An extensive amount of data on all comorbid conditions accumulated by a patient
prior to listing was collected for each patient on a pro-forma (appendix, page 348-
351). Comorbid conditions listed included:
> Diabetes
> Peripheral vascular disease
> Hypertension
> Ischaemic heart disease










Each comorbid condition was recorded only if a diagnosis was ascertained and not
just based on the presence of symptoms. The findings of all the investigations (X-ray,
ECG, cardiac echography, HLA grouping, lymphocytotoxic antibodies analysis,
blood group and other blood tests) were recorded from the appropriate forms. For
some of the comorbid conditions (e.g. diabetes, ischaemic heart disease, peripheral
vascular disease, heart failure, respiratory disease, cerebro-vascular disease, GI and
urological disorders) extensive details of the type and stage of disease and
complications were collected (appendix, page 348-351) (e.g. Claudication, ischaemic
ulcer/rest pain, revascularisation, amputation for peripheral vascular disease, type
ofdiabetes, number ofend-organ complications for diabetes).
The data was than fitted in a database containing sociodemographic factors,
indicators of renal disease and dialysis as well as listing, transplant and donor
information retrieved from the SRR and UKT.
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4.2.b Statistical analyses
Most of the comorbid conditions examined in this analysis have been shown to be
positively correlated with mortality (220). Therefore, some of them, might be
negatively associated with transplantation, simply because patients with these
conditions are likely to die before they are listed or receive a transplant. As a result,
the primary analysis method employed a time to event proportional hazards
regression (221) where the event analysed was i) listing for transplantation and ii)
transplantation. This method uses the information on whether a patient is
listed/transplanted and also incorporates the time between the start of dialysis therapy
and the eventual end point (if one occurred), death or end of the analysis period. That
is, if patients die, they are removed from the analysis (censored) at the time of death,
and the mortality risk of the comorbid conditions does not "compete" with the
likelihood of listing/transplantation.
The models were adjusted for all sociodemographic factors described in chapter 4
(age, gender, social deprivation, primary renal disease, type and year of first dialysis,
transplant centre, distance from patient's home to the transplant centre), to eliminate
the potential differences in the distribution of diseases across these groups. The
univariate models were built in a standard entry manner to identify the significant
variables. Statistical significance of individual factors was evaluated with a Wald
statistic. Probability values of 0.05 or less were considered statistically significant for
this analysis.
140
The multivariate model was built in a step-wise forward selection manner, which
includes only those variables with significant influence in a univariate analysis. A
level of significance of 0.10 was chosen as a cut-off point to ensure that all factors
with a significant impact are included in the analysis. In addition, this method
eliminates the potential interaction, which may occur when factors are highly co-
linear.
4.2.c Outcome
As all patients in this analysis were listed, the impact of comorbidity on the rates of
listing could not be evaluated (no data available for not-listed patients). However,
using comorbidity accrued until listing, an investigation could be undertaken into
whether there are any differences in the speed of access to the waiting list between
patients with different levels of comorbidity.
In the second part of the analysis, the impact of each comorbid factor on the rates of
access to transplantation was determined, as data was available for both transplanted
and censored patients (on dialysis).
In addition, a comparison between the median times of access to the waiting list and
transplantation for patients with any given comorbid condition and those where the
condition was absent was carried out.
Finally, a comparison between the predictive power of a basic socio-demographic




4.3.1 Access to the waiting list
Univariate analysis
Table 4.1 illustrates the impact of cardiovascular comorbid conditions on the speed
of access to the waiting list, compared with patients where such conditions are absent
(relative risk = 1, reference).
Factor Condition present
Relative risk




Hypertension 1.337 1.095-1.632 0.004*
Ischaemic heart disease 0.800 0.679-0.943 0.008*
Valvular disease 0.867 0.737-1.019 0.083**
Pulmonary embolism 0.695 0.409-1.181 0.178
Cardiac arrhythmias 0.865 0.646-1.157 0.329







Other cardiac conditions 0.873 0.721-1.057 0.165
Cardiac arrest 0.858 0.659-1.117 0.256
Table 4.1 Impact of cardiovascular comorbid conditions on the speed of access to
the waiting list (condition absent = reference group). (* = statistical significant at a
level of 0.05, ** = significant at a level of 0.10)
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Patients with heart failure spend a significantly longer time on dialysis pre-listing
compared with patients with normal heart function (RR = 0.717, p = 0.011). A
similar trend is noted for patients with left ventricular hypertrophy, ischaemic heart
disease and peripheral vascular disease while only a marginal effect (p = 0.083) is
noticed for those with valvular disease. These patients are likely to require additional
investigations prior to being considered suitable transplant candidates. Hypertension
is a frequent problem in end stage renal failure patients and is ubiquitous in the
advanced stages of the disease. Interestingly, these patients tend to be listed faster,
indicating that most patients in the advanced stages of the disease are referred for
transplantation.
The presence of other comorbid conditions (table 4.2) has a significant impact on
how quickly patients will be listed. Respiratory diseases (e.g. asthma, COAD,
emphysema, bronchitis) and previous cerebrovascular problems (e.g. transient
ischaemic attacks, cerebro-vascular accidents, hypertensive encephalopathy)
significantly lengthen the time a patient takes to be admitted on the waiting list (RR=
0.727, 95%CI: 0.601-0.879 and RR= 0.769, 95%CI: 0.617-0.959 respectively).
Patients with previous neoplasia are admitted on the waiting list, but as expected,
they will wait significantly longer (RR=0.550, 95%CI: 0.349-0.869) before doing so,
as most transplant centres will require a minimum period of 3-5 years of disease free
period, before exposing a cancer patient to the risk of immunosuppression.
Other conditions with a statistical significant impact on the speed of access to the
renal waiting list include a history of diabetes which does not lead to renal failure
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(RR = 0.569, p = 0.004) and a history of gastrointestinal disorders (duodenal ulcer,
gastric ulcer, GI bleed, GORD, surgery for any of these) (RR = 0.834, p = 0.024).
Factor Condition present
Relative risk
95% CI p value
Diabetes as a comorbid 0.569 0.387-0.837 0.004*
disease
Respiratory disease 0.727 0.601-0.879 0.001*
Cerebrovascular disease 0.769 0.617-0.959 0.020*
Positive hepatic virology 0.998 0.801-1.243 0.984
Alcoholic liver disease 1.148 0.878-1.501 0.314
Ascites 1.055 0.759-1.466 0.752
Cirrhosis 0.624 0.156-2.501 0.506
Neoplasia 0.550 0.349-0.869 0.010*
GI disorders 0.834 0.712-0.977 0.024*
Urological problems 0.894 0.743-1.076 0.236
Hyperlipidaemia 0.913 0.779-1.070 0.259
Active smoker 0.967 0.818-1.144 0.698
Ex-smoker 0.939 0.787-1.120 0.483
BMI 0.994 0.980-1.008 0.383
Hyperparathyroidism 0.953 0.869-1.044 0.303
Table 4.2 Impact of other comorbid conditions on speed of access to the waiting list
(condition absent = reference group, RR=1). (* = statistical significant at a level of
0.05, ** = significant at a level of 0.10)
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Patients wait for disproportionate lengths of time prior to being listed, depending on
their blood groups. Patients with blood group O and AB have the fastest access to the
list, while patients with blood group B seem to wait significantly longer, as shown in
table 4.3.
Factor Relative risk 95% CI p value
Blood group 0 1
Blood group A 0.982 0.845-1.140 0.810
Bloodgroup B 0.802 0.645-0.998 0.048*
Blood group AB 1.190 0.806-1.755 0.382
Table 4.3 Impact of patient's blood group on speed of access to the waiting list
(blood group O = reference group). (* = statistical significant at a level of 0.05)
Some of these comorbid conditions may have an overlapping effect as well as an
unequal distribution among different age groups, social deprivation or gender
populations. Therefore, we conducted a multivariate analysis adjusted for socio-
demographic variables, which included the comorbid conditions identified as




The results of the multivariate analysis are presented in table 4.4. After adjustment
for all the covariates, female patients have a 28% lower chance of being listed in an
equal length of time with males (RR=0.813, 95%CI: 0.695 - 0.952).
Even in patients considered suitable candidates for transplantation, there are
significant differences in the speed of access to the waiting list by age, younger
patients being listed faster than older patients.
Overall, deprivation category has a significant impact on the speed of access to the
waiting list (p= 0.002), but on close analysis, most patients spend similar lengths of
time on dialysis pre-listing, irrespective of their deprivation category, when
compared with group one (the least deprived patients) taken as reference group.
All patients are listed in similar intervals of time irrespective of how far away they
live from the transplant centre. However, there is a significant centre effect
(p<0.0001), patients referred to centre 4 waiting longest prior to being listed (RR =
0.550, 95%CI: 0.434 - 0.697).
There is a significant disproportion in the time taken to listing according to the
primary renal disease (p=0.0002), patients with multisystem disease and those with
diabetes as a cause of renal failure waiting significantly longer to be listed, compared
with patients with glomerulonephritis.
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Factor RR 95%CI p value
Gender Female vs. male 0.813 0.695 - 0.952 0.010
Age groups <0.0001
18-34 1
35-49 0.919 0.754- 1.120 0.401
50-59 0.641 0.517- 0.794 <0.0001
60-64 0.630 0.478- 0.832 0.001






1.386 0.969 - 1.982 0.074
3 1.124 0.798- 1.583 0.505
4 0.991 0.707- 1.387 0.956
5 0.781 0.533 - 1.145 0.206
6 0.785 0.542- 1.137 0.200
7 0.928 0.608- 1.416 0.728
Transplant centre <0.0001
Centre 1 1
Centre 2 0.973 0.740 - 1.278 0.842
Centre 3 0.646 0.505- 0.827 0.001
Centre 4 0.550 0.434- 0.697 <0.0001
Primary renal disease 0.004
Primary GN 1
Interstitial nephritis 0.977 0.795 - 1.201 0.827
Multisystem disease 0.686 0.548- 0.859 <0.0001
Diabetes 0.761 0.602 - 0.963 0.023
Other 0.837 0.653- 1.073 0.160
Type first dialysis (PI) vs. HD) 1.378 1.178 — 1.611 <0.0001
Diabetes as a comorbid condition 0.687 0.454- 1.040 0.076$
Hypertension 1.412 1.136 — 1.756 0.002
LVH 0.843 0.720- 0.987 0.034
CVD 0.786 0.621 - 0.994 0.045
Respiratory disease 0.804 0.652- 0.991 0.041
Neoplasia 0.583 0.356- 0.952 0.031
Urological pathology 0.812 0.655- 1.006 0.057$
Table 4.4 Impact of comorbidity conditions and demographic variables on the
speed of access to the waiting list (relative risk, patients without comorbid condition
= reference group), (J significant at p=0.10)
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Of the cardiovascular comorbid conditions with a statistical significant effect in a
univariate analysis only left ventricular hypertrophy and hypertension retain their
impact in a multivariate analysis (table 4.4). The other factors (peripheral vascular
disease, ischaemic heart disease and heart failure) do not reach statistical significance
in this model, probably due to their association with other, more predictive factors.
The presence of respiratory disease, cardiovascular problems or previous neoplasia
has a major impact even after adjustment for all the other covariates in the model.
Marginally significant adverse effects on access to the transplant waiting list are
noted for patients with diabetes as a comorbid disease (RR = 0.687, p = 0.076) and
those with urological disorders (e.g. neurological bladder, congenital abnormalities,
nephrectomies, ileal conduit) (RR = 0.812, p = 0.057). The effect of this later factor
must be interpreted with care. As no significant effect was observed in the univariate
analysis, the marginal effect noticed in the multivariate analysis may be due to an
interaction with other factors in the model.
Comparison of demographic and comorbidity adjusted models
The model presented above, adds the comorbidity conditions to the
sociodemographic covariates of the model presented in Chapter 4 (gender, age,
deprivation category, primary renal disease, type and year of first dialysis, transplant
centre and distance from patient's home to the transplant centre). Overall, the
148
addition of these factors improves the model's predictive power of the speed of
access to transplantation by about 8% (-2Log likelihood 9028.301, p<0.0001, df=28).
An examination of the relative rates for different groups of patients in the two
models (table 4.5) shows that including the comorbid conditions does not change
substantially the effects of each of the basic sociodemographic model variables.
Female patients, older patients, diabetics and patients with multisystem disease as
well as patients starting RRT on haemodialysis will wait longer prior to being listed
compared with the other patients that are listed.
A more complex model including all 25 comorbid conditions presented in table 4.1
and 4.2 rather than just those with significant impact on access to the waiting list,
showed no significant changes in the coefficients of the sociodemographic variables,






RR p value RR p value
Gender
Male 1 1
Female 0.830 0.013 0.813 0.010
Deprivation score
1 1 1
2 1.356 0.082 1.386 0.074
3 1.185 0.301 1.124 0.505
4 1.012 0.942 0.991 0.956
5 0.808 0.242 0.781 0.206
6 0.811 0.235 0.785 0.200
7 0.885 0.547 0.928 0.728
Age groups
18-34 1 1
35-49 0.945 0.555 0.919 0.401
50-59 0.628 <0.0001 0.641 <0.0001
60-64 0.610 <0.0001 0.630 0.001
>65 0.480 <0.0001 0.467 <0.0001
Primary renal disease
Glomerulonephritis 1 1
Interstitial nephritis 0.899 0.270 0.977 0.827
Multisystem disease 0.648 <0.0001 0.686 0.001
Diabetes 0.784 0.035 0.761 0.023
Other 0.821 0.101 0.837 0.160
Transplant center
1 1 1
2 0.920 0.532 0.973 0.842
3 0.613 <0.0001 0.646 0.001
4 0.567 <0.0001 0.550 <0.0001
Distance to Tx centre
<50 km 1 1
50-100 km 0.962 0.775 0.964 0.796
>100 km 0.772 0.293 0.886 0.639
Type first dialysis
Haemodialysis 1 1
Peritoneal dialysis 1.423 <0.0001 1.378 <0.0001
Year of first dialysis
peryear 0.998 0.846 1.000 0.996
Table 4.5 Sociodemographic and comorbidity factors and impact on the speed of
access to the renal transplant waiting list - comparison of a basic demographic and
comorbidity adjusted models
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An analysis of the length of time to listing shows that patients considered suitable for
transplantation wait on average 157 days from the moment they start dialysis until
they are listed. The comorbidity load exhibited by a particular patient may modify
this interval by a significant margin.
The presence of most cardiovascular conditions requires an additional 10-20 days
prior to the patient being listed (figure 4.1), with the exception of hypertensive
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Figure 4.1 Median time of access to the waiting list from first RRT for patients
with cardiovascular comorbidity (adjusted for all sociodemographic and comorbid
variables)
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As expected, previous neoplasia will lengthen the time on dialysis pre-listing by 75%
(figure 4.2), as a minimum of 3-5 years free of disease are required prior to the
patient being at risk of recurrence under immunosuppressive medication. The
presence of other serious comorbid conditions such as diabetes (not leading to renal
failure), cerebro-vascular or respiratory diseases increases the waiting time by 20 -
30%, while for other conditions such as hyperlipidaemia and gastrointestinal
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Figure 4.2 Median time of access to the waiting list from first RRT for patients
with various comorbid conditions (adjusted for all sociodemographic and comorbid
variables)
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4.3.11. Access to transplantation
Univariate analysis
Data was available for transplant recipients as well as patients who remained on the
waiting list by the end of the study period. Therefore it was possible to determine not
only the impact of the variables on the time of access to transplantation, but more
important, the impact on the likelihood of receiving a kidney, once admitted onto the
waiting list.
The influence of the individual cardiovascular comorbid conditions on access to
transplantation is shown in table 4.6. Cardiac arrhythmias seem to be the most
significant factor, their presence reducing the chances of transplantation by about
50% (RR=0.459, 95%CI: 0.283-0.744). There is a 30% lower chance of
transplantation for patients who have peripheral vascular disease or ischaemic heart
disease when listed (RR=0.702, 95%CI: 0.526-0.937 and RR=0.701, 95%CI: 0.555-
0.885 respectively) compared with those free from these diseases. Patients with left
ventricular hypertrophy are also less likely (RR=0.814, 95%CI: 0.676-0.980) to be
selected as recipients when a kidney becomes available, while the presence of other
cardiovascular conditions such as heart failure, previous cardiac arrests or








Hypertension 0.926 0.724- 1.185 0.543
Ischaemic heart disease 0.701 0.555-0.885 0.003*
Valvular disease 0.834 0.655- 1.061 0.139
Pulmonary embolism 1.307 0.676-2.528 0.426
Cardiac arrhythmias 0.459 0.283-0.744 0.002*
Heart failure 0.971 0.679- 1.388 0.870
Ventricular function
impairment




Other cardiac conditions 0.947 0.755- 1.188 0.636
Cardiac arrest 0.937 0.700- 1.254 0.661
Table 4.6 Impact of cardiovascular comorbid conditions on the rate of access to
transplantation (condition absent = reference group). (* = statistical significant at a
level of 0.05)
Other comorbid conditions with a significant impact on transplantation rates are a
history of gastrointestinal pathology (e.g. gallstones, ulcers, previous GI bleed,
GORD) (RR= 0.763, 95%CI: 0.619 - 0.942), hyperparathyroidism (RR= 0.871,




95% CI p value
Diabetes as a comorbid 0.896 0.527- 1.524 0.686
disease
Respiratory disease 0.912 0.712-1.169 0.469
Cerebrovascular disease 0.939 0.698- 1.263 0.678
Positive hepatic virology 0.730 0.476- 1.120 0.149
Alcoholic liver disease 1.002 0.653- 1.537 0.994
Ascites 0.950 0.582- 1.549 0.836
Cirrhosis 3.693 0.919-14.845 0.066
Neoplasia 0.927 0.523- 1.643 0.795
GI disorders 0.763 0.619-0.942 0.012*
Urological problems 1.091 0.867- 1.374 0.457
Hyperlipidaemia 0.913 0.779- 1.070 0.259
Active smoker 1.126 0.918-1.381 0.256
Ex-smoker 0.739 0.583-0.937 0.013
BMI 0.990 0.973- 1.007 0.244
Hyperparathyroidism 0.871 0.760-0.997 0.045*
Table 4.7 Impact of other comorbid conditions on the rate of access to
transplantation (condition absent = reference group). (* = statistical significant at a
level of 0.05)
There are significant differences in the likelihood of transplantation depending on
recipients' blood group (table 4.8). As kidney transplants are performed in blood
group matched recipients, these differences may reflect not only recipient causes, but
more likely a disproportion in the distribution of blood groups amongst donors.
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Table 4.8 Impact of recipient blood group on the likelihood of transplantation
Multivariate analysis
Leaving aside those factors with a potential donor correlation (blood groups), all
recipient demographic and comorbidity factors were included in a multivariate
model. After adjusting for all the covariates, only the factors shown in table 4.9
retain a significant impact on the chances of receiving a kidney graft. Once listed,
patients have comparable chances of being transplanted irrespective of their gender,
age, deprivation category, or primary renal disease. The type of dialysis and the time
spent on dialysis pre-listing have no impact on the chances of receiving a kidney
transplant, but there is a 4% (RR= 0.961, 95%CI: 0.928 - 0.994) lower
transplantation rate for each listing year closer to the end of the study.
There seem to be a persistent centre effect, but this is likely to be due to the outlying
value of centre 2, where patients, once listed, have a lower rate of transplantation
compared with the remaining centres (RR=0.464, 95%CI: 0.320 - 0.673).
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Of all the comorbid conditions significantly associated with lower transplantation
rates in a univariate analysis, only the presence of cardiac arrhythmias and
hyperparathyroidism reached statistical significance in the multifactorial Cox model.
Factor Relative risk 95%CI p value
Year of listing, peryear 0.961 0.928 - 0.994 0.022
Tx centre <0.001
Centre 1 1
Centre 2 0.464 0.320 - 0.673 <0.001
Centre 3 1.309 0.979 - 1.750 0.069
Centre 4 0.911 0.680- 1.222 0.535
Cardiac arrhythmias 0.531 0.318-0.886 0.015$
Hyperparathyroidism 0.785 0.655-0.940 0.009$
Table 4.9 Impact of demographic and comorbidity variables on access to
transplantation (multivariate analysis; $ compared with cases where condition is
absent)
Comparison of demographic and comorbidity adjusted models
The addition of comorbid diseases to a predictive model for access to transplantation
produces significant changes in the model (table 4.10).
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Factor Basic sociodemographic Model adjusted for
model comorbidity
RR p value RR p valu
Gender
Male 1 1
Female 0.962 0.669 0.971 0.762
Primary renal disease
Glomerulonephriti s 1 1
Interstitial nephritis 0.810 0.058 0.804 0.067
Multisystem disease 0.790 0.092 0.780 0.099
Diabetes 0.754 0.064 0.790 0.142
Other 0.643 0.004 0.672 0.016
Age groups
18-34 1 1
35-49 0.796 0.038 0.837 0.135
50-59 0.742 0.015 0.809 0.110
60-64 0.706 0.052 0.710 0.075
>65 0.526 0.001 0.610 0.011
Deprivation category
1 1 1
2 0.912 0.672 0.997 0.990
3 0.900 0.612 0.901 0.646
4 0.930 0.721 0.983 0.939
5 0.994 0.977 1.106 0.678
6 1.155 0.518 1.272 0.312
7 0.956 0.861 0.980 0.942
Transplant centre
Centre 1 1 1
Centre 2 0.462 <0.001 0.464 <0.00
Centre 3 1.299 0.064 1.309 0.069
Centre 4 0.878 0.354 0.911 0.535
Distance to Tx centre
< 50 km 1 1
50 -100 km 1.001 0.993 1.056 0.768
> 100 km 0.995 0.989 1.117 0.745
Year on the waiting list 0.963 0.017 0.961 0.022
Time for first RRT to listing 1.008 0.919 1.066 0.432
Type first dialysis 1.079 0.416 1.062 0.544
Table 4.10 Sociodemographic and comorbidity factors and impact on the speed of
access to the renal transplant waiting list - comparison of a basic demographic and
comorbidity adjusted models.
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In the basic socio-demographic model, primary renal disease and age at listing were
significant determinants of access to transplantation (p = 0.041 and p = 0.006
respectively, Cox regression analysis). After adjustment for the comorbid conditions,
both variables lose their impact on the likelihood of transplantation (p = 0.113 and p
= 0.87 respectively, Cox regression analysis), suggesting that their effect could have
been due entirely to an unequal comorbidity load for different age groups or causes
of renal failure.
Patients over 60 years old maintain a diminished chance of transplantation when
compared with patient aged 18-34 years old in both models. However, in the
comorbidity adjusted model, all patients under 60 years old have comparable chances
of receiving a kidney allograft, irrespective of the donor factors (p>0.05, Cox
regression).
The only variables with significant impact on the rate of transplantation are the year
of listing and the transplant centre. Patients listed in centre 3 have a 30% higher
chance of transplantation (RR = 1.30, p= 0.069) compared with patients listed in
centre 1, while those listed in centre 2 have a 54% lower transplantation rate when
compared with the same centre (RR=0.46, p<0.0001). All the remaining variables
presented in table 5.10 have no significant impact on the rates of transplantation in
neither the basic or the comorbidity adjusted models.
Once listed, patients spend on average 634 days (21 months) on the active waiting
list until they are transplanted. The comorbidity load exhibited by a particular patient
may lengthen this interval by a significant margin. As shown in figure 4.3, the
presence of cardiac arrhythmias will double the waiting time for a transplant, while
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patients with peripheral vascular disease will spent 26% more time on the waiting list
compared with those patients with normal blood vessels. Other cardiac conditions
(LVH, valvular disease, ischaemic heart disease) will lengthen the waiting time by
10-20%, while patients with heart failure will be transplanted quicker than those with










0 300 600 900 1200
Days
■ Condition absent B Condition present
Figure 4.3 Median time of access to transplantation from the listing moment for
patients with cardiovascular comorbidity (adjusted for all sociodemographic and
comorbid variables)
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Patients with diabetes not leading to renal failure tend to be transplanted quicker
(table 4.4) and this counterbalances the longer time of access to the waiting list as
shown in table 4.2.
A series of other comorbid conditions shown in table 4.4 will prolong the time spent
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Figure 4.4 Median time of access to transplantation from the listing moment for
patients with various comorbid conditions (adjusted for all sociodemographic and
comorbid variables).
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All these figures should be interpreted bearing in mind that despite a longer waiting
time for patients with most of the comorbid conditions, only the presence of cardiac
arrhythmias and hyperparathyroidism were found in the multivariate analysis to
reduce the transplantation rates by a significant margin.
Suspensions from the active waiting list
Around 26% of the transplanted patients were suspended or removed from the list
during the follow-up period. As patients are exposed to the risk of transplantation
only when they are on the active waiting list, for all the above analyses, only time
spent on the active list was taken into account. However, the amount of time spent
off the list during the follow-up period, until receiving a kidney graft, is a good
indicator of fitness for transplantation, as patients are usually removed/suspended
from the active list for medical reasons. To investigate this issue we compared the
difference in the proportion of patients suspended/removed from the active waiting
list (figure 4.5) and the median suspension times (figure 4.6) for various categories of















l% patients spending time off active waiting list
Figure 4.5 Proportion of patients spending time off the active waiting list in





















































□ Time off active waiting list
Figure 4.6 Time spent off the active waiting list (days) for different groups of
transplant recipients (*, Mann-Whitney U test, p<0.05 statistical significant)
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When the four transplant centres were compared, significant differences were
noticed. Centre 1 has the highest threshold for suspending patients from the list, only
6.3% of the transplant recipients spending time off the active waiting list, but the
actual suspension time is by far the longest (median 70 days). Almost 70% of the
patients that are eventually transplanted in centre 3 acquire suspensions from the
active waiting list. This unusually high proportion may be due a more precise record
keeping and patient status tracking to avoid unnecessary shipping of well-matched
kidneys for unsuitable recipients.
There are no differences in the proportion of suspended patients according to their
age. In fact the elderly group (>65 years old) has the lower proportion of suspensions
(15%) but these patients spend the longest time off the active list (median 137 days),
almost three times longer than all other transplant recipients.
Significant differences in both the proportion of patients and the length of time off
the list are noted according to the primary renal disease. Nearly one third of the
diabetic patients spend an average four months suspended or removed from the list
prior to receiving a transplant.
Although there are differences in the length of time spent on the active waiting list
depending on the associated medical pathology, the presence of any given comorbid
condition does not lead to a prolonged length of time spend off the list nor to
increased numbers of patients being suspended.
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4.4 DISCUSSION
The general health status of a patient is a significant factor in deciding eligibility for
the waiting list and renal transplantation. This decision is most frequently governed
by previous experience and strong clinical reasons (170;222) rather than being
evidence based, as data to support the impact of the associated medical conditions on
the likelihood of listing and transplantation (130; 131 ;218) and survival is scarce.
Comorbidity is not collected exhaustively and routinely and some of the difficulties
in determining the magnitude of its' impact have been alluded to in the introduction.
Although attempts have been made in the US, where the United States Renal
Database System (USRDS) and the Health Care Financing Administration (HCFA)
collected some core comorbidity data as part of quality-assurance monitoring (220),
no further significant developments have taken place. Therefore, there is a need to
collect accurate data prospectively, which will allow a systematic and "definitive"
analysis of the magnitude of comorbidity effect on access to the transplantation
service and survival.
This study presents, in a large sample of adult patients listed for transplantation in
Scotland, a systematic, national-level analysis of the relationship between the
comorbidity conditions present when patients are listed for transplantation and access
to the waiting list and renal transplantation.
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There are an important number of comorbid factors that determine how quickly a
patient is likely to be listed. Left ventricular hypertrophy, respiratory or cerebro¬
vascular diseases exert an independent negative effect on the speed of access to the
renal waiting list. In addition, marginal effects were noted for patients with diabetes
not leading to renal failure, and urological pathology, but the value of this latter
finding must be interpreted with care in the absence of a predictive value in the
univariate analysis. Interestingly, the presence of hypertension will lead to a shorter
time on dialysis pre-listing. If this is interpreted as a marker of an advanced stage of
the disease (when hypertension is almost the norm) and inadequacy of the
replacement dialysis therapy, one can speculate that patients reaching a certain phase
of the disease tend to be referred and accepted for transplantation much quicker than
other patients. A few other indicators of cardio-vascular status - ischaemic heart
disease, heart failure, valvular disease and peripheral vascular disease - despite a
significant association with a longer waiting time in a univariate analysis, did not
reach statistical significance in a multivariate Cox model. A few explanations may be
possible. First of all, there may be a potential association of these variables with
other factors included in the model. Secondly, this analysis was carried out in
patients that were eventually listed and hence their true impact on the likelihood of
listing could not be assessed. There is no reason to believe that the significant
association with lower transplantation rates noted elsewhere (130) will not be seen in
Scotland, particularly on a background of increased incidence of cardiovascular
morbidity. However, this point cannot be proven by the present study, but the longer
waiting time to listing can be used as a surrogate marker of the effect of each
comorbid condition.
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Although a number of comorbid conditions have a significant impact on the
likelihood of transplantation in a univariate analysis (peripheral vascular disease,
ischaemic heart disease, cardiac arrhythmias, left ventricular hypertrophy, GI
disorders and hyperparathyroidism), only two of them - cardiac arrhythmias and
hyperparathyroidism - remain predictive in a multivariate study. It is interesting to
note that the number of comorbid condition that influence the chances of listing is
much higher than those which will impact on the likelihood of transplantation. This
denotes a significant selection process when patients are assessed, few patients with
significant associated medical conditions being considered suitable for a kidney
transplant in the current practice. In other words, the prevalence of the comorbid
conditions is worse among patients on dialysis compared with kidney transplant
recipients.
The use of a complex model which controls for the comorbid conditions allows not
only to determine the impact of each associated medical condition, but more
important, to assess the changes in a basic model containing only socio-demographic
variables. When the two models predicting the access to the waiting list were
compared, a moderate improvement in the power of the model was noted. However,
the level of significance of the individual socio-demographic variables was not
diminished by the addition of comorbidity, female patients, elderly patients,
diabetics, patients with multisystem disease and patients on haemodialysis waiting
longer to be listed.
There are significant changes in the predictive value of the socio-demographic
variables when the model of access to transplantation is corrected for comorbidity. In
a basic model, patient's age was an independent predictor of access to
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transplantation, but after adjustment for comorbidity, the effect becomes non¬
significant, patients under the age of 60 having similar transplant rates when
compared with those aged 18-35 years old. This suggest that age does not have an
independent impact on access to transplantation until the age of 60 and that the lower
transplantation rates noted for the patients < 60 years old in the basic socio-
demographic model are due to a higher prevalence of comorbid conditions in this
group. A similar change was noted for the primary renal disease, after adjustment for
comorbidity, the differences between various diagnostic groups becoming less
prominent. The lower transplantation rates for diabetics compared with
glomerulonephritis patients approached statistical significance prior to comorbidity
adjustment but were comparable afterwards, implying that diabetic patients have a
higher index of associated medical conditions, which is responsible for their lower
transplantation rates.
It is not surprising that patients with certain comorbid conditions wait longer prior to
listing (figures 4.1 and 4.2) and transplantation (figures 4.3 and 4.4) but it is
important to highlight two important issues. First of all, with the current assessment
protocols, once a patient is listed, there is very little in terms of significant comorbid
illnesses that will preclude someone from becoming a kidney recipient. This is likely
to change with the trend towards more elderly and other higher risk patients being
put forward for assessment. Therefore a prospective study involving all patients
starting RRT may be the answer to address the impact of all these factors on access
to transplantation. Secondly, the differences highlighted here indicate that patients
who will remain longer on dialysis have a higher prevalence of comorbidity. As
previous studies focusing on survival found (as expected) a higher mortality risk
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associated with the presence of comorbid conditions (220), it is also important to
revisit the question of survival and to compare the benefit of transplantation with that
of dialysis in various groups of patients adjusting for the comorbidity load. By doing
so, one can estimate the risk of death on either treatment modality and than draw
valid, evidence-based criteria for selecting patients onto the waiting list.
Furthermore, this will allow patients to make a fully informed choice regarding the
best form of treatment, their chances of receiving a kidney transplant and the
likelihood of survival according to their general health status.
This study is one of the first of its kind to incorporate the comorbidity load and it
provides a more accurate picture of the equity of access to the transplantation service
across Scotland. However, the conclusions of this analysis are drawn on 60% of all
adult patients listed within the study period and therefore they must be interpreted
with care and not extrapolated to the whole population. The retrospective, single-
handed collection of comorbidity is far from ideal and may expose the results to bias.
Within these limitations, the value of these analyses lies in the fact that for the first
time in these sort of investigations a complete picture of the general health of the
transplant candidates has been accounted for. In terms of the findings, it is clear that
the differences in access to the waiting list and transplantation noted for different
socio-demographic variables cannot be explained entirely by the presence of the
comorbid conditions.
In summary, the presence of comorbid conditions in a transplant candidate is likely
to increase the waiting time by a significant margin, but the number of significant
factors may be lower than previously expected. The addition of comorbid conditions
to a model of access to renal transplantation improves its' predictive power but
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socio-demographic variables (gender, age, primary renal disease, type of first
dialysis, deprivation category, transplant centre) remain important indicators of








It is very important to highlight differences in access to the transplantation services
as kidney transplantation provides an important treatment option. Improvements in
immunosuppressive medication, organ procurement and preservation, patient
assessment and selection as well as surgical technique have resulted in graft survival
ranging between 80 and 90% after 1 year and 65 to 70% after five years (Table 1.1,
Chapter 1). Furthermore, renal transplantation is associated with a superior quality of
life and a significant cost-benefit (25;223). Survival on dialysis itself has improved
throughout the years due to better therapeutic regimens and patient monitoring.
Given the continuing increase in the number of patients requiring renal replacement
therapy and the considerable expenses associated with this treatment, it is important
to determine the likelihood of survival on both dialysis and transplantation.
Many of the epidemiological studies comparing the outcome of the two treatment
modalities in the 80's (224;225) failed to identify a significant survival benefit of
transplantation over dialysis and this obviously raised the issue of whether
transplantation is beneficial for all patients on dialysis (226). However, most of these
studies (138;225;227) were seriously biased for a few reasons. First, comparisons
were made between transplant recipients and all chronic dialysis patients. The benefit
of transplantation may have been exaggerated by this method, as patient selection is
likely to play a significant role, transplant recipients being selected from a group of
patients considered fit for transplantation, who are on average, younger and have less
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comorbidity (126;130;146). Furthermore, some investigations are not valid as they
compare survival from time of transplantation for transplant recipients with survival
from the start ofRRT for dialysis patients. Thirdly, in these analyses, there is a time-
to-treatment bias, as transplantation takes place at a variable interval from listing.
This needs to be corrected with a time-dependant analysis (228), which attributes
survival before transplantation to the dialysis group. On the other hand, these
comparisons were done in the pre-cyclosporine era, when transplant survival was
significantly lower than currently attainable.
Recent studies from Michigan (21) and Ontario (229) as well as a national-based US
investigation (19) have eliminated these biases, comparing survival in patients who
were listed for transplantation and using a "time-to-treatment" approach. A
comparison of the crude death rates in these studies (table 5.1) shows that
transplantation reduces the chances of dying by about 20-40%.
Study Patients listed Crude death rate Patients Tx Crude death rate
Michigan 1569 10.7 799 8.6
Ontario 1156 5.0 722 3.4
US study 46164 6.3 23275 3.8
Table 5.1 Crude death rate for listed patients and transplant recipients (death
calculated per 100 years of patient follow-up).
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An analysis of survival at various time points following a kidney transplant showed
that the risk of dying following transplantation is significantly higher in the
immediate postoperative period when compared with dialysis. The risk levels out
during the first year and becomes significantly lower after this period, as shown in
table 5.2.












































Table 5.2 The relative risk of death following transplantation at various time points,
compared with dialysis. (The reference group are all patients listed for
transplantation on dialysis)
The US based study published by Wolfe et al. (19) uses a more complex statistical
analysis, with an exponential decay component which is closer to real life situation
and allows the calculation of the number of days between placement on the waiting
list and the time when the death rates becomes equal in the two groups.
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However, most of the findings reported so far are based on the US experience, where
patient selection and access to transplantation are different from most other
programmes and therefore, these results cannot be extrapolated to a European setting.
Furthermore, survival on dialysis and the 5-year survival on transplantation are
significantly lower in the US than in United Kingdom (appendix, table A.2, page 330
and table A.3, page 331) and the rest of Europe (230;231). Although much more
limited, there is some data from European single centre analyses (152;232) that
confirm the results of the American studies, with a substantial benefit for
transplantation compared with dialysis (Relative risk of death of 0.23, 0.34 and 0.31
at 3, 5 and 8 years from listing respectively) (152).
Nevertheless, these studies are small, and there is no large, national experience
reported yet. As there are no UK data on this issue, we decided to investigate




All 1736 adult patients that started dialysis and who were listed for transplantation
between 1st of January 1989 and 31st ofDecember 1999 in Scotland were considered
for this study. Demographic data for these patients obtained from the Scottish Renal
Registry and UK Transplant included: age at listing/transplantation, dates of listing
and transplantation, dates of death and last follow-up, gender, primary renal disease,
type of first replacement therapy and length of dialysis pre-listing, deprivation score
and listing/transplant centre. Extensive data on comorbidity accrued until listing was
collected from the case-notes for 1022 patients (59% of all patients listed) (see
chapter 4).
Two Cox regression models (unadjusted and adjusted for comorbidity) were built to
identify the factors associated with an increased risk of death in the dialysis
waitlisted patients and among transplant recipients. Patients who received a
transplant were censored at the time of grafting in the dialysis group analysis.
Survival was considered from the time of listing until death, end of study (December
2000) or last follow-up available whichever came first. A time-dependant Cox
regression analysis (228), adjusted for the demographic (model 1) and comorbidity
variables (model 2), was employed to account for the fact that patients switch
between dialysis and transplantation during follow-up. All patients contributed
follow up time to the dialysis group, while those receiving a kidney transplant
contributed follow-up to the transplant group after grafting (221 ;233). The effect of
transplantation is reported as relative risk (RR) of death, which is the ratio of death
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among transplant recipients relative to dialysis patients on the waiting list. The
average relative risk of death was estimated for three intervals following
transplantation: 0-30 days, 31 - 365 days and beyond 365 days and is presented
with 95% confidence intervals. The analysis was performed in an intention to treat
manner, patients being kept in the analysis, irrespective of subsequent suspensions
from the waiting list or graft loss. This type of analysis will estimate the impact of
receiving a transplant on survival, irrespective of the subsequent fate of the
transplanted kidney. A separate analysis to estimate the impact of a functioning
transplant on survival was performed as a comparison, censoring transplant
recipients at graft failure (including death with functional graft). In this analysis,
after the transplant failed, surviving patients contributed follow-up to the dialysis
group.
Survival curves were generated using a Kaplan-Meier method, while differences in
proportions and means were tested using '/J test and t-test respectively, with a p value
< 0.05 considered as significant. The projected years of life on dialysis and with a
kidney transplant from the waiting list moment were determined assuming a constant
death rate throughout the study period. In the groups which are not followed up until
50% of the patients have died, a continuing death rate equal to the one observed was
assumed. Based on individual times of transplantation, the life expectancy was
determined for each patient. This allowed the calculation of an average for each
subgroup and for the whole study population.
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5.3 RESULTS
4532 adult patients started renal replacement therapy between 1st of January 1989
and 31st of December 1999. 1736 patients (38%) were listed and 1095 (24%)
received their first kidney transplant by the end ofDecember 2000.
The survival curves for all patients in the analysis according to their treatment
modality and irrespective of the "time-to-treatment" variation suggests a substantial
benefit of transplantation over patients on dialysis, irrespective of their waiting list
status. In addition, there seems to be a significant selection process for access to the
waiting list, as patients who are eventually listed have a large survival advantage
over patients on dialysis who have no access to the waiting list (Figure 5.1).
Survival from 1st RRT (years)
Figure 5.1 Survival curves for all patients starting RRT, according to the treatment
status
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There is a 63% reduction in the death rates for patients on dialysis who are listed
compared with their counterparts who are never listed. Patients who receive a kidney
transplant benefit from a further reduction in the mortality rates of 54% compared
with listed patients who remain on dialysis (table 5.3).
RRT patients Waiting list Tx group
Number Death rate Number Death rate Number Death rate
4532 24.30 1736 9.02 1095 4.13
Table 5.3 Mortality rates for patients on dialysis, patients listed for transplantation
and transplant recipients. (Rate per 100 patient-years of follow-up).
Table 5.4 shows the demographics at the listing moment for all patients and for the
two treatment groups (dialysis and transplantation). Although all these patients were
considered suitable for transplantation and listed, there are significant differences
between the two groups, transplant recipients being listed at a younger age (43 versus
53 years) and sooner after starting renal replacement therapy (0.5 versus 0.78 years).
In addition, there is a significantly higher prevalence of diabetes and multisystem
diseases as a cause of renal failure in the dialysis group (p<0.0001, % ) compared












Age at listing (mean±SD) 46.60±14.14 52.77±12.92 42.98±13.56 <0.0001 *t
Gender(%) 0.799
Male 61.4 61.8 61.2
Female 38.6 38.2 38.8
Time from 1st RRT to 0.60±0.91 0.78±1.01 0.49±0.82 <0.0001*{
listing (mean±SD)
Deprivation category (%) 0.545
1 5.4 5.9 5.0
2 12.6 12.0 12.9
3 24.3 26.3 23.0
4 25.7 24.0 26.7
5 14.3 13.2 15.0
6 12.1 12.6 11.8
7 5.7 5.9 5.6
Primary renal disease (%) <0.0001*
GN 25.8 20.4 29.0
IN 30.3 24.0 34.1
Multisystem 14.7 18.2 12.7
Diabetes 14.6 19.2 11.9
Other 14.5 18.2 12.3
Type of first dialysis (%) 0.393
PD 60.3 61.2 59.8
HD 39.7 38.8 40.2
Table 5.4 Demographic characteristics at listing for all patients and for the two
treatment groups. (* statistical significant, J Two independent samples T-test, all
other i2)
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A comparison of the comorbidity accrued until listing in the two treatment groups is
shown in table 5.5. Patients who remain on dialysis have a higher incidence of
cardiovascular problems and peripheral vascular disease. Those on dialysis have
twice the incidence ofmyocardial infarction and angina seen in transplant recipients,
while valvular disease, arrhythmias, heart failure and left ventricular hypertrophy are
also more common in the non-transplant group. There is a significantly higher
prevalence of respiratory disease, cerebrovascular diseases (TIA's, CVA's) and
gastrointestinal pathology in the dialysis group. These patients have higher lipid
levels and smoke (active or ex-smokers) in higher proportions than those who
receive a kidney transplant.
Using a Cox regression analysis unadjusted for comorbidity (table A. 16, appendix,
page 352 and table A. 18, appendix, page 354) the demographic factors with a
significant impact on the risk of dying, in both the dialysis and transplant groups,
were identified. As shown in table 5.6, there is a significantly higher risk of death for
both dialysis patients and transplant recipients with increased age.
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Dialysis group Transplant group p value
(n=312) (n=702)
PVD 20.2 9.0 <0.0001*















Valvular disease 17.3 8.7 <0.0001*
PE 1.6 1.4 0.830
Arrhythmias 10.0 3.0 <0.0001*




LVH 41.3 29.1 <0.0001*
Respiratory disease 17.2 12.8 0.061
CVD 12.9 8.6 0.035*
Previous neoplasia 2.3 2.1 0.919
GI disorders 29.7 19.4 <0.0001*
Hyperlipidaemia 15.3 8.3 0.002*
Smoker 50.1 41.7 <0.0001*
BMI (meaniSD) 24.7315.38 24.0414.87 0.051$
Table 5.5 Comorbidity prevalence in the two treatment groups at listing (*
statistical significant, J Two independent samples T-test, all other x2)
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Covariate Dialysis patients on p value Transplant patients p value
the waiting list
RR (95%CI) RR (95%CI)
Gender
female vs. male 0.913(0.713-1.171) 0.475 0.973 (0.705-1.343) 0.868
Renal disease <0.0001* <0.0001*
GN 1 1
IN 0.776 (0.515-1.169) 0.945 (0.620-1.441)
MS 1.139 (0.750-1.732) 1.081 (0.666-1.756)
Diabetes 3.454 (2.399-4.973) 2.642(1.705-4.091)
Other 1.352 (0.903-2.024) 1.139 (0.663-1.956)
Type of 1st RRT
HD vs PD 1.176(0.913-1.514) 0.210 1.424(1.049-1.932) 0.023*
Age at listing <0.0001* <0.0001*
18-34 1 1
35-49 2.743 (1.579-4.767) 2.303 (1.353-3.919)
50-59 4.518(2.648-7.710) 4.573 (2.728-7.666)
60-64 5.500 (3.069-9.854) 8.172 (4.513-14.797)
>65 7.588 (4.355-13.221) 8.679 (4.779-15.761)
Time to listing
per year 1.355 (1.189-1.544) <0.0001* 1.074 (0.880-1.311) 0.485
Time from
waiting list to Tx - 1.000(0.999-1.000) 0.436
peryear
Table 5.6 Risk of death by demographic factors in the dialysis group and after
transplantation (unadjusted for comorbidity). (*, Statistical significant)
Diabetes as a cause of renal failure leads to the highest risk of dying on the waiting
list, as well as after transplantation, when compared with glomerulonephritis patients
[RR=3.454, 95%CI: 2.399-4.973 and RR=2.642, 95%CI: 1.705-4.091 respectively].
The time elapsed between the start of RRT and listing is a significant predictor of
death for dialysis patients but not for the transplant recipients. Every increase of one
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year in the length of time on dialysis prior to listing is associated with an increase in
the risk of dying on the waiting list of 1.355 (95%CI 1.19-1.54). The time spent on
the waiting list before receiving a kidney allograft has no impact on the risk of dying
after transplantation. Interestingly, patients who start RRT on haemodialysis have a
higher risk of death compared with those on peritoneal dialysis if they receive a
kidney transplant, but not if they remain on dialysis on the waiting list.
When comorbidity conditions are taken into account (table A. 17, appendix, page 353
and table A. 19, appendix, page 355), all the variables identified in the previous
models remain predictors of a higher risk of death. As shown in table 5.7, the
presence of ischaemic heart disease, respiratory and cerebrovascular diseases in a
transplant candidate is associated with an increased risk of death on dialysis, while
previous neoplasia and gastrointestinal pathology are associated with a higher risk of
dying following transplantation.
Covariate Dialysis patients on p value
the waiting list



















Table 5.7 Comorbidity factors associated with an increased risk of death on dialysis
and after transplantation (adjusted for demographic variables). (*, Statistical
significant)
185
The relative risk of death for transplant recipients compared with patients on the
waiting list varies depending on the length of follow-up. The average risk (95%CI)
was determined for three periods following kidney transplantation: 0-30 days, 31-365
days and beyond 365 days and is shown in table 5.8.
All patients < 30 (lays 31 -365 days > 365 days
No comorbidity adjustment 1.35 (0.63-2.86) 0.67(0.48-0.95) 0.32(0.25-0.40)
Comorbidity adjusted 0.91 (0.22-3.70) 0.50(0.28-0.90) 0.28(0.20-0.39)
Table 5.8 Relative risk of mortality over time after transplantation versus dialysis
patients on the waiting list. (Non-proportional Cox models adjusted for age, gender,
primary renal disease, social deprivation, time since waitlisting [model 1] and
comorbidity [model 2])
When compared with patients on the waiting list, transplant recipients appear to have
an increased risk (although not statistically significant) of death within the first
month following grafting (RR=1.35, 95%CI: 0.63-2.86). The risk becomes lower
during the first year post transplant and is significantly reduced beyond one year. The
long-term mortality risk for transplant recipients is 68% lower than that of patients
on the waiting list (RR=0.32; 95%CI: 0.25-0.40; p<0.0001). The same evolution of
the risk of death was noted when the model was adjusted for comorbidity factors
(table 5.8).
The outcome varies among different subgroups of kidney transplant recipients, as
shown in table 5.9.
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Subgroup < 30 days 31 - 365 days > 365 days
Gender
Male 1.51 (0.37-6.28) 0.55 (0.26-1.17) 0.29(0.18-0.45)
Female - 0.50(0.20-1.29) 0.32 (0.18-0.59)
Primary renal disease
GN - 0.38(0.08-1.72) 0.16(0.07-0.39)
IN - 1.09(0.39-3.04) 0.28(0.13-0.61)
Multisystem disease 1.82 (0.22-14.80) 0.48 (0.13-1.77) 0.13 (0.04-0.38)
Diabetes 1.28(0.17-9.83) 0.40 (0.12-1.36) 0.33 (0.15-0.74)
Other - - 0.11 (0.02-0.70)
Age groups
18-34 - - 0.23 (0.05-1.14)
35-49 - 0.64 (0.25-1.61) 0.26(0.11-0.57)
50-59 1.44(0.19-11.19) 0.37(0.11-1.26) 0.12(0.05-0.27)
60-64 - 0.30 (0.03-2.81) 0.19 (0.04-0.98)
>65 2.38 (0.27-20.84) 0.81 (0.23-2.91) 0.34(0.14-0.83)
Table 5.9 Relative risk of mortality over time after transplantation versus dialysis
patients on the waiting list in different sub-groups of patients. (Non-proportional Cox
models adjusted for age, gender, primary renal disease, social deprivation, time since
waitlisting, comorbidity) (-; risk could not be calculated due to too few deaths)
In all groups where the risk could be calculated, there seems to be a higher
probability of dying in the immediate post-transplant period. The risk becomes equal
during the first year and is significant lower beyond one year in most patients
receiving a kidney transplant compared with patients on dialysis, with the exception
of patients aged 18-34 years old for whom the benefit of transplantation is not
significant even at this time point (RR=0.23; 95%CI, 0.05-1.14; p=0.07).
Diabetic patients have a 67% lower risk of dying at one year after transplantation
compared with patients on dialysis (RR=0.33; 95%CI, 0.15-0.74). Although the
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initial (<30 days) excess risk was small and not statistically significant, the long term
benefit is inferior to that observed in patients with multisystem disease or
glomerulonephritis who have an 87% and 84% lower risk of dying one year after
grafting. However, statistical comparisons between groups according to the primary
renal disease were not appropriate, as the reference group was different for each
cause (patients on the waiting list with the respective diagnosis).
There is a significant death risk reduction following transplantation in all age groups.
The greatest benefit is achieved in patients aged 50 - 59 years old, while patients
aged 18-34 years old see no significant benefit from being transplanted even at one
year after grafting.
When survival after transplant is censored for graft failure, the impact of a
functioning transplant on survival is determined. As shown in table 5.10, similar
results as the ones described so far are obtained. The immediate post-transplant risk
of death is significantly higher compared with dialysis and it evens out during the
first year. At 12 months, a functioning graft increases a patient's chances of being
alive by 70% compared to dialysis.
Allpatients < 30 days 31 - 365 days > 365 days
No comorbidity adjustment 4.69(3.06-7.17) 0.82 (0.60-1.14) 0.31 (0.24-0.39)
Comorbidity adjusted 3.22(1.48-6.98) 0.69(0.41-1.15) 0.30(0.21-0.43)
Table 5.10 Relative risk of mortality over time with a functioning transplant
compared to dialysis patients on the waiting list. (Non-proportional Cox models
adjusted for age, gender, primary renal disease, social deprivation, time since
waitlisting [model 1] and comorbidity [model 2])
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The projected life span was 5.84 years for patients remaining on dialysis and 17
years for the transplant recipients. The differences in the projected life expectancy
between transplant recipients and dialysis patients are shown in table 5.11. There is a
comparable increase in life expectancy for both genders. Although diabetic patients
seem to have the shortest life span, in fact transplantation in these patients leads to
the highest proportional increase in the life expectancy compared with other causes
of renal failure. In patients aged > 65 years old, transplantation leads to a twice
longer life expectancy compared with dialysis, this proportional increase being
greater than that noted in patients aged 18-34 years old.
Years of life on dialysis Years of life with a
kidney transplant











18-34 yr 27.22 41.50
35 - 49 yr 6.71 18.03
50 - 59 yr 5.12 11.18
60 - 64 yr 4.32 7.84
> 65 yr 3.69 7.60
Table 5.11 Projected years of life for patients on dialysis and transplant recipients,
from the moment of listing for transplantation
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5.4 DISCUSSION
The long term survival and risk of death are two of the main indicators for the
success of any medical procedure. Since the early days, the outcome of renal
transplantation has been compared with that of various dialysis methods. Most of
these studies however, were biased by the lack of accurate statistical methods (234).
Recent studies, which have eliminated the different biases, described earlier in this
chapter, have proven that transplantation provides a significant survival advantage
when compared with dialysis (19;21;229), however, data on comorbidity in these
studies are limited. Such comparisons based on UK data were not available until
now.
In Scotland, there is a significant selection process in listing patients for
transplantation. This is illustrated by a 60% reduction in the crude mortality rates for
those listed. Furthermore, patients who have access to transplantation, enjoy a further
reduction in the mortality risk of about 54%. These results are similar with those
reported by Wolfe et al. (19) and other researchers (229) and therefore any survival
comparisons between the two treatment modalities should be carried out only in
listed patients, to eliminate the selection process.
Although all patients in this analysis were considered suitable for transplantation,
there are significant differences between the two groups. Transplant recipients are
listed at a younger age and spend a shorter time on dialysis pre-listing than those who
remain on the waiting list. Also, fewer diabetics and patients with multisystem
disease were transplanted during the follow-up period. As this study covers an 11
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year period, these findings seem to suggest significant variations in the selection
process as well as a trend to include an increasing number of high-risk patients in the
transplantation programme more recently (229;235). A comparison of the
comorbidity load confirms this hypothesis, patients who are listed and on dialysis
having more comorbid conditions such as peripheral vascular disease, cardio¬
vascular, respiratory or cerebrovascular problems (table 5.5), which may preclude
them from receiving a transplant. Furthermore, some of the demographic variables
(age, primary renal disease, time to listing) and comorbid conditions (table 5.7) have
an impact on survival on both treatment modalities and therefore any survival
analysis must be adjusted for these factors.
The recipients of a kidney transplant have a 68% lower long term (> 1 year) risk of
dying compared with dialysis patients on the waiting list after adjustment for age,
gender, primary renal disease, length of time on dialysis. Similar reductions in the
mortality risk (64 to 75%) were reported in the US (19), Canada (229), Germany
(152) and Sweden (232). International comparisons are difficult, due to differences in
survival on dialysis (230;231) and transplantation between North America and
Europe, but despite the absolute differences in crude mortality rates, the results of
these similarly constructed and conducted studies indicate that the effect of
transplantation on survival is comparable across the western world.
As comorbidity accrued by patients until the listing moment has a significant impact
on the chances of transplantation and survival, we conducted a second analysis on
60% of the listed population for whom these data were available. Significantly more
high-risk patients remain on dialysis on the waiting list rather than receiving a
transplant, but even after adjustment for comorbid conditions as well as other
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demographic variables, transplantation has a persistent survival advantage at one
year (RR=0.28, 95%CI: 0.20-0.39) compared with dialysis. Although these results
cannot be extrapolated to the whole study population, they are a powerful indicator
that transplantation effect is real and it is not induced by selection of healthier
patients.
The effect of transplantation on survival varies with time. In the immediate
postoperative period, there seems to be an increased risk of death for transplant
recipients (RR=1.35, 95%CI: 0.63-2.86). Although these findings did not reach
statistical significance, they are in agreement with other published data, suggesting
that there is an increased risk of death in the immediate postoperative period. The
lack of statistical significance may be explained by an improved postoperative care -
which leads to fewer postoperative deaths, and a more strict selection of patients for
transplantation in the UK. This seems to be confirmed in the comorbidity adjusted
model, where the risk of dying following transplantation is lower than the risk of
death on dialysis at all time points.
The magnitude of transplantation survival benefit is not equal for all patients, as
shown in table 5.9 and previously reported (19;21;23;236). The risks of death on
either transplantation or dialysis are not significantly different in the first
postoperative year. Beyond a year, all patients have a better survival with a
transplant, irrespective of their primary renal disease. However, patients with
diabetes have an inferior long-term benefit when compared with glomerulonephritis
patients. This may be due to the fact that diabetic patients represent a high-risk
group, which is illustrated by the low proportion of transplants in diabetics (11% vs.
29% with glomerulonephritis). These findings are in contrast with previous reports
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from the US (21; 143), where over 30% of the transplants take place in diabetic
recipients and the survival advantage following transplantation is greater than that
attained in glomerulonephritis patients.
Age has a significant impact on the long-term survival chances of a patient,
irrespective of the treatment modality. These data indicate that in Scotland, the
greatest survival gain associated with transplantation is obtained in patients aged 50-
59 years old (RR=0.12, 95%CI: 0.05-0.27). But, perhaps more important, is the fact
that patients aged 60-64 years old enjoy a benefit from being transplanted of similar
magnitude as patients aged 18-34 years old, in whom, even at one year, survival on
dialysis is not significantly inferior to transplantation.
Diabetes is acknowledged as a powerful predictor of death among dialysis patients
(236;237) but as shown here and in most studies quoted before (19;21;229), these
patients do benefit from renal transplantation. If one compares the survival benefit in
diabetics (RR=0.33) with that obtained in patients over 65 years old (who are usually
considered to be medically high risk) (RR= 0.34) it is difficult to advocate why
transplantation should not be offered to these patients, and indeed other patients
considered high-risk, currently not transplanted.
The overall projected increase in the life expectancy with transplantation is 12 years,
with variation between 3.5 and 14 years for different groups of patients. Similar
benefits have been previously reported in only one large study from the USA (19).
These results should be interpreted with caution for several reasons. First of all, they
represent extrapolations and therefore the larger estimates may not be accurate.
Secondly, this study covers an 11 years period, and during this time there have been
improvements in survival for all patients, irrespective of their treatment modality.
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Therefore, for some groups of patients, these particular findings may not be
predictive.
This study uses an intention to treat analysis, whereby patients are considered to be
on the waiting list irrespective of subsequent periods of suspension or permanent
removal. Furthermore transplant recipients contributed for the survival on
transplantation, irrespective of whether they lost their grafts during the follow-up and
returned to dialysis. This has the potential to bias the results in favour of
transplantation. There is evidence, from a smaller single-centre study (152), where
both an intention to treat analysis as well as an analysis censoring patients at removal
from the waiting list or loss of transplant function were performed, that
transplantation does provide a significant survival benefit compared with dialysis. On
the other hand, most patients are removed from the waiting list due to deterioration in
general health and they are likely to die soon after. This has the potential of
rendering the death rate on the waiting list almost zero, which would make further
comparisons biased as well. In the current analysis it was impossible to identify with
certainty the reasons why patients were removed from the waiting list and hence an
intention-to-treat design was used. However, it was possible to determine when the
graft failed, and therefore a second analysis, censored for graft failure was carried
out. This analysis estimated the impact on survival of having a functioning graft and
confirmed that immediately after transplantation there is an increased risk of death,
but 12 months after a kidney graft, there is a substantial survival benefit over
dialysis.
In summary, this study provides evidence that in the current setting of end stage renal
failure care in Scotland, there is a substantial long-term survival advantage for
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transplantation compared with dialysis. This effect is intrinsic to the treatment itself,
rather than an effect of patient selection or higher dialysis mortality. As expected, the
survival advantage is not equal across all patients groups, but even high-risk patients
enjoy a substantial benefit from being transplanted. This should prompt us to re¬
consider selection and assessment for transplantation and perhaps a risk assessment
score rather than simple criteria such as old age or certain comorbidity should be
used to admit patients to the waiting list. In addition, these findings provide a
powerful clinical tool, which should be used when advising patients regarding the
suitability of dialysis or transplantation as treatment for their end stage renal disease.
In a wider perspective, in the current climate of organ shortage, emphasizing the life
saving benefit of renal transplantation to the public may have a positive effect on










Assessment for listing is the most important step in the pathway to transplantation
where someone may be denied further access to the service. There are no uniform
criteria for listing, and practices vary widely (199;238). These differences may lead
to serious bias against various groups of patients, depending on the transplant centre
where they are referred for assessment. Recently, guidelines for assessment and
listing were published by the American Transplant Society and suggested by the
European Dialysis Association. Most of these guidelines are evidence based and are
likely to minimise some of the differences noted previously.
There are no such guidelines in UK, and although the practice is pretty much
uniform, there are significant centre variations.
This study aims to present the current status in assessment for listing in Scotland and
to highlight whether there are any major differences in assessment between the
transplant centres as well as investigating the outcome of transplanting some high
risk patients.
To address these issues, a series of separate analyses investigating the differences in
practice across Scotland as well as the benefit of transplantation in high risk groups
of patients (elderly patients and diabetic recipients) were carried out.
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6.2 Patient assessment - current status
6.2.1 Methods
All 1736 adult patients listed for transplantation within the study period (1st of
January 1989 - 31st of December 1999) were considered for these analyses. As
shown in the previous chapters, sociodemographic data from the SRR and UKT was
collated for all patients and in addition, more than 40 comorbidity variables
(appendix, page 348-351) were gathered for 59% of the patients on the list (n=1022).
A comparison of the distribution of sociodemographic (age, gender, deprivation
category, primary renal disease, type of first dialysis method) and comorbidity
variables (diabetes, peripheral vascular disease, cardio-respiratory diseases, cerebro¬
vascular problems and other detailed in the appendix) across the waiting list
population and between the four transplant units was carried out to identify the
groups of patients where differences in practice are most obvious.
Chi-square, Fisher's exact test, t-test and Mann-Whitney U tests were used where
appropriate, to determine the statistical significance of the differences observed.
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6.2.2 Results
The distribution of the socio-demographic variables across the waiting list population
has been discussed in chapter 3. The summary shown in table 6.2.1 highlights that
there are significant differences, with female patients, elderly patients, diabetics and
more deprived patients being less likely to be listed for transplantation.
There is a significant centre effect and these differences may reflect a
sociodemographic disparity between the patients seen in each centre, as well as a
different clinical view to who actually represents a suitable candidate for
transplantation.
A comparison of the proportions of patients listed by gender (figure 6.2.1) revealed
significant differences, nearly 54% of all males starting dialysis in centre 1 being
listed compared with only 37% of those starting RRT in centre 4. A similar
disproportion (50% versus 33%) was noted for females between the same centres.
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RRT population WL population
Gender Male 58.5 61.4
Female 41.5 38.6












Primary renal disease Primary GN 16.8 25.8
Interstitial nephritis 21.7 30.3
Multisystem disease 23.3 14.7
Diabetes 16.2 14.6
Other/unknown 22.0 14.5
Type of first dialysis Haemodialysis 70.2 60.3
Peritoneal dialysis 29.8 39.7











Renal unit in same Yes 58.3 63.1
hospital with Tx centre No 41.7 36.9
Listing transplant centre Centre 1 12.6 16.4
Centre 2 10.0 11.6
Centre 3 20.8 21.8
Centre 4 56.6 50.2
Distance to listing centre <50 km 85.6 84.8
50- 100 km 7.2 7.9
>100 km 7.2 7.3
Table 6.2.1 Sociodemographic distribution of the dialysis and waiting list














□ Centre 1 □ Centre 2 □ Centre 3 □ Centre 4
Figure 6.2.1 Proportion of patients listed for transplantation from the total starting
dialysis in each centre, according to gender
There are significant differences in the proportions of patients listed in each of the
four centres according to the primary renal disease. While for some of the causes of
renal failure (glomerulonephritis, interstitial nephritis or other causes) the differences
between centres are in the range of 10-15%, the largest disproportion is noted for
diabetic patients. Nearly 50% of the diabetics starting RRT in centres 1 and 2 are
listed compared with only 38% and 29% respectively in centres 3 and 4.
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□ Centre 1 □ Centre 2 □ Centre 3 □ Centre 4
Figure 6.2.2 Proportion of patients listed for transplantation from the total starting
dialysis in each centre, according to the primary renal disease (IN = interstitial
nephritis, MS = multisystem disease)
Even more striking differences were noted according to patient's age. There seem to
be a uniform approach in all centres for listing young (18-34 years old) patients -
more than 80% listing rates - but the older the patient, the larger the differences. It
appears that patients over 60 years old starting dialysis in centres 1 and 2 have a
better chance of being listed compared with those starting RRT in the remaining two
centres. Although the overall number of patients starting RRT is much higher in
centres 3 and 4 (table 6.2.1), these differences cannot be explained only by the
workload and a longer time to assess the potential candidates.
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□ Centre 1 □ Centre 2 □ Centre 3 □ Centre 4
Figure 6.2.3 Proportion of patients listed for transplantation from the total starting
dialysis in each centre, according to age at the start ofRRT
It can be argued that more patients over 60 years old in centres 3 and 4 may be unfit
to be listed and hence the discrepancies between the proportions listed in each centre.
However, when the age distribution for the patients that were eventually listed in
each centre was compared (figure 6.2.4), these differences persisted. This clearly








Centre 1 Centre 2 Centre 3 Centre 4
□ 18-34 ■ 35-49 □ 50-59 □ 60-64 D>65
Figure 6.2.4 Age distribution for patients listed for transplantation in each centre.
Centre variations were also noted in the proportion of patients listed according to the
type of first dialysis regimen (figure 6.2.5), deprivation category (figure 6.2.6) and











□ Centre 1 □ Centre 2 □ Centre 3 □ Centre 4
Figure 6.2.5 Proportion of patients listed for transplantation from the total starting









Figure 6.2.6 Proportion of patients listed for transplantation from the total starting
dialysis in each centre, according to social deprivation









Figure 6.2.7 Proportion of patients listed for transplantation from the total starting
dialysis in each centre, according to the distance from the transplant centre (km)
Many of the differences noted so far could be explained by a different comorbidity
profile of the patients starting RRT in each centre or who are referred for
transplantation from other renal units. Of the total 1022 patients for whom
comorbidity was available, 1001 (98%) had at least one comorbid condition in
addition to their renal failure.
Data available does not allow comment on the prevalence of comorbidity in each
centre or on the proportions of patients with each condition that remain on dialysis,
as all patients, for whom information was extracted from the case notes, were listed
during the follow-up period. Nevertheless, a comparison of the incidence of
individual comorbid conditions among patients listed in each transplant centre (table
% /—7\
< 50 km 50 -100 km >100 km
□ Centre 1 □ Centre 2 □ Centre 3 □ Centre 4
206
6.2.2), provides a good indicator on the kind of comorbidity considered acceptable
for the purpose of listing and whether there are major differences between centres.
Factor Centre 1 Centre 2 Centre 3 Centre 4
Diabetes as a comorbid
condition
4 (2.4) 8 (4.7) 7 (2.5) 11 (2.7)
PVD* 16(9.6) 40 (23.7) 32(11.4) 38 (9.5)
Hypertension 136 (82.9) 147 (87) 243 (87.1) 358 (89.3)
IHD* 32(19.3) 50 (29.6) 35 (12.5) 76(19.1)
Valvular diseases* 20(11.9) 28(16.6) 33 (11.8) 34 (8.5)
Pulmonary embolism 2(1.2) 6(3.6) 3(1.1) 4(1.0)
Arrhythmias 10(6.0) 12(7.1) 11 (4.0) 19(4.8)
Heart failure 7 (4.3) 15(9.1) 19(6.9) 27 (6.9)
Left ventricular
hypertrophy
57 (35.0) 54 (32.9) 89 (34.1) 121 (31.3)
Other heart 7(4.2) 11 (6.5) 12 (4.3) 28 (7.03)
Respiratory disease 25 (15.1) 28(16.7) 32(11.6) 57(14.4)
CVD 17(10.2) 24(14.2) 20 (7.2) 39 (9.8)
Neoplasia 3(1.8) 2(1.2) 9 (3.2) 8 (2.0)
GI disorder* 34 (20.4) 51 (30.2) 45(16.1) 99 (24.9)
Urological disorders 27(16.2) 23(13.6) 45(16.1) 55 (13.9)
Hyperlipidaemia* 32(19.3) 16 (9.5) 15(5.4) 43(10.8)
Non-smoker* 82 (49.7) 85 (50.9) 183 (66.8) 187(52.2)
Obese* 54 (37.2) 62 (43.4) 115 (43.6) 114(31.4)
Hyperpa rathyroidism* 18(10.8) 16(9.5) 75 (27.4) 132 (33.1)
Table 6.2.2 Differences in the incidence of comorbid diseases between patients
listed in the four transplant centres during the study period (%) (*, p< 0.05, statistical
significant)
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The results presented in table 6.2.2 show that in general, there seem to be an
agreement on most of the conditions with a significant impact on the outcome of a
transplant, which is illustrated by comparable incidences of hypertension, cardiac
arrhythmias, left ventricular hypertrophy and previous neoplasia among patients
listed in each centre. As expected, some other risk factors such as peripheral vascular
disease and ischaemic heart disease are weighted differently (p< 0.05, x2) in each
transplant centre. As shown in the table, 10-20% of the patients listed in all but one
centre will have at least one of the two conditions, with the exception of centre 2
where the assessment is more liberal and between 25% and 30% of the patients
joining the transplant waiting list will have peripheral vascular disease and/or
ischaemic heart disease.
There is additional evidence for the more liberal practice of listing in centre 2, in the
form of a higher incidence, although not statistically significant, of respiratory and
cerebro-vascular diseases among patients listed in this centre.
Significant centre variations were also noted with regards to other comorbid




Clinical guidelines on assessment for transplantation have been published recently by
the American Society of Transplantation and the European Dialysis and Transplant
Association (18) (157). These guidelines acknowledge the impact of comorbid
conditions on the outcome of transplantation and the need for further investigations
in high-risk groups of patients such as elderly and diabetics prior to listing.
In the United Kingdom, there is no consensus on what criteria should be used in the
decision of fitness for transplantation and clinical guidelines to provide a
standardized approach are long overdue. Individual centres are likely to use the best
current practice, but inevitably, there will be significant variations, according to the
level of the clinical expertise available in a particular unit, the comorbidity load or
the attitude of transplant nephrologists and surgeons towards patient selection. Such
differences have been previously documented (199), but it is widely believed that
they are evidence based rather than being a true bias towards certain groups of
patients.
Throughout the duration of this study in Scotland there were four transplant centres,
which enjoyed a close cooperation and exchange of scientific information. In this
favourable setting, our aim was to assess whether there are any significant
differences in clinical practice, which can be addressed by the implementation of
clinical practice guidelines.
The analysis of sociodemographic differences includes all patients listed in the four
transplant centres, while comorbidity analysis is restricted only to those patients for
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whom data were available. The results of this latter investigation are based on 59%
of all patients listed within the study period, but a comparison of centre
representation, shown in table 6.2.3, indicates a similar (p=0.13, y2) distribution of
the two populations and therefore it is likely that the centre differences noted here are
applicable for all patients listed.
Study groups Centre 1 Centre 2 Centre 3 Centre 4
All patients 16.41 11.63 21.77 50.17
(n= 1736)
Patients with 16.34 16.53 27.69 39.43
comorbidity collected
(n= 1022) "
Table 6.2.3 Distribution of the study populations according to the centre of listing
(%).
When the proportions of patients listed out of the total number starting dialysis in
each centre were compared, there were substantial differences according to gender,
primary renal disease, age, social deprivation, type of first dialysis. It is difficult to
understand why there should be differences in listing patients of same gender or
patients with a similar deprivation score between the four centres, but it has been
suggested that variations in the index of comorbidity across various parts of the
country may potentially explain some of these disparities. However, the analysis has
shown that for some groups of patients, in particular those aged over 60 years old
and the diabetics, there is no consensus on the approach to listing. Centres 1 and 2
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list nearly 20% more diabetics or patients aged > 60 years old compared with centres
3 and 4. It can be argued that the latter two centres have a greater workload, and
hence in the constraints of the current organ shortage, a much tighter selection
process is used to ensure an appropriate use of the available donor kidneys. This is a
particularly important and controversial issue, as these patients are usually regarded
as high-risk groups, with an increased likelihood of kidney transplant failure or death
soon after transplantation. These differences will inevitably create a bias against
these groups of patients and raise the issue of equitable access to the renal transplant
waiting list across Scotland.
Although there are no uniform criteria for listing, the incidence of most comorbid
conditions in patients listed is comparable, of the 40 variables investigated, only 8
being weighted differently by the four centres. This analysis has shown that some of
the differences are due to a more liberal approach to listing in centre 2, where
patients with a more severe index of comorbidity are allowed to join the list. A few
of the factors where significant differences where noted (PVD, IHD, obesity and
hyperlipidaemia) are strongly correlated with an increased risk of death following
transplantation (168;239).
The demographic structure of the RRT population is changing rapidly, and with an
ageing population, it is likely to see more comorbid conditions in the patients
assessed for transplantation. Inevitably, listing criteria will have to change and the
ability to manage higher risk patients will have to improve. Nevertheless, practical
guidelines will ensure that a comparable level of care and an equitable access is
available for all patients across Scotland.
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The timing of referral for assessment is also an important issue, as patients could be
referred at different stages of their disease, when the number of accrued medical
conditions could make the all important difference between being accepted as a
transplant candidate or being denied access to the transplantation service. This aspect
of the practice could not be investigated with data currently available.
This study concentrates on patients already listed and therefore, further investigations
are required to determine the prevalence of the comorbid conditions in the ESRD




In summary, there are significant differences in the practice of assessing and listing
patients for renal transplantation between the four transplant centres in Scotland. The
comorbidity index is a significant factor but other issues such as clinical attitudes
towards listing may play an important role.
These differences have also highlighted several high-risk groups, such as advanced
age and diabetes, where a consensus regarding the optimal listing criteria needs to be
reached, in order to ensure the best outcome for patients and an adequate use of
donor organs. Further research into the outcome of transplantation compared with
dialysis in these groups of patients is required to provide an evidence-based approach
for any clinical practice guidelines.
To address some of these issues, two lines of investigation were followed in this
chapter: transplantation in elderly and transplantation in diabetics.
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6.3 The elderly and transplantation
6.3.1 Introduction
The number of elderly patients accepted in renal replacement programmes is
continuously increasing. In Scotland, the annual intake of new ESRD patients over
60 years old has risen from 42% in 1989 to more than 65% in 1999 (32). The largest
proportion of this rise is represented by patients aged over 65 years old, who make
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Figure 6.3.1 Proportion of new ESRD patients aged over 60 and 65 years old
starting dialysis each year.
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A similar trend was noted in the US, where the number of patients over 65 years old
requiring RRT doubled in the last decade (240), Australia (241), Japan, Canada and
the rest ofEurope (31).
On the basis of strong evidence that transplantation is safe and successful (153;242)
and survival with a kidney graft exceeds that on dialysis (19; 152) even in elderly
patients, there is a general agreement that age per se does not constitute a
contraindication to transplantation. And yet, many centres are still reluctant to accept
patients over 60 or 65 years old onto the waiting list [only 3% of patients over 65
years of age are transplanted in the US (125)], as these patients are frail and have
more comorbid conditions (150) and their overall life-expectancy is lower than the
younger population. In addition, an increased age at the time of transplantation has
been shown to have a major influence on long term graft survival (243) and death
with a functioning graft accounts for almost 40% of the grafts lost in long term
follow-up (151). Nevertheless, this higher post-transplant mortality must be
considered against an evident survival advantage of transplantation over dialysis
(Chapter 5} (19) and a continuous improvement in the outcome of transplantation in
the elderly over time (244) (table 6.3.1).
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Study No. of patients
Patient survival
1 yr 5 yr
Graft survival
1 yr 5 yr
Wedel (1980) 38 60 25 60 25
Tesi (1994) 133 88 68.1 82 62
Cantarovitch (1994) 117 92 80 86 80
Lufft (2000) 91 96 74 87 66
Saudan (2001) 48 98 78 93 65
Table 6.3.1 Improvements in patient and graft survival in recipients over 60 years
old in the last 20 years ((245-249)
Currently, in the UK there is no age limit for access to transplantation, but only 7.2%
of transplant recipients are aged over 65 years old (30). In the present climate of
organ shortage, there is a clear bias against the elderly patients, but in the absence of
UK based evidence for the outcome of transplantation in this particular age group, it
will be difficult to draw practice guidelines to address this issue.
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In this national study, two questions were addressed:
1. What is the impact of recipient age on the transplant outcome in Scotland and
is there any scope in setting an age limit for a transplant candidate?
2. Is there a survival advantage for transplantation over dialysis in patients over
60 years old who are considered suitable for transplant candidacy?
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6.3.2 How old is old for transplantation
6.3.2.1 Methods
All adult patients who started dialysis between 1st of January 1989 and 31st of
December 1999 and were transplanted (first graft) until 31st of December 2000
(n=1095) were grouped according to their age at grafting (18-49 years, 50-59 years,
60-64 years and >65 years old). The sociodemographic and comorbidity variables
presented in the previous chapters, as well as the level of HLA matching, the length
of the cold ischaemic time, patient and graft survival, the incidence of acute rejection
episodes and delayed graft function and the causes of death and graft failure were
obtained from the SRR and UKT databases and case notes and compared between
the four groups. Patient and graft half-life were calculated assuming a constant death
rate beyond a year after transplantation (figure 6.3.2) and compared according to
patients' age using a Log-rank test.
In (2) ln(2) = natural logarithm of 2
HL = -
M
M = Slope of the survival curve assuming a
constant death rate post-transplant
Figure 6.3.2 Formula used for calculating patient and graft half life (250)
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The risks of death and graft failure were calculated after adjustment for comorbidity
and other sociodemographic variables for each group of patients, using a Cox
proportional hazards model. Further comparisons were performed using %2, T-test,
Mann-Whitney U test, Kruskal-Wallis and ANOVA test where appropriate.
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6.3.2.2 Results
1095 patients starting dialysis between 1st of January 1989 and 31st of December
were transplanted during the study period and followed for up to 11 years, until 31st
of December 2000. The demographic characteristics of the study population
according to the age at transplantation are shown in table 6.3.2.
The gender ratio was more balanced in the youngest age group compared with the
remaining three groups, with a comparable distribution across the social deprivation
categories. All groups had a similar prevalence of diabetes as a cause of renal failure,
and almost 60% of the patients in each group started replacement therapy on
haemodialysis. The time spent on dialysis until transplantation increased
significantly with patient's age (p=0.031, Kruskal-Wallis test), from a median of 1,3
years in those aged 18-49 years old to almost 2 years in patients aged over 65 years
of age. On average, almost one third of all patients switched dialysis modalities until
transplantation. This occurred significantly more frequently in the younger patients
(p= 0.034, x2), while 76% of patients aged over 65 years old remained on the initial
RRT modality until grafting.
As shown previously, there are significant differences between centres, elderly









MalerFemale ratio 57.9 : 42.1 67.5 : 32.5 64.6 : 35.4 66.7 : 33.3 0.033*
Primary renal 0.174
disease (%)
Glomerulonephritis 28.7 30.2 23.2 34.7
Interstitial nephritis 35.0 34.9 31.7 25.3
Multisystem disease 11.2 13.5 17.1 18.7
Diabetes 13.7 8.3 11.0 8.0
Other 11.4 13.1 17.1 13.3
Deprivation category 0.62
(%)
1 5.0 5.2 6.1 4.0
2 12.0 13.1 14.6 18.7
3 22.6 21.8 23.2 30.7
4 26.1 26.6 29.3 29.3
5 15.3 16.3 15.9 6.7
6 12.6 11.5 8.5 9.3
7 6.4 5.6 2.4 1.3
HD as 1st RRT (%) 56.5 59.9 62.2 58.6 0.785
Dialysis duration 0.031$*
Median (years) 1.3 1.33 1.62 1.92
Number of dialysis 0.034*
switches (%)
0 65.7 64.5 61.7 76.0
1 21.3 21.6 29.6 13.3
>2 13.0 13.9 8.7 10.7
Listing Tx centre <0.0001*
(%)
Centre 1 56.5 23.2 6.5 13.7
Centre 2 49.5 25.3 7.4 17.9
Centre 3 62.1 26.0 7.8 4.1
Centre 4 66.9 21.2 7.7 4.3
Table 6.3.2 Comparison of baseline characteristics of transplanted patients
according to the age at transplantation (*- statistical significant, % - Kruskal Wallis
test, all other %2 test).
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As previously stated, comorbidity was available in approximately 65% of the
transplanted patients. A comparison of the incidence of comorbidity among
transplant recipients according to their age at grafting (table 6.3.3) shows that there is
a significant increase in the incidence of peripheral vascular disease with increased
age.
All patients over 50 years of age have a significantly higher incidence of ischaemic
heart disease, heart failure, arrhythmias, left ventricular hypertrophy and GI disorders
compared with those aged 18-49 years old.
Valvular diseases and pulmonary embolism are most frequent among patients over
65 years of age, while respiratory disease was more often seen in patients aged 60 -
64 years old. Patients in the 18-49 years old group have half of the prevalence of
CMV compared with all other groups, while the highest incidence of active or ex-
smokers seems to be at the extreme age groups.
In fact, the overall prevalence of comorbid conditions seems to be higher in patients
aged 60-64 rather than in those aged over 65 years old. This indicates, that the eldest
patients who are eventually transplanted undergo a tight assessment process and only
those with limited comorbidity are selected.
All transplants performed in each of the four age groups had comparable levels of
HLA matching (table 6.3.4), between 48% and 58% of them being well matched (i.e.
000 mismatches [Tier 1] or maximum 2 A and/or B mismatches but no DR
mismatches [Tier 2]). Overall, there was a tendency to offer fewer fully matched
kidneys to recipients aged > 65 years old, but this was compensated by a higher
proportion ofTier 2 (010,010 or 110 mismatches) grafts.
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18-49 years 50-59 years 60-64 years >65 years p value
(n=446) (n=160) (n=46) (n=55)
Comorbid diabetes (%) 2 1.9 6.7 3.6 0.235
% diabetic cases with 2.6 7.9 9.8 10.5 0.449
end-organ complications
PVD (%) 5.0 11.9 16.3 27.3 <0.0001*
Hypertension (%) 86.6 88.8 86.4 87.3 0.919
Mean number of 1.22 1.24 1.09 1.00 0.284J
antihypertensive drugs
IHD (%) 5.9 23.8 40.0 27.3 <0.0001*
Valvular disease (%) 6.5 10.0 8.9 21.8 0.002*
PE (%) 0.2 2.5 2.3 7.3 <0.0001*
Arrhythmias (%) 1.6 4.4 6.8 7.3 0.021*
HF (%) 3.7 7.0 16.7 7.3 0.003*
LV hypertrophy (%) 24.9 32.7 39.0 44.4 0.005*
Other heart disorders 5.0 3.1 11.1 5.5 0.074
t/0)
Respiratory disease (%) 10.3 15.7 26.7 12.7 0.009*
CVD (%) 8.2 11.3 6.8 5.5 0.491
Previous neoplasia (%) 1.1 4.4 2.3 3.6 0.09
GI disorders (%) 12.7 27.5 38.5 34.5 <0.0001*
Urological disorders (%) 15.0 11.3 13.6 25.5 0.086
Hyperlipidaemia (%) 8.2 8.8 6.7 9.1 0.338
CMV +ve (%) 27.8 48.1 50.0 47.3 <0.001*
Smoker (%) 61.9 49.3 53.7 60.0 <0.001*
Table 6.3.3 Comparison of comorbidity characteristics of transplanted patients






























Mean (S.D.) 38.0(14.8) 43.4(15.2) 48.0(15.3) 48.2(16.2)
<0.0001 J
Donor gender
















34.7 25.2 27.9 23.6 0.092
Chronic rejection
(%)
11.9 8.5 7.0 9.1 0.398
DGF (%) 19.2 27.7 20.9 32.7 0.053
Recurrent primary
renal disease (%)
2.7 1.9 2.3 0 0.126
Table 6.3.4 Comparison of donor characteristics, level of HLA matching, cold
ischaemic time and transplant outcome according to recipient's age at transplantation
(*- statistical significant, X - One way ANOVA test, all other yj test).
As expected, the donor age increased, the older the recipient, from 38 years in the
younger recipients, to 48 years old in those > 65 years of age, but there was a
comparable gender distribution.
Younger patients were transplanted within a shorter cold ischaemic time (mean 1126
minutes), but had a higher incidence of acute rejection episodes, while elderly
patients had a higher incidence of delayed graft function, almost reaching statistical
significance (p=0.053, x2)-
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All patients had an excellent one-year survival rate (figure 6.3.3). There are no
significant differences between the survival curves in the first three years post¬
transplantation, but as expected, there are substantial differences in the long-term
survival between those younger and those older than 60 years of age. Both groups of
patients over 60 years of age have comparable survival and even at 9 years post-
transplant, almost one quarter of them are still alive.







Age group I year 3 years 5 years 10 years
18-49 98 93 91 77
50-59 92 88 81 53
60-64 87 76 59 25 (9 yr)
>65 91 77 66 33 (9 yr)
Figure 6.3.3 Patient survival following transplantation (p<0.0001, Log rank test)
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Similar differences were noted for the graft survival (figure 6.3.4), almost 50% of the
transplants performed in patients younger than 60 years old functioning at 10 years,
in contrast with only 20 to 30% in those over 60 years old.
When the two groups of elderly recipients were compared, patients over 65 years of
age had a better graft survival throughout the study period.
Graft survival (years)
Age group 1 year 3 years 5 years 10 years
18-49 88 78 70 54
50-59 82 76 68 46
60-64 75 62 53 21(9 yr)
>65 88 77 64 31 (9 yr)
Figure 6.3.4 Graft survival (p<0.0001, Log rank test)
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This advantage persisted when graft survival censored for death with functioning
graft was analysed (figure 6.3.5). In fact, the older group had the best graft survival
of the four groups at all time points, but overall, the differences between the study
groups were not statistically significant (p=0.2685, Log rank test). This does indicate





















0 2 4 6 8 10 12
Graft survival censored for death with functioning graft (years)
Age group 1 year 3 years 5 years 10 years
18-49 89 81 75 64
50-59 88 85 79 71
60-64 82 74 72 72 (9 yr)
>65 93 91 83 72 (9 yr)
Figure 6.3.5 Graft survival censored for death with functioning graft (p=0.2685,
Log rank test)
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An examination of the crude death rate (table 6.3.5.) shows a 4 fold increase of the
rate from 2.4 per 100 years of patient follow-up in patients age 18-49 years old to
10.35 in those aged > 65 years old. This is further illustrated by the differences in the
proportion of patients from each group, dying within the study period. Patient half-
life, calculated using the method described earlier, shows a significant reduction in




(per 100 years of 2.4 5.55 10.04 10.35
patient follow-up)
Deaths (%) 10.3 24.6 35.4 40.0 <0.0001*
Patient half-life 37.62 17 9.62 7.88 0.0001*
Adjusted RR of 1 2.37 2.84 7.19 <0.0001*
death (95%CI) (1.28-4.39) (1.12-7.18) (3.54-4.59)
Graft failure (%) 28.3 34.1 43.9 41.3 0.004*




Graft half-life 9.71 9.00 5.54 6.96 <0.0001*
Adjusted RR of 1 0.91 0.63 1.51 0.2012
graft failure (0.59-1.38) (0.28-1.42) (0.86-2.41)
(95%CI)
Table 6.3.5 Comparison of patient and graft outcome according to recipient's age at
transplantation (*- statistical significant, y} test).
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When the relative risk of death, adjusted for comorbidity conditions, was determined,
all patient groups had a largely increased risk of death compared with the baseline
represented by age group 18-49 years old (table 6.3.5). A similar tendency was
observed for graft failures, more than 40% of the grafts in the eldest group being lost
during the follow-up, a large proportion of these due to death with functioning graft.
Although the overall proportion of lost grafts increases with age, after censoring for
death with functioning graft, more grafts appear to be lost in the younger age groups,
but these differences are not statistical significant (p=0.457, % ).
Despite a significant disproportion in the graft half-life between the four groups, a
kidney allograft transplanted in patients under 60 years old is likely to function for at
least 9 years, while patients over 65 years old enjoy an almost entire dialysis free life
following transplantation (graft half life 6.96 and patient half life 7.88, respectively).
A comparison of the relative risk of graft failure adjusted for the confounding
comorbidity, showed no significant differences between the four groups of
transplanted patients (p=0.201, Cox regression analysis, table 6.3.5).
The incidence of death with functioning graft was three times higher in patients aged
> 65 years old compared with those aged 18-49 years old, in contrast to
immunological failures which had an entirely opposite trend and were most frequent
in the youngest age group (table 6.3.6). These differences could be even more
striking, ifwe consider that almost one quarter of the causes of graft failure in the 18-
49 year old age group are yet unknown.
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Cause of graft failure 18-49 years 50-59 years 60-64 years >65 years p value
(n=686) (n=252) (n=82) (n=75)
Death with functioning
graft (%)
20.6 43.0 47.2 61.3 <0.001*
Immunological failures
(%)
34.5 22.1 19.5 16.1 <0.001*
Vascular problems (%) 10.8 9.3 11.2 6.5 0.647
Unknown (%) 22.7 16.3 19.4 6.5 0.002*
Table 6.3.6 Comparison of causes of graft failure according to recipient's age at
transplantation (*- statistical significant, x2 test).
Significant differences in the proportion of patients dying due to infection or vascular
causes were noted between the four groups (table 6.3.7), but these results could be
significantly modified, taking into account that between one in four and one in five
deaths are not accounted for in each group. If we consider these unknown cases to
represent sudden deaths, and therefore have a cardiac origin, this will increase the
cardiac causes of death to 50% of all kidney transplants performed in Scotland.
Cause of death 18-49 years 50-59 years 60-64 years >65 years p value
(n=686) (n=252) (n=82) (n=75)
Cardiac (%) 29.2 33.9 21.4 36.7 0.098
Vascular (%) 11.1 16.1 25.0 3.3 <0.001*
Infection (%) 22.2 12.9 17.9 23.3 0.018*
Cancer (%) 8.3 8.1 3.6 10.0 0.407
Unknown (%) 23.6 24.2 21.4 20.0 0.876
Table 6.3.7 Comparison of causes of death according to patients' age at
transplantation (*- statistical significant, X test).
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6.3.2.3 Discussion
The demographics of end stage renal disease demonstrate a constant increase in the
age of new patients starting replacement therapy every year. Currently in Scotland,
as in many other parts of the world (31;241), more than half of the new patients are
aged 65 years old or more, but only few of them will ever be transplanted. These
patients represent a particular controversial category (153) and therefore in this
analysis we decided to investigate the outcome of transplantation in those over 65
separately from patients aged 60- 64 years old.
Despite a general agreement that age should not represent a contraindication for
transplantation, the proportion of kidney transplants performed in elderly patients in
UK has not changed much in the last decade (30;251) and many units are still
reluctant to accept older patients as transplant candidates. This is clearly illustrated
by 10% lower transplant rates in two of the centres, compared with the national
average.
Elderly transplant recipients spend a longer time on dialysis and this may be partly
due to a lengthier assessment period necessary to confirm suitability for
transplantation. It is fairly clear from the present analysis that elderly transplant
recipients have a higher index of comorbidity and serious conditions, which shorten
the life expectancy, such as cardiovascular and respiratory conditions are more often
present in those aged over 60 years old. This does indicate that the lower transplant
rates may be a result of the high prevalence of comorbid conditions in this particular
age group, which renders most of the patients unsuitable for transplant candidacy.
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Older recipients receive kidneys from older donors, but the donor age range is
comparable between the four groups, with an upper limit as high as 75 years old.
Donor age is a controversial point in kidney transplantation as graft failure rates are
higher with increased donor age (96;252). Nevertheless, the use of older donors is
considered acceptable due to the scarcity of cadaveric kidneys and good results have
been reported when such kidneys were transplanted in aged matched recipients
(253). If kidneys from donors as old as 75 years of age can be accepted for
implantation, there is no real justification why an increased number of elderly
patients could not receive a kidney graft in elderly-for-elderly programmes
(215;254), which would eliminate potential allocation obstacles as well as shifting
younger donor kidneys to younger recipients.
An older donor age combined with the increased cold ischaemic time for kidneys
received by elderly recipients may explain the higher incidence of delayed graft
function noticed in these patients. This was counterbalanced by a lower incidence of
acute and chronic rejection (although not statistical significant), which is in keeping
with a diminished inflammatory and immunological response previously noted in the
elderly (245;255).
All groups have excellent one year patient survival rates, ranging between 87% and
98%. The risk of dying increases significantly with age, and beyond three years there
is a substantial survival benefit for younger patients, while the two groups of patients
aged over 60 years old have comparable, but diminished survival rates. A similar
trend is noticed for the graft survival, with comparable one-year figures (75% to
88%) and a long-term advantage for younger recipients. The crude rate of graft loss
increases with age, but as reported elsewhere (245;256;257), a significant proportion
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of the grafts in elderly patients are lost due to patient death. This should not
necessarily be interpreted as a waste of kidneys, as immunological failures are less
common in patients over 60 years of age (247;248) and the overall risk of graft loss
is comparable irrespective of the recipient's age (258;259). It is important to note
that while in the youngest group the estimated graft half life is nearly 10 years,
against an estimated patient half life of 37 years, a 7 years graft half life in the eldest
group ensures a dialysis free life in the context of a half life of eight years, offering a
substantial improvement in the quality of life (25).
The patient and graft survival probabilities noted here are comparable with previous
reports (96;153;248;260;261) and 60-66% respectively 55-64% 5 years patient and
graft survival in patients over 60 are considered the norm. In addition, the controlled
comparison performed in this study has shown that results in patients over 65 years
of age are similar to those obtained in patients aged 60-64 and therefore these
patients should be considered for transplantation.
The assessment process is critical to the success of transplantation in the elderly and
there is evidence that with a strict evaluation, 80% 5-year patient and graft survival
in these patients is achievable (245). The incidence of death due to cardiovascular
diseases or infection was not significantly different in the four groups in this study.
This suggests that elderly patients, despite a higher prevalence of these conditions,
when correctly assessed and selected may not exhibit a higher risk of death as a
direct result of them.
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6.3.2.4 Conclusion
Older patients with ESRD present health care professionals with a significant
challenge and many management issues such as the timing or choice of replacement
therapy or the assessment protocol remain subject to debate. With a prevailing
shortage of organs, kidney transplantation should not be used indiscriminately in the
elderly, nor should the elderly be denied access simply on the basis of age. Careful
assessment of "biological" rather than "chronological" age should be used on an
individual basis instead of applying rigid age limits, as there is little doubt from this
analysis that transplantation even in those of advanced age is successful and provides
dialysis-free and good quality of remaining life.
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6.3.3 Transplantation versus dialysis in
elderly recipients
6.3.3.1 Methods
All patients 60 years old or over accepted onto the waiting list and who started
dialysis between 1st of January 1989 and 31st of December 1999 were selected for
this analysis. 15 patients who were listed pre-dialysis were excluded from the
analysis. Socio-demographic, listing, transplant data as well as comorbidity were
obtained from the national renal (SRR) and transplant (UKT) databases and case-
notes review. Survival was compared between those who were transplanted and
those who were listed but remained on dialysis by the end of the follow-up period
(31st ofDecember 2000). In calculating the survival curve for transplantation, follow-
up was considered from the date of transplant. For the dialysis curve, all patients on
dialysis were considered and the follow-up time started at the moment of listing, but
those patients who received a transplant were censored at the time of grafting.
Survival at 1, 3, 5 and 8.5 years was estimated for each treatment modality using the
Kaplan Meyer method and a Log-rank test to determine the statistical significance of
the findings. The rates of death per 100 patient-year were determined for
transplantation and dialysis. A time-dependant Cox regression analysis adjusted for
sociodemographic variables (gender, age, social deprivation, primary renal disease,
distance from patient's home to the transplant centre, time on dialysis pre-listing)
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was employed to calculate the relative rate of death for transplantation versus
dialysis, allowing for the changes in the treatment status (dialysis or transplant)
during the follow-up period. For the purpose of this analysis, an intention to treat
method was applied, whereby all patients were considered to be on the waiting list at
any time, until death, end of study or transplantation (whichever occurred first),
irrespective of suspension and removal periods. Transplant recipients contributed
survival towards transplantation until the graft failed. Any subsequent length of life
was counted towards survival on dialysis. Survival was considered from the moment
of listing for transplantation. Data on comorbidity illnesses was available in 60% of
all patients and the distribution of the comorbidity burden was compared between
transplant recipients and those who remained on dialysis. A separate time-dependant
Cox regression analysis, adjusted for sociodemographic and comorbidity variables
was built and the results compared with the time-dependant model adjusted only for
sociodemographic factors. %2, Student t-test, Kruskal-Wallis and Fisher's exact tests
were used to estimate the statistical significances of any other differences.
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6.3.3.2 Results
340 patients over 60 years old were listed during the study period. 137 (40.3%) of
them received a first transplant, while the remaining 203 (59.7%) continued to
undergo dialysis, in stark contrast to 957 (68.6%) of the 1396 patients under the age
of 60 who were listed and transplanted in the same period.
A comparison of the baseline demographics at the time of listing for patients over 60
years old, according to their subsequent treatment status is shown in table 6.3.8. Both
genders and all social deprivation categories were equally represented among
patients who were transplanted and those who remained on dialysis, but fewer
patients with diabetes or multisystem diseases leading to ESRD received a kidney
graft.
The transplant recipients were listed at a younger age (64 years versus 66 years),
spent half the time on the active waiting list (250 days versus 530 days) and were on
dialysis for a similar length of time (7 months) compared to those who were listed
but remained on dialysis. In both groups nearly two thirds of the patients had
haemodialysis as the first type of replacement therapy and a similar proportion
remained on the initial dialysis modality until listing. The transplant recipients lived
significantly closer to the transplant centre compared with those who were listed but
not transplanted.
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Median age at listing 66.3 64.0 <0.0001*#
(I.Q.R.) (63.0-72.9) (58.5-69.5)
Primary renal disease (%) 0.029*
Glomerulonephritis 19.8 30.5
Interstitial nephritis 20.8 28.1
Multisystem disease 23.4 18.8
Diabetes 11.2 7.8
Other 24.9 14.8








HD as first dialysis method (%) 66.3 60.2 0.288|
Median dialysis duration pre- 0.65 0.65 0.688#
listing (I.Q.R.) (yr) (0.29-1.01) (0.24-0.96)





Distance (km) to the transplant 42.45±4.6 27.22±3.65 0.043* #
centre (mean ±SEM)
Time on active waiting list 529 252.5 <0.0001*#
(days) (181-877) (21-484)
Table 6.3.8 Baseline demographics for patients on dialysis and transplant recipients
who were 60 years or older at listing (*-statistical significant, p<0.05), (J- Fisher's
exact test, # - Mann Whitney U test, all other y})
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An extensive comorbidity index was available for 191 (60%) of all patients.
Although all patients went through the assessment process and were deemed suitable
for transplantation, there was a higher incidence of ischaemic heart diseases, cardiac
arrhythmias and cerebrovascular diseases in patients who were listed but remained
on dialysis until the end of the follow-up period. All the other associated conditions
were equally distributed between the two groups.
Remain on dialysis Transplanted p value
n=107 n=84
Comorbid diabetes (%) 4.7 4.8 1.000
PVD (%) 25.2 21.7 0.609
Hypertension (%) 84.1 85.5 0.841
IHD (%) 45.4 28.6 0.024*
Valvular disease (%) 28.7 16.7 0.121J
PE (%) 2.8 6.0 0.301
Arrhythmias (%) 17.6 6.0 0.016*
HF (%) 13.1 10.8 0.662
LV hypertrophy (%) 42.1 43.2 0.883
Other heart disorders (%) 6.5 7.1 1.000
Respiratory disease (%) 17.0 20.2 0.578
CVD (%) 15.1 4.8 0.03*
Previous neoplasia (%) 1.9 2.4 1.000
GI disorders (%) 32.4 38.1 0447
Urological disorders (%) 13.9 22.2 0.130
Smoker (%) 55.3 43.9 0.089J
Table 6.3.9 Comorbidity for patients on dialysis and transplant recipients who were
> 60 years old when listed (*-statistical significant, p<0.05), (J - x2, all other Fisher's
exact test)
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During the follow-up 116 (58.9%) dialysis patients and 52 (40.6%) transplant
recipients died (p<0.0001, y}). The overall rate of death was 16 per 100 patient-year
in the dialysis group and 7 per 100 patient-years for transplant recipients with a
functioning graft. There were no significant differences (p=0.211, x2) between the
various causes of death in both groups of patients (table 6.3.10).
Cause of death Remain on dialysis Transplanted
n=116 n=52
Cardiovascular (%) 47.4 43.2
Infection (%) 17.2 17.6
Cancer (%) 6.0 7.8
GI (%) 1.8 5.9
Unknown (%) 21.6 21.6
Table 6.3.10 Causes of death in patients on dialysis and transplant recipients.
The survival curve for dialysis patients is shown in figure 6.3.6.a. Survival is
expressed from the listing moment and it is censored at the time of transplantation
for those patients that received a graft. Survival for the transplant recipients, from the
moment of grafting is shown in figure 6.3.6.b. Although, the curves are not directly
comparable, having a different starting point, they provide a good indicator of the
survival advantage for transplantation, bearing in mind that during this study, in
Scotland patients waited on average 17 months prior to receiving a kidney allograft.
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3. Survial for dialysis patients (censored at transplantation) (years)
b. Survival for transplanted patients (years)
Transplant Dialysis 1
1 year 93% 81%
3 years 83% 53%
5 years 70% 30%
8.5 years 27% 6%
Figure 6.3.6.a&b Patient survival (Kaplan Meier) and proportion surviving at 1, 3,
5 and 8.5 years in each group, adjusted for sociodemographic factors
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Using a time-dependant Cox model to control for the variable time until
transplantation, a long-term (beyond one year) relative risk of death of 0.37 (95%CI:
0.24 - 0.57) was determined in favour of transplantation. In other words, after
adjusting for gender, age at listing, type of renal disease, social deprivation and
distance between patient's home and the transplant centre, transplant recipients have
a 63% lower risk of dying at one year after transplantation compared with patients on
dialysis. There is an increased risk of death (although not statistical significant)
immediately following transplantation as shown in table 6.3.11. The risk evens out
during the first year post-transplant and from there onwards there is an increased
likelihood of survival for the transplant recipients. When the sample was restricted to
those for whom comorbidity data was available, the hazard ratio associated with
transplantation was 0.30 (95% CI: 0.16-0.56), but the same trend for the risk of death
as for the whole study population was observed (table 6.3.11).
Subgroup < 30 days 31 - 365 days > 365 days
Allpatients 2.35 (0.73-7.59) 0.73 (0.38-1.42) 0.37 (0.24-0.57)*
Patients with 1.52 (0.20-11.81) 0.54 (0.19-1.54) 0.30 (0.16-0.56)*
comorbidity data
Table 6.3.11 The relative risk of death following transplantation compared with
dialysis patients at 30 days, within one year and beyond one year (Time-dependant
Cox regression analysis, * = statistical significant, p<0.05)
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These results do not take into account whether the transplants fail and therefore they
estimate only the impact of receiving a transplant on the likelihood of survival. To
estimate the impact of a transplant with a functioning graft on survival, a similar
analysis, but censored at graft failure, was carried out (table 6.3.12). The results
confirm a higher initial postoperative risk associated with transplantation, which was
suggested in the previous table, and describe an identical trend with a 65%
improvement in survival beyond a year offered by kidney transplantation.
Subgroup <30 days 31 - 365 days > 365 days
Allpatients 4.91 (2.09-11.52)* 0.71 (0.35-1.41) 0.35 (0.22-0.54)*
Patients with 5.03 (1.43-17.73)* 0.43 (0.13-1.40) 0.27 (0.14-0.52)*
comorbidity data
Table 6.3.12 The relative risk of death following transplantation compared with
dialysis patients at 30 days, within one year and beyond one year (Time-dependant




The number of elderly patients requiring replacement therapy has increased
worldwide and this trend is likely to continue in the next decade (31;32;262). There
is a substantial amount of evidence that transplantation is very effective in patients
aged 60 and over (244;245;247;248;260) and provides a quality of life superior to
that on dialysis (25;263) but with the current shortage of organs however, it is
sometimes difficult to justify the use of a donor kidney in a patient with a limited life
expectancy, such as the elderly patient. Therefore it is important to demonstrate that
in the current era of significant improvements in survival on both forms of therapy
(264), transplantation does indeed provide a major advantage compared to dialysis.
The results of this study present strong evidence that renal transplantation in
Scotland confers a substantial survival advantage over dialysis in patients over 60
years old who are considered suitable for listing and transplantation.
Elderly patients who remain on dialysis have a death rate two times higher than
transplant recipients. Similar findings have been reported from single centre (258) as
well as population based investigations (22). This lower death rate translates into
excellent patient survival after transplantation at 93%, 70% and 27% at one, five and
8.5 years respectively. In contrast, survival on dialysis is much lower, at 81%, 30%
and 6% at the same intervals. The survival rates reported in this study are comparable
with those found by other authors (22;153;265), and although care must be taken
when comparing results from various studies, as the approach towards the covariates
may be different, in general comparisons are usually achievable. Early studies
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comparing the outcome of transplantation with that of dialysis in the elderly revealed
contradictory findings. Some of them (266;267) identified a higher mortality rate for
transplantation, while others (227;268) found no difference in long term patient
survival. Other studies reported a better short term (269) and long term (270)
survival following transplantation. It is essential to note that such historical
comparisons are confounded by several factors (256). First of all survival after
transplantation cannot be directly compared with survival on dialysis from waiting
list registration, as the starting points are different and those patients who receive a
transplant must survive long enough to do so. In addition, comparisons between
patients on dialysis, irrespective of their listing status and transplant recipients will
inherently be biased towards transplantation, as not all patients on RRT will be
suitable candidates for a kidney graft. Thirdly, transplantation itself is time-
dependant and accordingly, any change in the treatment status must be taken into
account (21) and comparative survival analyses should include only listed patients
and start at the moment of registration onto the waiting list.
Using a time-dependant Cox regression analysis, the risk of dying beyond one year
following transplantation was found to be 70% lower than on dialysis (RR=0.30,
95%CI: 0.13-0.70). This risk is increased in the immediate postoperative period
(although not statistically significant) and becomes comparable with the risk of death
on dialysis during the first year, before decreasing to a beneficial long-term effect. A
similar finding was reported by Wolfe et al (19) who noted a 61% lower risk of death
at 18 months post-transplant compared with dialysis for patients aged 60-74 years
old. The survival advantage was identical when the study sample was restricted to
those in whom comorbidity data was available and when the model was adjusted for
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these additional factors. This indicates that the survival benefit estimated in
population-based studies such as the current one, or the one by Wolfe et al (19)
where a full comorbidity profile in all patients is missing, may be slightly over¬
estimated. Such differences were reported by Schaubel et al (22) who noted that the
greatest survival benefit for transplantation is attained among older ESRD patients
with no comorbid illnesses. The lack of comparable comorbidity data in most of the
studies to date is a potential source of bias in any comparative analyses of the results
published so far.
The impact of comorbidity highlights the crucial role of the assessment process in
obtaining the best results (18;245). This study has shown that although all patients
were considered suitable for transplantation, those who were eventually selected as
recipients tended to be younger and had less diabetes and multisystem diseases
leading to ESRD. In addition, ischaemic heart disease, arrhythmias and
cerebrovascular diseases were more frequent in those who remained on dialysis
indicating that these factors have an important role in deciding who receives a kidney
transplant. It is also important to highlight that these elderly patients, despite being
considered suitable potential recipients, have a high incidence of comorbid
conditions illustrated by 80% hypertension, 40% left ventricular hypertrophy, 30%
ischaemic heart disease, 20% peripheral vascular disease and 20% respiratory
diseases which will need a huge amount of expertise and resources to manage.
Clearly, as the comorbidity conditions were not available for all patients it is difficult
to extrapolate these findings to the whole patient population, but even if one
hypothesises that the remaining 40% of patients had no comorbidity at all, we are
still faced with a large proportion of high-risk patients. In addition, this comorbidity
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burden has a significant impact on the causes and rates of death, nearly 60% of




In conclusion, this analysis of Scottish data suggests that elderly transplant recipients
have a significant survival advantage over similar patients who are considered
suitable for transplantation but remain on dialysis. Transplantation in the elderly is
not only safe and successful, but it is also the best treatment available to these
patients and therefore patients should not be denied this option purely on the basis of
age. A careful evaluation of renal disease's stage and comorbid illnesses and an
individual assessment of the likelihood of surviving on either treatment modalities
should form the basis of the medical decision and an informed choice for the
patients.
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6.4 Patients with diabetes and
transplantation
6.4.1 Introduction
Diabetes mellitus represents a significant problem in the Western society. The
incidence is increasing continuously and 221 million people are likely to be affected
by 2010 (271). Huge financial and human resources are spent to target at risk
populations and to deal with the devastating effects of the disease, which often leads
to premature death from macrovascular disease. Diabetes mellitus is today the
leading cause of renal failure in Japan, Scandinavia and the USA (31;272) and the
incidence is rising in most European countries (273;274). Renal replacement for end-
stage renal failure is more frequent in those with type I (insulin-dependent) diabetes
in Northern Europe and the UK, whilst in Central and Southern Europe those with
Type 2 diabetes comprise the majority of diabetics on RRT (275). The increasing
number of patients with type 2 diabetes will represent a significant burden for the
future of any transplant programme.
Until the development of transplantation, diabetic nephropathy led to a dramatic
reduction in the life expectancy for most of these patients, as survival on dialysis was
and still is poor (276). A renal transplant will not cure the disease, but will provide a
better quality of life and a significantly longer life than dialysis (19;21) {Chapter 4}.
Data exists to suggest that renal transplantation may actually improve some of the
249
other end-organ complications of the disease (277). Patients with diabetes are
considered to be high-risk candidates for a kidney transplant as most studies reported
to date have shown a poorer outcome for diabetic patients compared with non-
diabetics (278-281). This is not only due to the disease itself but also to a significant
amount of comorbid illnesses (274), which will lead to a poor long-term outcome,
mainly due to advanced disease related complications (281-284). However, due to
advances in the transplant care as well as the management of complicated diabetes,
success rates comparable with non-diabetics are now attainable (285;286).
With an excellent long-term survival, simultaneous kidney-pancreas (287) or more
recently, islet cell transplantation (288), offers additional treatment options for these
patients. However which patients are suitable (289), when should they be referred
and which are the indications for one or another form of therapy must be based on
individual patient assessment in order to maximise the benefit and ensure and
optimal use of the resources. By the time of referral and full assessment, a large
proportion of these patients will be unsuitable for a large undertaking such as a
simultaneous kidney-pancreas transplant and therefore a renal transplant remains the
reasonable choice of treatment.
One of the questions we need to answer is how useful and successful is renal
transplantation in these patients. Although high-risk patients, most type I diabetics
are young and therefore it would be difficult to argue against not transplanting, even
if the life expectancy is shorter. The question is even more difficult to answer for
patients with type 2 diabetes, who are likely to be older and have significantly more
comorbid conditions. It can be argued that these patients should be deferred from
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transplantation, but recent investigations have shown outcomes comparable with type
I diabetes (290).
On this background, an investigation was designed to examine the proportion of
patients with diabetes in a cohort of new ESRD patients in Scotland and to determine
the success of renal transplantation over the last decade in managing these patients.
This will allow conclusions on the role and place of renal transplantation in the
management of diabetic patients.
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6.4.2 Methods
All adult patients (n=4532) starting dialysis during the study period (1st of January
1989 and 31st of December 1999) were grouped according to their diabetic status.
For the purpose of this study a patient was considered diabetic only if diabetes was
the primary renal disease.
As described in the previous chapters, data was collected from the SRR and UKT
databases as well as case-notes review.
A comparison between listing and transplantation rates as well as demographic
differences between the two groups was carried out. The outcome variables (patient
survival, graft survival, acute rejection, delayed graft function, causes of death and
graft failure) were analysed for those patients with diabetes and compared with the
remaining patients.
Comorbid illnesses were collected for 1022 patients at the time of listing for
transplantation and a comparison of the disease prevalence between diabetics and
non-diabetics admitted onto the waiting list was carried out. This subset represented
59% of all patients listed and had an identical distribution between diabetics and non-
diabetics as the whole study population (figure 6.4.1, p=0.369, Fisher's exact test),
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Figure 6.4.1 Proportion of patients with diabetes in the two populations
Finally, a comparison of the survival on transplantation versus dialysis in patients
with diabetes was performed. Survival curves were obtained using a Kaplan Meier
analysis and statistical significance was estimated using a Log-rank test. A time-
dependant Cox regression analysis was used to estimate the relative risk of death for
transplantation versus dialysis at 30 days, within the first year and beyond the first
year following transplantation, y}, Fisher's exact test, T-test, ANOVA and Kruskal-
Wallis test were used to quantify the statistical significance of all the other
differences noted in this study.
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6.4.3 Results
4532 adult patients that started dialysis between 1st of January 1989 and 31st of
December 1999 were included in this analysis. 704 patients (15.5%) had diabetes
mellitus recorded as their cause of renal failure, two thirds having type I diabetes (n
= 474) while the remaining 230 (32%) had type 2 diabetes. 253 (36%) of the
diabetics were listed and only 130 (18%) were transplanted. The proportions of
patients with diabetes among the 1736 listed patients and the 1095 patients that were






■ Diabetics □ Type I ■ Type II
Figure 6.4.2 Overall incidence of diabetes and of the two types in the RRT, waiting
list and transplant populations
RRT Waiting list Transplant
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A significantly lower proportion of diabetic patients were listed (p=0.020, % ) and
transplanted (p<0.0001, % ) compared with non-diabetics. On close examination, the
proportion of type I diabetics that were listed and transplanted remained relatively
constant and most of the reduction in listing and transplantation rates is due to type 2
diabetic patients. Only 5% of all type 2 diabetic patients starting RRT were
transplanted during the study period.
Diabetic patients are accepted onto the waiting list having significantly more
comorbid conditions compared with the non-diabetic patients (table 6.4.1). Diabetic
transplant candidates have almost five times more peripheral vascular disease and
twice as much ischaemic heart disease compared to non-diabetic patients (p<0.0001,
X,2). One in six listed diabetic patients has advanced peripheral vascular disease and
almost one in ten has had a myocardial infarction prior to being accepted onto the
waiting list. Nearly half of these patients are obese (BMI>35) - significantly more
than non-diabetics - in addition to 40% of them having left ventricular hypertrophy
and a smoking habit.
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Comorbid condition Non-diabetics Diabetics p value
PVD (%) 8.0 39.7 <0.0001*
Ischaemic ulcer/restpain 0.3 5.7
Revascularization procedures 0.9 3.5
Amputations 0.001 6.38
Hypertension (%) 85.8 96.4 <0.0001*
IHD (%) 16.3 36.2 <0.0001*
Myocardial infarction 3.3 8.5
Valvular disease (%) 11.6 9.9 0.663J
PE (%) 1.6 0.7 0.708
Arrhythmias (%) 5.1 5.7 0.685
HF (%) 6.3 10.1 0.105
LV hypertrophy (%) 31.8 39.9 0.064
Other heart disorders (%) 5.0 9.9 0.058J
Respiratory disease (%) 14.8 10.0 0.150
CVD (%) 9.2 14.2 0.069
GI disorders (%) 22.9 20.6 0.588
Urological disorders (%) 15.8 8.5 0.021*
Smoker (%) 44.0 45.9 0.747J
CMV+ve (%) 36.0 41.1 0.468J
EBV+ve (%) 12.4 15.6 0.252J
Obese (%) 36.2 47.2 <0.0001*
Table 6.4.1 Comorbidity conditions present in patients listed for transplantation,
according to their diabetic status (*-statistical significant, p<0.05), ({- x, all other
Fisher's exact test)
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This higher comorbidity index has a significant impact on the rate of death on
dialysis on the waiting list as well as after transplantation (table 6.4.2). While on the
waiting list, diabetic patients have a three times higher rate of death compared with
non-diabetics. In both groups, there is a significant reduction in the rate of death after
transplantation, but the magnitude of the effect is greater in non-diabetics. If
transplant survival is censored at the time of graft failure, the death rates are
improved (6.69 for diabetics and 2.37 for non-diabetics), but the rate is still almost
three times higher in diabetic transplant recipients.
Waiting list Tx group
Number Death rate Number Death rate
Diabetics 253 20.63 130 7.91
Non-diabetics 1483 7.08 965 3.64
Table 6.4.2 Death rate per 100 patient-years for diabetics versus non-diabetics on
renal replacement therapy, after placement on the waiting list and with a functioning
transplant.
In comparing all transplant recipients according to their diabetic status, the baseline
demographics are well matched (table 6.4.3). The two groups have a similar gender,
age at transplantation, social demographic and geographic distribution. Both groups
spent an equal length of time on dialysis, but a higher proportion of diabetic patients
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Median age at transplantation 44.1 40.6 0.336#
(I.Q.R.) (32.8-55.5) (32.3-48.9)








HD as first dialysis method (%) 62.0 43.8 <0.0001*$
Median dialysis duration pre- 0.4 0.4 0.749 #
listing (I.Q.R.) (yr) (0.1-0.7) (0.2-0.6)





Median distance (km) to the 18.3 20.5 0.282 #
transplant centre (IQR) (4.02-32.7) (0.5-40.6)
Time on active waiting list 315 248.5 0.426 #
(days) (37-593) (1-538)
Table 6.4.3 Baseline demographics for the transplant recipients according to their
diabetic status (^-statistical significant, p<0.05), ($- Fisher's exact test, # - Mann
Whitney U test, all other x2)
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All patients, irrespective of their diabetic status, received comparable matched
kidney grafts, from donors with a mean age of 40 years old and within an average
cold ischaemic time of 20 hours. The incidence of acute and chronic rejection as well
as delayed graft function was comparable between the two groups as shown in table
6.4.4.














Mean (S.D.) 40.8(15.7) 39.7(13.7)
0.575J
Donor gender

















DGF (%) 22.6 19.7 0.573
Table 6.4.4 Comparison of transplant indicators according to the diabetic status of
the recipient (J Two samples t-test, all other x2 test).
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Patient survival following transplantation is significantly better (p<0.0001, Log rank
test) for non-diabetic patients (mean: 9.6 years, 95%CI: 9.3 - 9.9 years) compared














Number at risk Survival (%)
Diabetics
Number at risk Survival (%)
1 year 826 96 108 90
3 years 53 91 73 79
5 years 409 86 48 73
10 years '19 68 5 35
Figure 6.4.3 Patient survival following transplantation according to the diabetic
status of the recipient






Only 73% of the diabetic transplant recipients are alive at 5 years compared with
86% of the non-diabetics, while at 10 years the differences are even greater, 35% for
the diabetics versus 68% for all other patients.
A similar trend is noted for graft survival (figure 6.4.4), with a mean graft survival of
7.8 years (95%CI: 7.4 - 8.2 years) for non-diabetics, compared with a mean of 6
years for the diabetics (95% CI: 5.1 - 6.9 years), (p=0.0004, Log rank test).
Years post-transplant
Non diabetics
Number at risk Survival (%)
Diabetics
Number at risk Survival (%)
1 year 747 87 91 77
3 years 503 78 60 65
5 years 322 70 37 58
10 years 34 51 4 27
Figure 6.4.4 Graft survival according to the diabetic status of the recipient
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When graft survival was censored for death with functioning graft, the two survival
curves (figure 6.4.5) were comparable (p=0.52, Log rank test), indicating that a large






Number at risk Survival (%)
Diabetics
Number at risk Survival (%)
1 year 747 90 91 83
3 years 503 83 60 77
5 years 322 76 37 75
10 years 34 66 4 67
Figure 6.4.5 Graft survival, censored for death with functioning graft, according to
the diabetic status of the recipient
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As the rate of death is higher in the first 12 months post-transplantation, compared
with the remaining follow-up period, patient and graft half-life were estimated using
the formula shown in figure 6.3.2.
Non-diabetics Diabetics p value
n=965 n=130
Patient half-life 19.8 9.4
Adjusted RR of death 1 2.65 (1.83 -3.85) <0.0001
(95%CI)
Graft half-life 11.8 7.8
Adjusted RR of graft 1 1.68(1.23-2.29) 0.001
failure (95%CI)
Table 6.4.5 Patient and graft half-life and the relative risks of death and graft
failure for diabetic transplant recipients compared to all other transplanted patients
(Cox regression analysis)
Patient half-life expectancy in a diabetic patient following transplantation is 9 years,
half of that for all other transplant recipients. Similarly, the half-life of a kidney graft
in a diabetic recipient is 7.8 years, which is 66% of that expected in non-diabetic
transplant recipients. The presence of diabetes is a significant risk factor for both
patient death and graft loss following transplantation. In a multivariate model
adjusted for sociodemographic variables, the presence of diabetes was the strongest
factor predicting patient's death and graft loss (table 6.4.5). These results were
identical when the analysis was restricted to those patients where the comorbid index
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was available and the Cox regression model was adjusted for the presence of these
illnesses.
It is important to note that 50% of all grafts lost in the diabetic recipients are due to
patient's death, twice as many as in the non-diabetic group. The number of kidneys
lost to immunological causes or due to vascular problems is comparable in the two
groups of patients, while in a higher proportion of non-diabetic recipients a cause of
graft failure could not be ascertained.
Non-diabetics Diabetics p value
Cause of graft failure n=298 n=58
Death with functioning 29.1 50 0.004*
graft (%)
Immunological failures (%) 29.7 20.7 0.208
Vascular problems (%) 9.7 12.1 0.762
Unknown (%) 20.8 12.1 0.174
Table 6.4.6 Causes of graft failure according to the diabetic status of the recipient
(X2, * - statistical significant)
Although diabetic patients have a significantly higher comorbidity index, there is a
similar distribution of the causes of death between the two groups, one in three
patients dying due a cardiac problem (table 6.4.7) and almost one quarter without a
documented reason for death in either group.
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Non-diabetics Diabetics p value
Cause of death n=150 n=42
Cardiac (%) 30 30.3 0.973
Vascular (%) 13.3 14.3 0.923
Infection (%) 19.3 16.7 0.867
Cancer (%) 7.3 9.5 0.887
Unknown (%) 22.7 23.8 0.958
Table 6.4.7 Causes of patient death according to the diabetic status of the recipient
(x2)
The results of transplantation in diabetics are inferior to those obtained in all other
patients and therefore an important question to answer is whether renal
transplantation is the optimum treatment modality for these patients. As pancreatic
transplantation is a fairly recent acquisition to the therapeutic armamentarium in
Scotland, no direct comparisons were feasible. However, a comparison between
survival on dialysis and survival following transplantation could be carried out. This
allows diabetic patients to make an informed choice when deciding on the
opportunity of listing and transplantation and whether the higher operative and
postoperative risks are counterbalanced by significant long-tenn benefit. To
investigate this issue, the risk of death following transplantation at 30 day, between
30 and 365 days and beyond a year was compared with the risk of death on dialysis
(table 6.4.8).
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Subgroup <30 days 31 -365 days > 365 days
Diabetic recipients 0.58 (0.08-4.24) 0.56 (0.29-1.10) 0.30 (0.18-0.52)*
Non-diabetic recipients 0.90 (0.33-2.42) 0.72 (0.50-1.03) 0.33 (0.26-0.43)*
Table 6.4.8 The relative risk of death following transplantation at different intervals
compared with dialysis for diabetics and non-diabetics (The reference group are all
patients on dialysis listed for transplantation) (Time dependant Cox regression
analysis adjusted for socio-demographic variables, * = statistical significant, p<
0.0001)
Renal transplantation in diabetics does not provide any significant survival benefit
over dialysis in the first postoperative year. Beyond a year, however, the risk of
dying is 70% lower compared with the risk on dialysis. For comparison, an identical
trend was noticed for non-diabetics patients who enjoy a 67% reduction in the risk of
death at one year following transplantation. So, renal transplantation in diabetics,
although not as successful in prolonging life as in non-diabetics, is clearly a better
treatment option compared with dialysis.
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6.4.4 Discussion
Diabetes mellitus is the leading cause of renal failure in many countries. As the
number of patients with diabetes referred for transplantation is likely to continue to
increase, in the current shortage of donor organs, it is important to ascertain the
utility of kidney transplantation in diabetic patients relative to other primary renal
diseases as well as relative to maintenance dialysis.
In this study, diabetic nephropathy was present in only 16% of all adult patients
starting RRT, but the incidence may very well be higher, as comorbidity data was not
available for all patients, and therefore only those with diabetes leading to renal
failure have been considered.
Patients with diabetic nephropathy are less likely to be listed for transplantation and
transplanted compared with non-diabetics. The reduction is largely due to those with
type 2 diabetes - only 5% of the patients with this type of diabetes mellitus in the
present cohort being transplanted. This may be partly explained by a higher index of
comorbidity and poorer transplant results described in these patients (279) and partly
by a lack of agreement on the appropriateness of transplanting a kidney in a patient
with type 2 diabetes (291).
There is no doubt from the present data that diabetic transplant candidates have a
significantly higher comorbidity load compared with non-diabetic patients listed for
transplantation. In particular, high-risk factors for patient death and graft loss such as
peripheral vascular disease (284), coronary disease (292) and obesity are present in
more than 40% of the patients. It is not surprising that with such high comorbidity
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these patients have a reduced functional capacity (274;293) and an increased
mortality risk (290), both on dialysis as well as after transplantation. A diabetic's risk
of dying is three times higher while on the waiting list and twice higher after
transplantation compared with non-diabetics patients.
Despite being a high-risk group, diabetic patients are not discriminated against when
it comes to transplantation and they receive grafts of similar quality in terms ofHLA
matching, length of cold ischaemia time or donor age. It can be argued that most of
the diabetics in this cohort were type I and hence younger, and in order to provide the
best chance of survival, better quality kidneys should be given to them. At the other
extreme, there are some who consider that these patients are better served by
undergoing long-term dialysis (291) due to the poorer long-term results.
Survival of the diabetic patients is worse than for the non-diabetics on all forms of
replacement therapy (31;276). At five and ten years following transplantation, 13%
and respectively 33% fewer diabetics are alive compared with non-diabetic
recipients.
The survival rates noted in this study are better than most other reported data (table
6.4.9). In addition, this is one of the few investigations to report a 10 year survival
rate for diabetic recipients (281;294;295). The discrepancies in the reported survival
rates may be explained in part by differences in patient population, pre-transplant
assessment and selection methods.
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Study Type of Patient survival Graft survival
diabetes 1 year 5 years 1 year 5 years
Hirschl 1 69 62
2 75 58
Greenfell 1 + 2 69 54 (3 yr)
Gonzalez 1 + 2 92 (3 yr) 92
Rodriguez 1 + 2 87 83 (3yr) 70 55 (3yr)
Khauli 1 + 2 81 45
Kim I 86 71
Carlstrom I 75 60
Ekstrand 1 + 2 82 45 (7 yr)
Kronson 2 61 53
Kumar I 76 81 62
Mazucchi 1 + 2 89
Nyberg 2 89 67 81 56
e 6.4.9 Patient and graft survival in other published :
(274;279;281;283;290;292;296-301)
As far as graft survival is concerned, at 5 and 10 years, 12% and respectively 24%
fewer grafts were functional in diabetic compared with non-diabetic patients, but as
previously noted, graft survival censored for death with functioning graft is
comparable between the two groups, as a result of the fact that 50% of the grafts
were lost due to patient's death in the diabetic group. There are indications that living
donation rather than cadaveric transplantation may be a better solution for patients
with diabetic nephropathy (286).
The expected patient and graft life is 50% and respectively 60% shorter in diabetics
versus non-diabetics. Although these differences are striking, it is worthwhile noting
that most of the remaining life for diabetics is likely to be dialysis free (9.4 years
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patient half-life and 7.86 years graft half-life respectively), which will provide at
least a better quality of life (24).
The presence of diabetes in a transplant recipient is the most significant factor
predicting patient's death (RR=2.65, 95%CI: 1.83-3.85) and the loss of a functioning
graft (RR=1.68, 95%CI: 1.23-2.29) in a multivariate analysis. Some (291) use such
findings as the main argument for continuing the diabetics on dialysis, but such a line
of treatment will deprive these patients of a better treatment option. Our data agree
with other studies (19;21;236;300) in observing that the risk of death among
diabetics recipients of a kidney transplant is significantly lower compared with
diabetic waitlisted patients. In fact, the magnitude of the survival benefit noted here
(RR = 0.30) is comparable with that noted in two studies from the US (RR=0.25 (21)
and RR=0.27 (19) respectively) that were constructed in a similar manner, using a
time-dependant Cox-regression analysis to eliminate the time-to-treatment bias.
Pancreas transplantation has emerged as an important option (302) for the
management of patients with type I diabetic nephropathy, but clearly, not all patients
will be suitable for such a major procedure (289). Recent progresses in islet
transplantation could make this procedure an attractive alternative to whole organ
transplantation as it is a simpler and safer procedure, but the exact indications remain
to be defined (288). As a well-established pancreas transplant programme has only
been started in Scotland in 2000, a proper comparison between the results of
simultaneous kidney-pancreas versus kidney alone transplantation was not feasible,
but results reported elsewhere seem to indicate that both procedures are equally
successful (287;294).
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The data available for this study did not allow us to compare the results for the two
types of diabetes, as the number of those with type 2 receiving a transplant was
small. It is conceivable that the true incidence of type 2 diabetes is higher in
Scotland, but the lack of a comprehensive comorbidity data set as well as the
possibility of miscoded diagnosis (most of the diabetic patients starting RRT will be
on insulin) made such an investigation futile. Nevertheless, data from countries
where the incidence of type 2 is much higher seem to indicate that nowadays,
comparable success rates are within reach (290).
271
6.4.5 Conclusion
In conclusion, diabetic nephropathy represents one of the biggest challenges facing
transplant activity. With an increased number of comorbid illnesses and a diminished
life expectancy, these patients are far from being an ideal candidate, but as many
other risk groups, they have an equal right for a chance of transplantation. The lower
success rate achieved in these patients should be put into perspective, with
consideration given to a longer and a better quality life achieved in transplant
recipients compared with dialysis patients.
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Summary
These analyses of Scottish data have highlighted a series of important issues for the
transplant activity in this country:
1. Centre effect:
Patient assessment is the crucial step in deciding eligibility for transplantation
and despite generally acceptable listing criteria, there are wide variation in the
clinical practice. These differences may lead to potential bias in access to the
service and therefore, there is a clear need for clinical practice guidelines, such as
the ones already in place in the USA (18).
2. Elderly patients:
Elderly patients represent the largest and fastest growing group of patients
requiring replacement therapy. These patients have a higher comorbidity index
and a shorter life span, but transplantation should not be denied on the grounds of
age, as it is a feasible and successful undertaking and provides a longer and better
quality of life compared to dialysis.
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3. Diabetic patients:
The incidence of diabetic nephropathy and in particular that associated with type
II diabetes is likely to increase in the near future. Although the results of
transplantation are not as good as those obtained in other renal diseases, a kidney




A RISK ASSESSMENT SCORE TO PREDICT




Patients who are referred for transplantation are in general quite knowledgeable
about their renal disease and its impact on their life style, as most of them have spent
some time on dialysis. The assessment process and subsequent acceptance onto the
waiting list opens the gate towards a new and uncharted dimension and patients will
have a lot of questions. Some of these questions are relatively easy to answer. There
is enough evidence to enable the health professionals to inform patients about how
organs are allocated, what happens when a kidney becomes available, how great is
the risk of complications, what is the likelihood of a successful transplant. Some
questions, such as how long does someone have to wait for a transplant, will be more
difficult to answer as there are many factors involved, and some of them, such as
availability of donor organs, are beyond the control of the local transplant team.
However, the question - "How long am I likely to survive?" - remains difficult to
answer. The reasons reside with the complexity of the issue and there are many
variables which must be considered. First of all, from the patient's point of view, the
presence of certain medical conditions will reduce life expectancy (303-305)
(174; 186). This would happen in a normal population as well, but under dialysis
conditions, some of these illnesses are likely to progress at a faster rate and
sometimes the patient may become unsuitable for transplantation or worse, die,
before a kidney is available. Secondly, it is quite difficult to estimate when a donor
organ will be available and it has been suggested that a longer time spent on dialysis
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will negatively impact on survival after transplantation (47). Finally, assuming that a
kidney is available, there are numerous other factors - donor's age and cause of
death (306), length of cold ischaemic time, degree of HLA matching (96), acute
rejection and delayed graft function episodes (307) - that will affect the success rate
of a transplant and inevitably patient's survival.
As a large set of data for patients listed for transplantation in Scotland in the last
decade was available, we attempted to devise a method of estimating survival from
the moment of acceptance to the waiting list. This risk assessment score could be
used to help patients in making an informed choice regarding the best treatment




1022 adult patients listed for transplantation between 1st of January 1989 and 31st of
December 1999 were included in this analysis. Socio-demographic data was
collected from the SRR and UKT and extensive comorbidity data was retrieved from
case notes, as described in the previous chapters.
Actuarial survival from the time of admission onto the renal transplant waiting list
was calculated at 1, 3, 5 and 10 years using a Cox proportional hazards model. The
likelihood of survival was predicted based on demographic variables (age, gender,
social deprivation, centre of treatment, blood group) and associated medical
condition (peripheral vascular disease, ischaemic heart disease, left ventricular
hypertrophy, cardiac arrhythmias, diabetes, previous neoplasia, respiratory disease,
CVD, smoking status and BMI) present in any given patient when listed.
The treatment modality is time-dependant and therefore at listing, the precise
moment when the patient will be transplanted is unknown. To solve this problem, the
model was built to predict survival from the listing moment under different
scenarios:
1. "Averase treatment" - which predicted survival irrespective of the treatment
modality (for this model it was assumed that all patients were going to
receive the same kind of treatment, which was unknown at listing).
2. "No transplant" - in this model it was considered that patients remained on
maintenance dialysis. For this particular model, patients were censored once
they were transplanted.
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3. "Post transplant" (Survival with a transplant) - assuming that patients were
transplanted the following day after listing. This particular estimate may not
be of practical use at the time of entry to the waiting list, as it is highly
unlikely that a patient will be transplanted the following day after listing. In
real terms, patients must be fit enough to survive on average 17 months until
transplantation.
4. "Transplant 17mo" (Transplant after a median time of 17 months on the
waitins list). The median waiting time for a kidney transplant in Scotland
throughout the follow-up period (1st of January 1989 - 31st of December
2000) was 17 months. For a uniform approach and an easier clinical use, the
impact of transplantation after this average waiting time was determined.
In order to identify which factors should be used in the predictive models, a baseline
Cox regression analysis was built to determine the socio-demographic and comorbid
conditions with a significant impact on survival, under the assumption of an
"average treatment". The analysis was built in a stepwise manner, which allowed
only significant factors to be retained in the final model. A level of significance of
20% was set and all factors with p-values < 0.20 (figure A.4.1, appendix, page 356)
were retained for inclusion in all subsequent models.
Three survival models were built: "average treatment", "no transplant" and "post
transplant" (figure A.4.2-A.4.4, appendix, page 357-359) and for each predictive
variable identified in the baseline model, an estimate of impact on survival under
each scenario was determined from the Cox regression (table 7.1).
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35-49 years old 0.75389 -0.01494 1.13495
50-59 years old 1.46363 1.00082 1.58291
60-64 years old 1.54045 0.91014 1.99169
>65 years old 2.32296 1.27792 2.75975
Female gender 0.24861 0.00564 0.39573
Transplant centre 2 0.82955 0.64872 1.04668
Transplant centre 3 -0.44666 -1.09392 -0.04090
Diabetes 0.97736 1.35650 0.91256
Ischaemic heart disease 0.34356 0.38346 -0.04642
Hypertension 0.42601 0.11743 0.67537
Valvular disease 0.48013 0.66919 0.43998
Pulmonary embolism -0.76258 -0.36521 -0.86400
Arrhythmias 0.38039 0.08141 0.14464
Other heart diseases 0.58845 0.44600 0.52389
Cerebrovascular disease 0.41491 0.78555 0.15750
Respiratory disease 0.46732 0.50438 0.34763
GI disorders 0.22936 0.17034 0.31930
Neoplasia 0.73981 0.49526 1.20736
Smoker 0.29710 -0.09141 0.69125
BMI < 20 0.53309 0.36899 0.73837
Blood group A -0.26312 -0.01486 -0.17645
SUM OF VARIABLES (z) Score_ave Scorent Scoret
Table 7.1 Predictive variables and individual estimates of impact on survival in
three separate models (Cox regression analysis)
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According to the Cox regression model (228) survival at a given time point - -
can be calculated by:
S,(z=0)expW
where "z" is the linear sum of all parameters included in the model:
Z = L xi hi
where b, - ith parameter estimate from Cox model
x; = value of ilh parameter (usually 0 or 1 defining the presence or
the absence of the factor)
St(z=0) is the survival at time "t", for a patient with all predictive variables listed
above equal to zero ("baseline survival"). In other words, in each of the three
models, at any given time point, a baseline survival for a patient with none of the
factors listed in table 7.1 can be determined. Survival probability for any other
patient can be calculated by raising this baseline survival at an exponent, which is the
sum of the estimates for all the predictive variables present in that particular patient
("Score ave", "Score nt" and "Score t" respectively).
To estimate survival after transplantation after an average waiting time of 17 months
("transplant_17mo") a more complex approach is necessary. Survival at 1 year is the
same as survival at 1 year under the 'no transplantation' scenario. Survival at 3, 5
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and 10 years is obtained as the product of the probability that the patient survives to
17 months with no transplant, multiplied by the probabilities that he/she survives a
further 19, 53 and 353 months following transplant (all calculated using the formula
described). It is expected that survival at 10 years will be less accurate than at 1-5
years because fewer patients had been followed up for this length of time in the
prediction models.
The equations obtained to calculate survival under each scenario at 1,3,5 and 10
years are listed in table 7.2.





1 year = 0.99858exp(score-ave)
3 years = 0.99447exp(score-ave)
5 years = 0.98832exp(soore-ave)
10 years = O.96365exp(soore-ave)
1 year = 0.99460exp(soore-nt)
3 years = 0.96920exp(score-nt)
5 years = 0.90946exp(score-nt)
10 years = 0.65756exp(score-nt)
1 year = 0.99938exp(score-t)
3 years = 0.99832exp(scoreJ)
5 years = 0.99717 exp(score-°
10 years = 0.98818exp(scoreJ)
1 year = 0.99460exp(score-nt)
3 years = 0.9874exp(score-nt) * 0.99933exp(scoreJ)
5 years = o.9874exp(score-nt) * 0.99809exp(score-t)
10 years = o.9874exp(score-nt) * 0.98996exp(scoreJ)
Table 7.2 Equations used to calculate survival at 1,3,5 and 10 years in each of the
prognostic models
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To make the use of this score more practical, a spreadsheet was devised. For each
new patient, survival is obtained by entering a value of "1" for all factors present
with the exception of gender, where a "1" is entered for males and "2" is entered for
females. If a field is left missing it is assumed that the factor is absent. Survival
predictions will automatically appear in the appropriate columns of the spreadsheet.
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7.3 Practical examples
To illustrate how the score can be used in a practical setting, in the assessment clinic,
consider the following clinical scenarios and the predictive score for these
hypothetical individuals.
a. The "Ideal candidate"
A 28-year-old male is assessed for listing for transplantation in centre 4. He has
renal failure due to glomerulonephritis, no associated comorbidity, is a non-
smoker, has a normal body mass index (BMI) and is blood group O. This patient
has no contraindication to transplantation and therefore is listed. According to
this model, this patient will have 66% chances of surviving at ten years if a
transplant is not available and 97% probability of being alive at the same time
point if a transplant becomes available in 17 months (Case A, figure 7.1).
Survival probabilities will be identical for a female patient of similar age and
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Figure 7.1 Practical examples for the use of the prognostic scores
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b. The "hish-risk candidate"
A 55-year-old female is assessed for listing for transplantation in centre 1. She
has renal failure due to diabetic nephropathy. She is hypertensive and had a
myocardial infarction 7 years previously. 5 years prior to the assessment she had
a documented cerebrovascular accident from which she made a full recovery. She
smokes 2 cigarettes per day and has a degree of emphysema on her chest X-ray.
Her body mass index (BMI) is normal and she is blood group AB. After
consultation between nephrologists, surgeons and anaesthetists, this patient is
listed. According to the model:
a. she will be dead within 5 years without a transplant
b. if a transplant becomes available in 17 months, she will have a 35% and 9%
chance of being alive at 5 years and 10 years respectively (Case C, figure
7.1).
A 65 year-old diabetic male is referred for assessment at the transplant centre 2.
He is hypertensive, has angina of effort, had one episode of transient ischaemic
attack and has chronic obstructive airway disease. He has no other associated
illnesses, is a non-smoker and his weight is within the normal range for his age
and height. After careful consideration, this patient is admitted onto the waiting
list. According to the model he has 60% chances of being alive at one year and
only 5% probability of living to 3 years. Assuming he survives 17 months and is
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transplanted, his long-term survival will be 16% better at 5 years, but he is still
likely to die within 10 years (Case D, figure 7.1).
c. The "average candidate"
A 40 year-old male with renal failure due to hypertension is assessed for
transplantation in centre 1. He has a history of duodenal ulcer and chronic
bronchitis and smokes 2-3 cigarettes per day. He has no major contraindication to
transplantation and is listed. His survival probability without transplantation is
good, with a 70% chance of being alive at 5 years and 20% chance of living
beyond 10 years. In his case, after transplantation, the prognosis is poorer in the
first years, but on long-term, there is a 15% better chance of surviving at 10 years
(Case E, figure 7.1).
287
7.4 Discussion
Kidney transplantation is well accepted nowadays as the best form of treatment for
patients with end-stage renal failure as it provides a better and a significantly longer
life (19). The majority of patients are aware of these advantages and not surprisingly,
most of their questions at assessment and listing for transplantation surround the
issues of access to a kidney graft and survival benefit. Although a better survival has
been demonstrated in large population-based studies, to try and estimate individual
patient survival is a more complex matter. There are numerous factors that will
determine survival and some of them, such as availability of a donor organ, are
impossible to predict at the moment of listing.
In this study we describe for the first time, a survival estimate for individual patients,
derived from a large population sample of adult patients listed for transplantation in
Scotland in the last decade. These estimates are based on socio-demographic criteria
and patient's general health status data, which are readily available at the moment of
listing. As treatment modality is itself a time-dependant variable (21), it would be
quite difficult to predict when transplantation will occur and how it will affect
survival in each patient. To resolve this issue, survival was estimated under three
different scenarios that cover all clinical possibilities (no transplant, following a
transplant, average treatment and following a transplant which is received 17 months
after listing). The 17 months figure was considered for the latter model, as it
represents the median waiting time to a kidney transplant in Scotland, as determined
from the study cohort.
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This prognostic score could provide a useful clinical tool, which can be easily
applied in the assessment clinic to estimate a patient's survival, as illustrated by the
practical examples given above. Although some of the cases presented seem unlikely
to be listed, they are in fact very similar to real-life patients that have been listed and
transplanted throughout the duration of this study. The use of a prognostic score, like
the one proposed here, will enable clinicians to recommend whether transplantation
or dialysis is the best form of treatment for a particular patient, based on health status
and estimated survival probability. As shown in some cases, prognosis may be
poorer after transplantation, particularly in the early years, and this may influence the
choice of therapy. Patients will be able to make an informed decision regarding the
benefits and the risks associated with either form of treatment and choose the course
of therapy deemed suitable to them.
The idea of a prognostic score is not new and there is no right or wrong model. The
advantages of the model presented here are that it takes into account a large number
of comorbid conditions - and hence provides a better clinical picture of the recipient
- and allows an instant estimate of survival without being too cumbersome to use.
One of the potential drawbacks of the model presented here is that it was derived
based on retrospective data which was available only for about 60% of all patients
listed during the study period. Therefore, this score needs to be validated
prospectively, and with the ever changing demographics of the waiting list
population it may well be the case that some of the variables considered will see an
alteration of their individual predictive power.
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7.5 Conclusion
In summary, based on the best data currently available in Scotland, these prognostic
models allow, for the first time, an estimation of survival for patients listed for
transplantation, providing a useful clinical and research tool. The advent of such a
score is a step forward towards an evidence-based and truly informed choice of




As everywhere else in the world, transplantation in Scotland has seen an incredible
advance in the last three decades, making it one of the fastest growing fields of
medicine. This progress has established transplantation as the preferred choice of
treatment for patients with end stage renal failure disease, but the current logistic
constraints and in particular, the lack of donor organs, seriously jeopardize any
further developments of the service. The current climate of transplantation has raised
yet again serious concerns regarding issues such as organ allocation, equity of
access, standards of the assessment process and appropriateness of transplantation in
certain groups of patients.
As there were virtually no data on these issues in Scotland, and indeed very little
elsewhere in the United Kingdom, this thesis had as the first aim to correlate the
information available and to provide a longitudinal perspective for end-stage renal
failure patients from the moment they start renal replacement therapy and following
onto listing for transplantation, transplantation and beyond. Scotland has the unique
privilege of having an extensive database for all renal failure patients on dialysis, in
the form of the Scottish Renal Registry (SRR), while transplant and post-transplant
data for all kidney recipients is collected and stored at the UK Transplant. In
addition, case notes can provide the clinical data, which is not stored in either of the
two databases. Despite these extensive sources of information, an actual link between
them has never been established until the present work. Creating this link, the aims
of the thesis were to address the issues outlined above and to answer the questions set
out at the end of the first chapter:
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1. What are the benefits of the current allocation schemes and the influence of
the new regional Scotland-Northern Ireland Alliance on the transplant
activity?
2. Is there equity of access to the transplantation service? If not, which are the
sociodemographic and comorbidity factors which may be responsible for
these differences?
3. Does transplantation provide a survival advantage over dialysis in various
renal failure subpopulations? Is there any benefit in transplanting high-risk
groups of patients?
4. Are there any differences in the assessment process? Can the risk factors
identified at the assessment process be quantified into a patient survival risk
score?
Each of the questions will be answered individually on the basis of the information
gained during these studies.
1. What are the benefits of the current allocation schemes and the influence of
the new regional Scotland-Northern Ireland Alliance on the transplant
activity?
The impact of this new alliance was examined in Chapter 2. As the analysis clearly
demonstrated, this regional level of organ sharing had significant benefits. There was
a substantial improvement in the level of HLA matching, 79% of the transplants
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performed in the Alliance being very well matched (Tier 1 or Tier 2) compared with
only 64% across the UK. The improvement in HLA matching was sustained over the
two-year period of the study, whilst very little improvement was noted for the rest of
the UK after the first year of the new allocation scheme. Furthermore, the higher
degree of matching was achieved through an increased organ exchange, only 23% of
the kidneys being retained locally by the retrieving centre. These improvements were
reflected in the structure of the waiting list, with a reduction in the proportion of the
long waiting patients, highly sensitised patients and re-transplants. This study has
shown that an increased regional organ exchange has no detrimental effect on the
length of the cold ischaemic time or graft survival. However, there was a persistent
disproportion in kidney distribution amongst the participating centres, a large centre
being a net kidney importer.
Further monitoring and computer modelling are required to ensure that the benefits
of the alliance are persistent and the balance of exchange is corrected.
2. Is there equity of access to the transplantation service? If not, which are the
sociodemographic and comorbidity factors which may be responsible for
these differences?
The study performed in Chapter 3 indicated that there were significant differences in
access to the transplantation service in Scotland over a period of 11 years. Access to
the renal transplant waiting list was found to be dependant on a variety of
sociodemographic factors, elderly patients, females, patients with a higher
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deprivation score, patients starting RRT on haemodialysis, patients with diabetes and
patients living closer to the transplant centre having fewer chances of being admitted
onto the waiting list. In addition, there was a significant centre effect, the analyses
described in chapter 3 indicating that patients starting dialysis in a renal centre which
is in the same hospital as a transplant unit, were more likely to be listed. Once a
patient was listed, age, the primary renal disease and the transplant centre remained
the only factors with a significant impact on the access to a kidney graft. It is
important to note that these findings are not random and they are consistent with the
inequities of access noted in the USA (143).
Comorbidity may account for the differences noted in Chapter 3. However, the
difficulties in considering the associated medical conditions have long been
acknowledged and this is reflected by the paucity of studies incorporating
comorbidity in a predictive model of access to transplantation (130; 131). The study
presented in Chapter 4 overcame some of these difficulties and investigated the
impact of comorbidity on the access to the renal transplant waiting list and renal
transplantation in Scotland. The presence of left ventricular hypertrophy, cerebro¬
vascular disease, respiratory disease and previous neoplasia had a negative impact on
the likelihood of listing. However, it is important to note that although the addition of
comorbid conditions to the model of access to the waiting list presented in Chapter 3
improved the predictive power of the model, it did not diminish the level of
significance of the individual socio-demographic variables. In contrast, there were
significant changes in the predictive value of the socio-demographic variables when
the model of access to transplantation was corrected for comorbidity. After
adjustment for comorbidity, the primary renal disease and age lost their impact on
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the likelihood of transplantation, suggesting that their effect could have been due
entirely to an unequal comorbidity load across different age groups or causes of renal
failure.
The findings presented in Chapter 3 and 4 suggest that the differences in access to
the waiting list and transplantation noted for different socio-demographic variables
cannot be explained entirely by the presence of the comorbid conditions. Secondly,
these studies indicate that the prevalence of the comorbid conditions is worse among
patients on dialysis compared with kidney transplant recipients. With a significantly
higher number of factors determining the access to the renal waiting list it is clear
that the main obstacle on the pathway to transplantation is at the listing stage rather
than at transplantation once on the waiting list.
Further prospective investigations into the reasons behind some of these differences
as well as a comprehensive database containing socio-demographic and comorbidity
data may identify the changes in the demographics of the RRT population and help
correcting the inequities in access to the service noted in these studies.
3. Does transplantation provide a survival advantage over dialysis in various
renal failure subpopulations? Is there any benefit in transplanting high-risk
groups of patients?
The study performed in Chapter 5 identified a substantial long-term survival
advantage for transplantation compared with dialysis in patients considered suitable
candidates for renal transplantation. Transplant recipients appeared to have a higher
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immediate postoperative (30 days) mortality compared with mortality on continued
dialysis, this finding being even more obvious when survival was censored for graft
failure. However, beyond a year, transplant recipients have a significantly lower risk
of death, which leads to a substantially longer life expectancy compared with patients
on dialysis on the waiting list. As shown by the results of chapter 5, this effect seems
to be intrinsic to the treatment itself rather than an effect of patient selection or
higher dialysis mortality. As expected, the outcome varies among different kidney
transplant recipients, but the survival advantage conferred by transplantation is
present is all subgroups of patients, including high-risk ones.
This issue was further investigated in Chapter 6. The results presented in this chapter
have shown that elderly patients enjoy a significant benefit from being transplanted
rather than continuing on dialysis. Furthermore, despite a higher index of
comorbidity in elderly patients on renal replacement therapy, transplantation seems
to be a safe and feasible undertaking in these patients and provides a dialysis-free
and good quality of remaining life.
The issue of renal transplantation in patients with diabetes mellitus was explored in
Chapter 6. This analysis found that diabetic patients have an increased number of
comorbid illnesses and a diminished life expectancy and are far from being an ideal
candidate for renal transplantation. Although the results are inferior to those obtained
in non-diabetic patients, this study has clearly shown that transplantation provides a
substantial long-term benefit compared with dialysis and should be the preferred
method of treatment whenever possible.
297
4. Are there any differences in the assessment process? Can the risk factors
identified at the assessment process be quantified into a patient survival risk
score?
The initial analysis described in Chapter 6 confirmed that there are significant
differences in the practice of assessing and listing patients for renal transplantation
across Scotland. The study has shown wide variations with regards to factors such as
the primary renal disease, age, gender, type of first renal replacement therapy and
social deprivation between the four transplant centres. The comorbidity index is a
significant factor, different weight being given in each of the four centres to factors
such as peripheral vascular disease, ischaemic heart disease, obesity and
hyperlipidaemia, which are strongly correlated with an increased risk of death
following transplantation.
These findings confirmed previously documented differences in patient selection
(199) and highlighted again the need for a consensus and clinical guidelines on
assessment for transplantation such as those published by the American Society of
Transplantation and the European Dialysis and Transplant Association (157;308).
A variety of socio-demographic (age, gender, transplant centre) and comorbidity
factors (cardiovascular disease, respiratory disease, cerebro-vascular disease,
neoplasia, gastro-intestinal disorders) have a significant impact on survival. Using
these factors, in the analysis in Chapter 7, a complex statistical model was built, to
estimate the likelihood of survival from the moment the patient is admitted onto the
waiting list, under different clinical scenarios. As the precise moment of
transplantation is unpredictable, this risk assessment score presents the patients with
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the probability of survival continuing dialysis, receiving a transplant the day after
listing, or under the assumption of transplantation after the average waiting time for a
kidney graft in Scotland. This score is "user-friendly" and could provide a useful
clinical tool to enable patients to make an informed decision regarding the risk and
benefits associated with either form of treatment.
With respect to the questions set out at the end of Chapter 1, the following
conclusion can be made:
1. There is a significant improvement in the HLA matching, with increased
organ sharing, similar cold ischaemic time and graft survival in a wider
regional kidney sharing alliance.
2. At present in Scotland there are significant inequalities in access to the
transplantation service, which cannot be entirely explained by the presence of
comorbidity.
3. Transplantation provides a significant reduction in the long-term risk of death
and a substantial increase in the life expectancy compared with dialysis. This
benefit is present at different magnitude in all patients considered suitable for
transplantation.
4. Currently in Scotland, there is no consensus regarding the assessment and
listing for renal transplantation. Based on individual socio-demographics and
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comorbidity, a prognosis of the likelihood of survival can be made, to allow
patients to make an informed choice of treatment.
In addition to these findings, the work in this thesis has established a novel link
between the Scottish Renal Registry and United Kingdom Transplant and clinical
data, providing a longitudinal picture of the transplant patients. This thesis has
identified a core set of clinical data which has a significant impact on the outcome of
the transplant recipient and which could be included in a future prospective
comprehensive database. With the rapid changing demographics of the renal
replacement population and with the increased ability to treat more complex cases,
the advent of such complex data will allow rapid analysis of all the issues described
in this thesis and computer modelling of potential solutions.
The work presented in this thesis has highlighted some of the controversial issues
confronting the transplant services in Scotland at the dawn of the third millennium
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Year of transplant No. at risk at day 0 % survival 95% CI
1989-1992 367 89 86-92
1993-1995 358 92 89-95
1996-1998 480 95 93-97
Table A.l One year transplant survival after living donor kidney in UK, by year of
transplant {Source: UK Transplant Activity report 2000)
1 year 3 years 5 years
Type of Year of % 95% % 95% % 95%
survival graft survival CI survival CI survival CI
1990-1992 82 80-84 74 72-76 66 64-68
Transplant 1993-1995 83 82-85 76 74-77
1996-1997 85 83-86
1990-1992 86 85-88 81 79-83 76 74-77
Graft 1993-1995 87 86-88 82 80-83
1996-1997 88 86-90
1990-1992 95 94-96 91 90-93 87 85-88
Patient 1993-1995 96 95-96 92 91-94
1996-1997 96 95-97
Table A.2 One, three and five year transplant, graft and patient survival after first
adult cadaveric kidney transplant in UK 1990-1997, by year of graft {Source: UK
Transplant: Renal Transplant Audit 1990-1998)
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„ _ Survival Year ofgraftingGraft type . ,interval 19g4 19g5 19g6 19gy 19gg }9g9 1990 199J J992 1993 1994
„ , 5 years 42.5 44.5 44.4 46.1 53.0 56.3 57.2 59.1 58.0 58.5 59.1
i QnQttpnp
10 years 25.3 25.8 26.6 28.4 33.3 35.4
Living 5 years 67.8 71.1 73.6 72.5 70.3 73.7 72.1 74.3 71.5 70.0 71.8
donor 10 years 49.8 49.9 52.1 50.3 51.3 54.5
Table A.3 Five and ten year graft survival for cadaveric and living donor transplants






















Figure A.l Crude incidence ofRRT 1990-1999, by country (Source: ERA-EDTA
Registry)
199ft 1991 1992 1993 1994 1995 1996 1997 1998 1999 1
Ratepmp 190 210 226 232 266 266 276 297 310 317
Table A.4 Change in incident rates ofESRD in USA, 1990 - 1999 {Source:
USRDS)
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No. of alleles Antigen No. of alleles Antigen
HI,A-A 3 B53
4 A1 1 B54(22)
32 A2 7 B55(22)
6 A3 5 B56(22)
5 All 5 B57(17)
1 A23(9) 2 B58(17)
21 A24(9) 1 B59
2 A25(10) 3 B60(40)
12 A26( 10) 4 B61(40)
4 A29( 19) 15 B62(15)
7 A30(19) 2 B63(15)
4 A31(19) 1 B64(14)
3 A32(19) 1 B65(14)
3 A33(19) 2 B67
2 A34(10) 1 B70
1 A36 2 B71(70)
1 A43 2 B72(70)
3 A66(10) 1 B73
10 A68(28) 5 B75(15)
1 A69(28) 3 B76(15)
3 A74(19) 1 B77(15)
1 A80 4 B78
HLA-B 1 B81
14 B7 1 B82
6 B8 HLA-DR
4 B13 6 DR1
17 B15 3 DR2
7 B18 10 DR3
16 B27 35 DR4
28 B35 2 DR6
2 B37 3 DR7
4 B38(16) 26 DR8
19 B39(16) 1 DR9
13 B40 1 DR10
3 B41 39 DR11(5)
2 B42 8 DR12(5)
11 B44(12) 36 DR13(6)
3 B45(12) 33 DR14(6)
1 B46 10 DR15(2)
3 B47 8 DR16(2)
5 B48 3 DR17(3)
1 B49(12) 2 DR18(3)
1 B50(21) 14 DR51
17 B51(5) 19 DR52
3 B52(5) 10 DR53
Table A.5 Recognized human leukocyte antigen (HLA) specificities (adapted from




A01C Al, A3, A11, A29,A30, A31, A36, A80
A10C A10, Al 1, A19, A25, A26, A32, A33, A34, A43, A66, A74
A02C A2, A9, A23, A24, A28, A68, A69, A203, A210, A2403, B17,
B57, B58
B05C B5, B15, B17, B18, B21, B35, B46, B49, B50, B51, B52, B53,
B57, B58, B62, B63, B70, B71, B72, B73, B75, B76, B77,
B78, B4005, B5102, B5103
B07C B7, B13, B22, B27, B40, B41, B42, B47, B48, B54, B55, B56,
B59, B60, B61, B67, B81, B8201, B703
B08C B8, B14, B16, B18, B38, B59, B64, B65, B67, B3901, B3902
B12C B12, B13, B21, B37, B40, B41, B44, B45, B47, B49, B50,
B60, B61, B4005
BW4 B5, B13, B17, B27, B37, B38, B44, B47, B49, B51, B52, B53,
B57, B58, B59, B63, B77, B5102, B5103
BW6 B7, B8, B14, B18, B22, B39, B40, B41, B42, B45, B48, B50,
B54, B55, B56, B60, B61, B62, B64, B65, B67, B70, B71,
B72, B73, B75, B76, B78, B81, B8201, B703, B3901, B3902,
B4005













Aberdeen 28 0.71 14(19.7) 11(14)
Edinburgh 26 1.2 13 (10.8) 27 (22.5)
Glasgow 68 2.7 34(12.6) 69 (25.5)
Belfast 50 1.6 25(15.6) 37(23.1)
Dundee 8 0.4 4(10) 14(35)
Total 180 6.61 90 (13.6) 158 (23.9)












Aberdeen 38 0.71 19(26.7) 16 (22.5)
Edinburgh 34 1.2 17(14.1) 34 (28.3)
Glasgow 55 2.7 28(10.3) 66 (24.4)
Belfast 46 1.6 23 (14.3) 39 (24.3)
Dundee 10 0.4 5 (12.5) 9 (22.5)
Total 183 6.61 92 (13.9) 164 (24.8)












Aberdeen 14 0.71 7(9.86) 25 (35.2)
Edinburgh 54 1.2 27 (22.5) 35(21.8)*
Glasgow 58 2.7 29(10.7) 92 (34)
Belfast 36 1.6 19(11.8) 34 (21.2)
Dundee 5 0.4 3 (7.5) 0
Total 167 6.61 85 (12.8) 186 (28.1)
Table A.7.c Year 2 (1.09.1999 -31.08.2000) (*, Dundee merged with Edinburgh, pmp
rate calculated for 1.6 million people)
Table A.7.a-c Retrieval activity, total population (millions), number of donors per
million population and number of transplants performed for each centre in the pre-






centre ("<>) Export I KT (%)
Export
Alliance ("o)
Edinburgh 24 7(29.1) 9 (37.5) 8 (33.4)
Aberdeen 27 5 (18.5) 8 (29.6) 14(51.8)
Glasgow 65 44 (67.7) 20 (30.8) 1 (1.5)
Belfast 47 21 (44.7) 22 (46.8) 4(8.51)
Dundee 8 0 5 (62.5) 3 (37.5)
Total 171 77 (45) 64 (37.5) 30 (17.5)





centre ("„) Export CRT ("<>)
Export
\liiance ("<>)
Edinburgh 34 5(14.7) 13 (38.2) 16(47)
Aberdeen 34 1 (2.9) 14(41.2) 19(55.9)
Glasgow 48 17(35.4) 19(39.6) 12 (25)
Belfast 45 11 (24.4) 15 (33.3) 19 (42.2)
Dundee 10 2 (20) 5 (50) 3 (30)
Total 171 36 (21) 66 (38.6) 69 (40.4)





centre ("<>) Export I KT (%)
Export
illiance (°o)
Edinburgh 52 9(17.3) 15 (28.8) 28 (53.8)
Aberdeen 12 1 (8.33) 5(41.6) 6(50)
Glasgow 56 25 (44.6) 13 (23.2) 18(32.1)
Belfast 35 2 (5.7) 15 (42.8) 18(51.4)
Dundee 5 0 1(20) 4(80)
Total 160 37 (23.1) 49 (30.6) 74 (46.3)
Table A.8.c Year 2 (1.09.1999-31.08.2000)






Aberdeen Edinburgh Glasgow Belfast Dundee
□ Export to UKT M Import from UKT






Aberdeen Edinburgh Glasgow Belfast Dundee
□ Export to UKT a Import from UKT
Figure A.2.b Individual centre balance of exchange with UKT in the first alliance
year (1.09.1998-31.08.1999)
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Aberdeen Edinburgh Glasgow Belfast Dundee
□ Export to UKT □ Import from UKT
Figure A.2.c Individual centre balance of exchange with UKT in the second




Aberdeen Edinburgh Glasgow Belfast Dundee
Tola!
imports
Aberdeen 3 1 1 4
Edinburgh 8 3 12
Glasgow 1 2 3
Belfast 1 1
Dundee 6 3 1 10
Total exports 14 8 1 4 3 30
Balance of exchange +10 -4 -2 +3 -7




Aberdeen Edinburgh Glasgow Belfast Dundee
Total
imports
Aberdeen 2 3 2 7
Edinburgh 8 4 6 3 18
Glasgow 6 8 10 2 26
Belfast 5 4 4 1 14
Dundee 2 1 1 4
Total exports 19 16 12 19 3 69
Balance of exchange +11 +2 -14 +5 -1




Aberdeen Edinburgh Glasgow Belfast Dundee
Total
imports
Aberdeen 5 5 6 2 18
Edinburgh 4 7 8 19
Glasgow 1 13 4 2 20
Belfast 1 10 6 17
Dundee
Total exports 6 28 18 18 4 74
Balance of exchange -12 +9 -2 +1 +4
Table A.9.c Year 2 (1.09.1999-31.08.2000)









accepted and not used (%)
Aberdeen 10 6 2(33.3)
Edinburgh 20 16 4(25)
Glasgow 15 10 7(70)
Belfast 8 5 4(80)
Dundee 20 12 2(17)
Total 73 49 19(38.78)







accepted and not used ("»)
Aberdeen 29 8 1 (12.5)
Edinburgh 27 18 1(6)
Glasgow 63 43 17(39.6)
Belfast 52 26 12 (46.2)
Dundee 26 8 3 (37.5)
Total 197 103 34 (33)







accepted and not used (%)
Aberdeen 50 21 3 (14.3)
Edinburgh 43 21 2 (9.5)
Glasgow 38 30 10(33.3)
Belfast 85 25 8(32)
Dundee 6
Total 222 97 23 (23.7)
Table A.lO.c Year 2 (1.09.1999 -31.08.2000)
Table A.lO.a-c Internal offers made, accepted and accepted and not used by each
centre for each of the three year period
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, ,
, kidneys accepted tiiiri „ . . , Positive crossmatchL entre • ' , Positive crossmatch /n .
not used ("n
Aberdeen 2 0 0
Edinburgh 4 3 75
Glasgow 7 4 57
Belfast 4 4 100
Dundee 2 1 50
Total 19 12 63
Table A.ll.a Pre-alliance year (1.09.1997 - 31.08.1998)
Aberdeen 1 1 100
Edinburgh 1 1 100
Glasgow 17 12 70
Belfast 12 8 66
Dundee 3 1 33
Total 34 23 52
Table A.ll.b Year 1 (1.09.1998 - 31.08.1999)
Aberdeen 3 1 33
Edinburgh 2 1 50
Glasgow 10 6 60
Belfast 8 6 75
Dundee
Total 23 14 61
Table A.ll.c Year 2 (1.09.1999-31.08.2000)
Table A.ll.a-c Kidneys accepted and not implanted due to positive crossmatching





Year 1 Year 2
I Tier 1 □ Tier 2 I Tier 3




Pre-alliance year Year 1
Edinburgh
Year 2
I Tier 1 □ Tier 2 I Tier 3








I Tier 1 □ Tier 2
Year 2
I Tier 3












Tier 1 □ Tier 2
Year 2
I Tier 3




Pre-alliance year Year 1
Dundee
Year 2
Tier 1 □ Tier 2 ■ Tier 3
Figure A.3.e % HLA matching for transplants performed in Dundee in each year of
activity
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Table A.12.a One year graft survival for Tier 1 transplants in the pre- and post-
alliance periods (p = 0.7760, Log-Rank test)





Table A.12.b One year graft survival for Tier 2 transplants in the pre- and post-
alliance periods (p = 0.2377, Log-Rank test)





Table A.12.C One year graft survival for Tier 3 transplants in the pre- and post-
alliance periods (p = 0.0532, Log-Rank test)
Table A.12.a-c One year graft survival for all transplants in the pre- and post-
alliance periods, according to the HLA matching tier
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Variable Postcode Xj SDj
Overcrowding V, X! sd!
Male unemployment v2 x2 sd2
Low social class v3 x3 sd3
No car v4 x4 sd4
n=4
Deprivation score = £ (Vj-X)/SD,
Vi = The value for each variable for individual postcodes
X; = Mean for each variable for all Scottish postcode sectors
SD! = Standard deviation for each variable for all Scottish postcode sectors







Cases with missing values 187 4.3%
Cases with non-positive time 122 2.8%
Censored cases before the 0 .0%
earliest event in a stratum
Total 309 7.1%
4356 100.0%
Cases available in analysis
Cases dropped
Total
a Dependent Variable, time elapsed from 1st RRT to listing (years)
Omnibus Tests of Model Coefficients
-2 Log
Likelihood











a Beginning Block Number 0, initial Log Likelihood function: -2 Log likelihood: 23769.178
b Beginning Block Number 1. Method = Enter
Variables in the Equation
B SE Wald df Sig. Exp(B) 95.0% CI for Exp(B)
Lower Upper
Gender -.179 .054 11.075 1 .001 .836 .753 .929
Age group at 1st RRT 892.620 4 .000
35-49 yr -.304 .069 19.194 1 .000 .738 .644 .845
50-59 yr -.803 .073 120.495 1 .000 .448 .388 .517
60-64 yr -1.550 .098 251.928 1 .000 .212 .175 .257
> 65 yr -2.672 .100 720.095 1 .000 .069 .057 .084
Carstairs dep. cat. 18.479 .005
Carstairs 2 -.308 .136 5.106 1 .024 .735 .562 .960
Carstairs 3 -.275 .128 4.599 1 .032 .759 .590 .977
Carstairs 4 -.373 .126 8.720 1 .003 .688 .537 .882
Carstairs 5 -.492 .135 13.376 1 .000 .611 .470 .796
Carstairs 6 -.406 .137 8.795 1 .003 .667 .510 .871
Carstairs 7 -.525 .159 10.909 1 .001 .592 .433 .808
Transplant center 174.702 .000
Centre 2 -.155 .109 2.047 1 .153 .856 .692 1.059
Centre 3 -.800 .096 69.052 1 .000 .449 .372 .542
Centre 4 -.944 .084 125.113 1 .000 .389 .330 .459
Distance to Tx Centre 20.334 .000
0-50 km .124 .099 1.584 1 .208 1.132 .933 1.373
50-100 km -.457 .118 14.956 1 .000 .633 .503 .798
>100 km .202 .223 .820 1 .365 1.223 .791 1.892
Primary renal disease 88.026 .000
Interstitial nephritis -.206 .071 8.447 1 .004 .814 .708 .935
Multisystem disease -.577 .085 46.608 1 .000 .561 .476 .663
Diabetes -.650 .084 59.556 1 .000 .522 .443 .616
Other/unknown -.453 .084 28.880 1 .000 .636 .539 .750
Type 1st RRT .364 .054 44.853 1 .000 1.439 1.294 1.601
Year first RRT -.051 .009 34.571 1 .000 .950 .934 .967
Table A.14 Relative risk of access to the wai
model including all cases)




Cases available in analysis Event 1015 58.4%
Censored 638 36.7%
Total 1653 95.2%
Cases dropped Cases with missing values 80 4.6%
Cases with non-positive time 2 .2%
Censored cases before the 1 .1%
earliest event in a stratum
Total 84 4.8%
Total 1736 100.0%
a Dependent Variable: total time (days) on active wl - only time effectively on the ist
Omnibus Tests of Model Coefficients
-2 Log
Likelihood











a Beginning Block Number 0, initial Log Likelihood function: -2 Log likelihood: 13426.333
b Beginning Block Number 1. Method = Enter
Variables in the Equation
B SE Wald df Sig. Exp(B) 95.0% CI for Exp(B)
Lower Upper
Age group at listing 47.838 4 .000
35-49 yr -.282 .078 12.928 1 .000 .754 .647 .880
50-59 yr -.395 .087 20.439 1 .000 .674 .568 .800
60-64 yr -.505 .131 14.994 1 .000 .603 .467 .779
> 65 yr -.852 .148 33.109 1 .000 .427 .319 .570
Primary renal disease 9.583 4 .048
Interstitial nephritis -.115 .079 2.086 1 .149 .892 .763 1.042
Multisystem disease -.248 .107 5.410 1 .020 .780 .633 .962
Diabetes -.185 .108 2.897 1 .089 .831 .672 1.028
Other/unknown -.270 .107 6.350 1 .012 .764 .619 .942
Transplant center 25.407 3 .000
Centre 2 -.476 .133 12.818 1 .000 .621 .479 .806
Centre 3 .106 .104 1.057 1 .304 1.112 .908 1.363
Centre 4 -.145 .093 2.401 1 .121 .865 .721 1.039
Year of listing -.044 .011 16.446 1 .000 .957 .936 .977
Table A.15 Relative risk of access to transplantation (Cox proportional hazards
model including all cases)
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Pro-forma for patient data collection






Date on W.L. Date
Date start RRT Date





Length of RRT Time
Number ofRRT switches






D.M. comorbid No 1
condition Yes 2
D.M. type: I 1
II 2
Level ofhyperglycaemia (HbAic)
D.M. stages: No complication 0
Ophtalmic complications (retinopathy 1
cataract)






Peripheral circulatory problems 4
(gangrene, peripheral angiopathy, ulcer)
Arthropathy 5
Peripheral vascular No 1
disease Claudication 2
Ischaemic ulcers/rest pain 3
Revascularization (surgical/angioplasty) 4
Amputation 5





Number of anti hypertensive drugs
(waiting list moment)
Ischaemic heart disease No 1
Abnormal ECG (otherwise unspecified) 2
Unstable angina (crescendo, de novo 3
effort, worsening effort, preinfarction
syndrome, intermediate coronary
syndrome)
Angina with documented spasm 4
(Prinzmetal, angiospastic, spasm
induced, variant)
Other forms of angina (angina of effort, 5
stenocardia)




MI with complications (ASD, VSD, 9
haemopericardium, rupture of chordae
tendienae, papillary muscle, thrombosis)
Chronic ischaemic heart disease 10




Valvular disease No 1
Yes 2
Previous valvular surgery 3






Heart failure No 1
LVF 2
CHF 3
Ventricular function (Good / Mild / Moderate / Severe)
Ventricular ejection fraction
LV Hypertrophy (Grade: Mild / Moderate / Severe)
Diagnostic modality:
ECG = a / Echo = b
Other heart conditions No 1
Yes- (pericarditis, endocarditis, 2
myocarditis, cardiomyopathy,
conduction disorders)










Other (pneumoconiosis of various 7
origin, TB)
Respiratory failure 8
Other (pleural effusion, pleural plaque, 9
lung abscess)
FEV1/FVC
Cerebro-vascular disease No 1






Liver disease abnormal No 1
LFT's: Yes 2
Serum albumin > 3g/dL 1
>2.5 to < 3g/dL 2
<2.5g/dL 3





Hep C +ve 4
ALD No 1
Yes 2
Other (portal hyper No 1





Malignancy other than No 1
BCC Primary 2
Metastatic 3












Yes - for IHD 2


















GI disorders Duodenal ulcer / Surgery

















Blood group and HLA Blood group
A B
Lymphocytotoxic Ab level
Mismatch tier (1, 2, 3)
DR






















































Cases dropped Cases with missing values 76 4.4%
Cases with non-positive time 50 2.9%
Censored cases before the 42 2.4%
earliest event in a stratum
Total 169 9.7%
Total 1736 100.0%
a Dependent Variable: survival from wl for patients on dialysis censored for tx
Omnibus Tests of Model Coefficients3,13
-2 Log
Likelihood











a Beginning Block Number 0, initial Log Likelihood function: -2 Log likelihood: 3417.882
b Beginning Block Number 1. Method = Enter
Variables in the Equation
B SE Wald df Sig. Exp(B) 95.0% CI for Exp(B)
Lower Upper
Gender - 090 .127 .510 1 .475 .913 .713 1.171
Primary renal disease 82.033 4 .000
Interstitial nephritis - 253 .209 1.470 1 .225 .776 .515 1.169
Multisystem disease 131 .214 .373 1 .541 1.139 .750 1.732
Diabetes 1 239 .186 44.419 1 .000 3.454 2.399 4.973
Other/unknown 301 .206 2.140 1 .144 1.352 .903 2.024
Type 1st RRT 162 .129 1.570 1 .210 1.176 .913 1.514
Age group at listing 66.154 4 .000
35-49 yr 1 009 .282 12.815 1 .000 2.743 1.579 4.767
50-59 yr 1 508 .273 30.587 1 .000 4.518 2.648 7.710
60-64 yr 1 705 .298 32.820 1 .000 5.500 3.069 9.854
> 65 yr 2 027 .283 51.177 1 .000 7.588 4.355 13.221
1st RRT-listing time (year) 304 .067 20.783 1 .000 1.355 1.189 1.544
Carstairs dep. cat. 4.445 6 .617
Carstairs 2 - 288 .297 .941 1 .332 .750 .419 1.342
Carstairs 3 - 297 .274 1.173 1 .279 .743 .435 1.271
Carstairs 4 - 221 .272 .662 1 .416 .802 .471 1.365
Carstairs 5 - 140 .291 .232 1 .630 .869 .492 1.537
Carstairs 6 076 .289 .069 1 .793 1.079 .612 1.902
Carstairs 7 - 338 .416 .662 1 .416 .713 .316 1.611
Distance to Tx center (km) 000 .001 .115 1 .735 1.000 .998 1.003
Table A.16 Cox model for risk of death on dialysis on the waiting list (unadjusted
for comorbidity).
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Cases with missing values
Cases with non-positive time
Censored cases before the










a Dependent Variable: survival from wl for patients on dialysis censored for tx
Omnibus Tests of Model Coefficients3,13
-2 Log
Likelihood











a Beginning Block Number 0, initial Log Likelihood function: -2 Log likelihood: 1206.784
b Beginning Block Number 1. Method = Enter
Variables in the equation B SE Wald Df Sig. Exp(B) 95.0% CI for Exp(B)
Lower Upper
Gender .130 .225 .335 1 .563 1.139 .733 1.770
Primary renal disease 18.729 4 .001
Interstitial nephritis -.386 .354 1.187 1 .276 .680 .339 1.361
Multisystem disease .197 .340 .336 1 .562 1.218 .625 2.372
Diabetes 1.050 .354 8.796 1 .003 2.856 1.428 5.716
Other/unknown -.045 .380 .014 1 .906 .956 .454 2.013
Type 1st RRT -.022 .230 .009 1 .923 .978 .624 1.534
Age group at listing 20.413 4 .000
35-49 yr .396 .473 .699 1 .403 1.485 .588 3.754
50-59 yr 1.003 .472 4.517 1 .034 2.726 1.081 6.873
60-64 yr 1.118 .525 4.535 1 .033 3.058 1.093 8.557
> 65 yr 1.622 .476 11.613 1 .001 5.064 1.992 12.874
1st RRT-listing time (year) -.050 .148 .113 1 .736 .951 .712 1.271
Carstairs dep. cat. 10.414 6 .108
Carstairs 2 -.890 .435 4.178 1 .041 .411 .175 .964
Carstairs 3 -.148 .414 .127 1 .721 .863 .383 1.942
Carstairs 4 -.523 .400 1.708 1 .191 .593 .270 1.299
Carstairs 5 -.480 .481 .996 1 .318 .619 .241 1.589
Carstairs 6 .253 .439 .332 1 .564 1.288 .544 3.049
Carstairs 7 -.276 .639 .186 1 .666 .759 .217 2.656
Distance to Tx center (km) .000 .002 .015 1 .904 1.000 .996 1.004
PVD .315 .261 1.447 1 .229 1.370 .820 2.286
Hypertension .196 .352 .312 1 .576 1.217 .611 2.425
IHD .623 .241 6.699 1 .010 1.864 1.163 2.988
Valvular disease .673 .285 5.582 1 .018 1.960 1.122 3.427
Arrhythmias .507 .306 2.746 1 .098 1.660 .911 3.025
Heart failure .320 .329 .948 1 .330 1.377 .723 2.621
LVH -.593 .223 7.061 1 .008 .553 .357 .856
Respiratory disease .787 .252 9.759 1 .002 2.197 1.341 3.600
CVD .898 .276 10.603 1 .001 2.455 1.430 4.215
Neoplasia .942 .669 1.984 1 .159 2.564 .692 9.507
Gl Disorders .290 .224 1.669 1 .196 1.336 .861 2.074
Urological disorders -.157 .334 .220 1 .639 .855 .444 1.647
Hyperlipidaemia .195 .328 .354 1 .552 1.216 .639 2.314
BMI -.019 .020 .928 1 .335 .981 .943 1.020





Cases available in analysis Event3 181 16.5%
Censored 845 77.2%
Total 1026 93.7%
Cases dropped Cases with missing values 61 5.6%
Cases with non-positive time 8 .7%
Censored cases before the 0 .0%
earliest event in a stratum
Total 69 6.3%
Total 1095 100.0%
a Dependent Variable: survival for transplanted patients (years)
Omnibus Tests of Model Coefficients3'"
-2 Log
Likelihood











a Beginning Block Number 0, initial Log Likelihood function: -2 Log likelihood: 2252.550
b Beginning Block Number 1. Method = Enter
Variables in the Equation
B SE Wald df Sig. Exp(B) 95.0% CI for Exp(B)
Lower Upper
Gender -.027 .164 .028 1 .868 .973 .705 1.343
Primary renal disease 27.115 4 .000
Interstitial nephritis -.057 .215 .070 1 .792 .945 .620 1.441
Multisystem disease .078 .247 .099 1 .753 1.081 .666 1.756
Diabetes .971 .223 18.934 1 .000 2.642 1.705 4.091
Other/unknown .130 .276 .223 1 .637 1.139 .663 1.956
Type 1st RRT .353 .156 5.133 1 .023 1.424 1.049 1.932
Age group at transplantation 75.923 4 .000
35-49 yr .834 .271 9.454 1 .002 2.303 1.353 3.919
50-59 yr 1.520 .264 33.252 1 .000 4.573 2.728 7.666
60-64 yr 2.101 .303 48.089 1 .000 8.172 4.513 14.797
> 65 yr 2.161 .304 50.386 1 .000 8.679 4.779 15.761
Carstairs dep. cat. 5.471 6 .485
Carstairs 2 .015 .408 .001 1 .970 1.015 .457 2.258
Carstairs 3 -.145 .399 .131 1 .717 .865 .396 1.893
Carstairs 4 .299 .382 .616 1 .433 1.349 .639 2.850
Carstairs 5 .001 .418 .000 1 .999 1.001 .441 2.269
Carstairs 6 .278 .417 .444 1 .505 1.320 .583 2.988
Carstairs 7 .183 .524 .122 1 .727 1.201 .430 3.357
Distance to Tx center (km) .004 .001 5.561 1 .018 1.004 1.001 1.006
1st RRT-listing time (year) .071 .102 .488 1 .485 1.074 .880 1.311
Listing-transplant time (year) .000 .000 .608 1 .436 1.000 .999 1.000
Table A.18 Cox model for risk of death following transplantation (unadjusted for
comorbidity)
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Cases available in analysis Event3 80 7.3%
Censored 482 44.0%
Total 562 51.3%
Cases dropped Cases with missing values 530 48.4%
Cases with non-positive time 2 .2%
Censored cases before any event 1 .1%
Total 1095 100.0%
a Dependent Variable: survival for transplanted patients (years)
Omnibus Tests of Model Coefficients3,13









Beginning Block Number 0, initial Log Likelihood function: -2 Log likelihood: 894.655
b Beginning Block Number 1. Method = Enter
Variables in the equation B SE Wald df Sig. Exp(B) 95.0% CI for Exp(B)
Lower Upper
Gender .124 .274 .204 1 .651 1.132 .662 1.935
Primary renal disease 15.328 4 .004
Interstitial nephritis .062 .360 .030 1 .862 1.064 .525 2.157
Multisystem disease .198 .399 .247 1 .619 1.219 .558 2.664
Diabetes 1.161 .366 10.089 1 .001 3.194 1.560 6.539
Other/unknown -.357 .592 .364 1 .546 .700 .219 2.233
Type 1st RRT .059 .256 .053 1 .817 1.061 .642 1.753
Age group at transplantation 21.616 4 .000
35-49 yr 1.398 .514 7.414 1 .006 4.048 1.480 11.074
50-59 yr 1.890 .522 13.122 1 .000 6.622 2.381 18.417
60-64 yr 1.780 .641 7.717 1 .005 5.927 1.689 20.802
> 65 yr 2.617 .581 20.282 1 .000 13.700 4.385 42.797
Carstairs dep. cat. 4.503 .609
Carstairs 2 1.244 1.055 1.393 1 .238 3.471 .439 27.421
Carstairs 3 .954 1.067 .799 1 .371 2.596 .321 21.026
Carstairs 4 1.427 1.053 1.837 1 .175 4.165 .529 32.787
Carstairs 5 .814 1.089 .559 1 .455 2.257 .267 19.076
Carstairs 6 1.382 1.074 1.657 1 .198 3.983 .486 32.670
Carstairs 7 1.115 1.152 .937 1 .333 3.051 .319 29.189
Distance to Tx center (km) .001 .003 .074 1 .785 1.001 .994 1.008
1st RRT-listing time (year) .104 .178 .341 1 .559 1.110 .782 1.574
Listing-transplant time (year) .000 .000 .535 1 .464 1.000 .999 1.000
PVD .199 .336 .351 1 .554 1.220 .632 2.355
Hypertension .665 .513 1.682 1 .195 1.945 .712 5.316
IHD -.147 .332 .196 1 .658 .863 .450 1.656
Valvular disease .288 .402 .513 1 .474 1.334 .606 2.933
Arrhythmias .473 .650 .529 1 .467 1.604 .449 5.734
Heart failure -.002 .537 .000 1 .997 .998 .348 2.860
LVH .254 .297 .734 1 .391 1.290 .721 2.308
Respiratory disease .068 .368 .034 1 .853 1.070 .521 2.200
CVD .584 .423 1.899 1 .168 1.792 .782 4.111
Neoplasia 1.100 .558 3.894 1 .048 3.005 1.008 8.962
Gl disorders .571 .280 4.153 1 .042 1.771 1.022 3.067
Urological disorders .037 .366 .010 1 .919 1.038 .507 2.126
Hyperlipidaemia .016 .462 .001 1 .973 1.016 .410 2.514
BMI -.054 .028 3.642 1 .056 .947 .896 1.001




Convergence criterion (GCONV=lE-8) satisfied.
Model Fit Statistics
Criterion Without Covariates With Covariates
-2 LOG L 2288.729 2018.118
AIC 2288.729 2060.118
SBC 2288.729 2127.859
Testing Global Null Hypothesis: BETA=0
Test Chi-Square DF Pr>ChiSq
Likelihood Ratio 270.6110 21 <0001
Score 356.4909 21 <0001
Wald 262.6021 21 <0001
The PHREG Procedure
Analysis ofMaximum Likelihood Estimates
Parameter Standard Hazard 95% Hazard Ratio
Variable DF Estimate Error Chi-Square Pr > ChiSq Ratio Confidence Limits
35-49 yr 1 0.80557 0.32585 6.1118 0.0134 2.238 1.182 4.239
50-59 yr 1 1.52512 0.32645 21.8258 <0001 4.596 2.424 8.714
60-64 yr 1 1.60521 0.36214 19.6473 <0001 4.979 2.448 10.125
> 65 yr 1 2.35622 0.33648 49.0349 <0001 10.551 5.456 20.404
Gender 1 0.26698 0.16618 2.5812 0.1081 1.306 0.943 1.809
Centre 2 1 0.82691 0.18887 19.1687 <0001 2.286 1.579 3.310
Centre 3 1 -0.41083 0.21600 3.6177 0.0572 0.663 0.434 1.013
Diabetes 1 0.97042 0.17876 29.4688 <0001 2.639 1.859 3.746
Hypertension 1 0.41558 0.25289 2.7006 0.1003 1.515 0.923 2.487
IHD 1 0.34544 0.17266 4.0028 0.0454 1.413 1.007 1.981
Valvular dis. 1 0.48764 0.20278 5.7833 0.0162 1.628 1.094 2.423
PE 1 -0.72978 0.49491 2.1743 0.1403 0.482 0.183 1.272
Arrhythmias 1 0.38298 0.24691 2.4059 0.1209 1.467 0.904 2.380
Other heart dis 1 0.59693 0.26498 5.0748 0.0243 1.817 1.081 3.053
Respiratory dis 1 0.44432 0.19947 4.9618 0.0259 1.559 1.055 2.305
CVD 1 0.39571 0.21599 3.3564 0.0669 1.485 0.973 2.268
Neoplasia 1 0.73939 0.37079 3.9764 0.0461 2.095 1.013 4.332
GI disorders 1 0.22040 0.17372 1.6096 0.2045 1.247 0.887 1.752
smoker 1 0.31094 0.16578 3.5178 0.0607 1.365 0.986 1.889
Malnourished 1 0.54074 0.26620 4.1262 0.0422 1.717 1.019 2.894
Blood gr.A 1 -0.23385 0.16727 1.9544 0.1621 0.791 0.570 1.099
Figure A.4.1 Summary of the baseline Cox regression analysis used to determine
the factors for the survival predictive model.
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Average treatment
Total Event Censored Percent Censored
874 193 681 77.92
Convergence Status
Convergence criterion (GCONV=lE-8) satisfied.
Model Fit Statistics
Criterion Without Covariates With Covariates
-2 LOG L 2394.628 2113.209
AIC 2394.628 2155.209
SBC 2394.628 2223.726
Testing Global Null Elypothesis: BETA=0
Test Chi-Square DF Pr > ChiSq
Likelihood Ratio 281.4191 21 <0001
Score 374.1650 21 <0001
Wald 276.0495 21 <0001
The PF1REG Procedure
Analysis ofMaximum Likelihood Estimates
Parameter Standard Hazard
35-49 yr 1 0.75389 0.31449 5.7465 0.0165 2.125
50-59 yr 1 1.46363 0.31181 22.0336 <0001 4.322
60-64 yr 1 1.54045 0.35305 19.0384 <0001 4.667
> 65 yr 1 2.32296 0.32494 51.1064 <0001 10.206
Gender 1 0.24861 0.16341 2.3147 0.1282 1.282
Transplant center 2 1 0.82955 0.18309 20.5294 <0001 2.292
Transplant center 3 1 -0.44666 0.21209 4.4353 0.0352 0.640
Diabetes 1 0.97736 0.17634 30.7206 <0001 2.657
Ischaemic heart dis 1 0.34356 0.17068 4.0514 0.0441 1.410
Valvular disease 1 0.48013 0.20196 5.6519 0.0174 1.616
Pulmonary embolism 1 -0.76258 0.49251 2.3974 0.1215 0.466
Arrhythmias 1 0.38039 0.24572 2.3965 0.1216 1.463
CVD 1 0.41491 0.21153 3.8473 0.0498 1.514
Hypertension 1 0.42601 0.24624 2.9933 0.0836 1.531
Respiratory disease 1 0.46732 0.19445 5.7756 0.0162 1.596
Other heart dis 1 0.58845 0.26466 4.9437 0.0262 1.801
GI disorders 1 0.22936 0.16879 1.8465 0.1742 1.258
Neoplasia 1 0.73981 0.37011 3.9955 0.0456 2.096
Smoker 1 0.29710 0.16254 3.3410 0.0676 1.346
Malnourished 1 0.53309 0.24739 4.6433 0.0312 1.704
Blood group A 1 -0.26312 0.16448 2.5590 0.1097 0.769
Figure A.4.2 Summary of the Cox regression analysis for the survival under
"average treatment" scenario
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No transplant - censored at time of transplant
Total Event Censored Percent Censored
878 116 762 86.79
Convergence Status
Convergence criterion (GCONV=lE-8) satisfied.
Model Fit Statistics
Criterion Without Covariates With Covariates
-2 LOG L 1209.836 1042.683
AIC 1209.836 1084.683
SBC 1209.836 1142.509
Testing Global Null Hypothesis: BETA=0
Test Chi-Square DF Pr > ChiSq
Likelihood Ratio 167.1527 21 <.0001
Score 208.9190 21 <0001
Wald 153.2053 21 <0001
The PHREG Procedure
Analysis ofMaximum Likelihood Estimates
Parameter Standard Hazard
Variable DF Estimate Error Chi-Square Pr> ChiSq Ratio
35-49 yr 1 -0.01494 0.45914 0.0011 0.9740 0.985
50-59 yr 1 1.00082 0.43467 5.3014 0.0213 2.721
60-64 yr 1 0.91014 0.50215 3.2851 0.0699 2.485
>65 yr 1 1.27792 0.46122 7.6769 0.0056 3.589
Gender 1 0.00564 0.22740 0.0006 0.9802 1.006
Transplant center 2 1 0.64872 0.24285 7.1354 0.0076 1.913
Transplant center 3 1 -1.09392 0.32479 11.3441 0.0008 0.335
Diabetes 1 1.35650 0.24383 30.9509 <.0001 3.883
Ischaemic heart dis 1 0.38346 0.23509 2.6606 0.1029 1.467
Valvular disease 1 0.66919 0.25960 6.6446 0.0099 1.953
Pulmonary embolism 1 -0.36521 0.65094 0.3148 0.5748 0.694
Arrhythmias 1 0.08141 0.29415 0.0766 0.7820 1.085
CVD 1 0.78555 0.25841 9.2412 0.0024 2.194
Hypertension 1 0.11743 0.32134 0.1336 0.7148 1.125
Respiratory disease 1 0.50438 0.24747 4.1541 0.0415 1.656
Other heart dis. 1 0.44600 0.36195 1.5184 0.2179 1.562
GI disorders 1 0.17034 0.22191 0.5892 0.4427 1.186
Neoplasia 1 0.49526 0.61722 0.6438 0.4223 1.641
Smoker 1 -0.09141 0.23068 0.1570 0.6919 0.913
Malnourished 1 0.36899 0.32737 1.2704 0.2597 1.446
Blood group A 1 -0.01486 0.23133 0.0041 0.9488 0.985




Total Event Censored Percent Censored
611 77 534 87.40
Convergence Status
Convergence criterion (GCONV==lE-8) satisfied.
Model Fit Statistics
Criterion Without Covariates With Covariates
-2 LOG L 877.677 774.147
AIC 877.677 816.147
SBC 877.677 865.367
Testing Global Null Hypothesis: BETA=0
Test Chi-Square DF Pr > ChiSq
Likelihood Ratio 103.5300 21 <.0001
Score 130.1759 21 <0001
Wald 98.7582 21 <0001
The PHREG Procedure
Analysis ofMaximum Likelihood Estimates
Parameter Standard Hazard
Variable DF Estimate Error Chi-Square Pr > ChiSq Ratio
35-49 yr 1 1.13495 0.44764 6.4284 0.0112 3.111
50-59 yr 1 1.58291 0.46686 11.4957 0.0007 4.869
60-64 yr 1 1.99169 0.53637 13.7883 0.0002 7.328
>65 yr 1 2.75975 0.50158 30.2733 <0001 15.796
Gender 1 0.39573 0.26001 2.3164 0.1280 1.485
Transplant center 2 1 1.04668 0.32380 10.4492 0.0012 2.848
Transplant center 3 1 -0.04090 0.30721 0.0177 0.8941 0.960
Diabetes 1 0.91256 0.30386 9.0193 0.0027 2.491
Ischaemic heart dis 1 -0.04642 0.32479 0.0204 0.8863 0.955
Valvular disease 1 0.43998 0.37566 1.3718 0.2415 1.553
Pulmonary embolism 1 -0.86400 0.81627 1.1204 0.2898 0.421
Arrhythmias 1 0.14464 0.63641 0.0517 0.8202 1.156
CVD 1 0.15750 0.41756 0.1423 0.7060 1.171
Hypertension 1 0.67537 0.45263 2.2264 0.1357 1.965
Respiratory disease 1 0.34763 0.35722 0.9470 0.3305 1.416
Other heart disease 1 0.52389 0.46152 1.2886 0.2563 1.689
GI disorders 1 0.31930 0.29287 1.1886 0.2756 1.376
Neoplasia 1 1.20736 0.49958 5.8407 0.0157 3.345
Smoker 1 0.69125 0.24968 7.6648 0.0056 1.996
Malnourished 1 0.73837 0.39202 3.5475 0.0596 2.093
Blood group A 1 -0.17645 0.25932 0.4629 0.4962 0.838
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